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ABSTRACT
Approximately 85,000 heart valve replacement surgeries are performed every
year in United States and about 300,000 surgeries worldwide. It is estimated that half of
them are mechanical valve replacements and the other half bioprosthetic valve
replacements [1-3]. The use of bioprosthetic heart valves is slowly increasing.
Bioprosthetic heart valves are made from porcine aortic valves or bovine pericardium.
Commercially these bioprostheses are currently crosslinked using glutaraldehyde
(GLUT) to prevent tissue degradation and reduce tissue antigenicity. GLUT crosslinks
these bioprostheses by stabilizing the collagen present in the tissue via a Schiff base
reaction of the aldehyde with the hydroxylysine / lysine residues of collagen. However,
Glut crosslinked BHVs fail due to structural dysfunction or calcification and need second
replacements. 10 years after surgery, 20-30% of these valves become dysfunctional, and
more than 50% of them fail between 12 – 15 years postoperatively [1, 2].
GLUT is known to be a good fixative for the collagenous component of the heart
valves. However, GLUT is known to cause cytotoxicity and it is one of the causes of
calcification of BHVs. Several alternative fixatives have been researched for BHV
stabilization. Physical methods of crosslinking include ultraviolet irradiation [4] and dye
mediated photo-oxidation (PhotoFix®, Carbomedics, Austin, TX) [5]. Alternative
chemical

fixatives

include

stabilization

using

epoxy

compounds

[6,

7],

diphenylphosphorylazide [8], acyl azides [9], cyanamide [9], diisocyanates [10],
diglycidyl ether [11], polyethylene glycol (PEG) [12], carbodiimide (Ultifix®, Medtronic,
Minneapolis, MN) [1, 13, 14], diamine bridges [15] [16], triglycidylamine [17-19],
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sodium metaperiodate [20-22], reuterin [23, 24] and genepin [25]. They have shown
significantly lower calcification of BHVs, however none of the above mentioned
crosslinker is proven successful in long-term clinical studies. Glutaraldehyde is still the
only major crosslinker used for clinically used BHVs.
Glycosaminoglycans (GAGs) and elastin the other two major components of heart
valves apart from collagen are not stabilized by GLUT fixation. It has been shown that
GAGs are lost during harvesting, fixation, storage, in vitro cyclic fatigue and after in vivo
animal implantation [26, 27]. Clinically explanted BHVs also show GAG depletion [28].
GAGs are an important component of the valves and they maintain a hydrated
environment in the valves and help in absorbing compressive and shear stresses acting on
the valve and resisting local tissue buckling. It has been hypothesized that loss of these
important matrix elements might result in the accelerated degeneration of BHVs.
Furthermore, fixation of these components in the valves may help in the better
biomechanics of the valves and also improve in vivo durability of the valves. Better
extracellular matrix (ECM) stabilization to prevent degeneration will determine the longterm success and durability of these valves.
Crosslikers such as carbodiimide, triglycidylamine, and sodium metaperiodate
were tried as GAG-targeted fixatives; however, they were unable to completely inhibit
the enzyme mediated degradation of GAGs. The focus of this study is on using neomycin
trisulfate, a hyaluronidase inhibitor, along with GAG-targeted fixative carbodiimide for
stabilizing the GAGs present in the valves. Systematic approach is used in our studies to
determine the tissue GAG content, resistance to enzymatic GAG degradation, collagen
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and elastin stability, in vitro cyclic fatigue, in vivo calcification, effect on biomechanical
properties of valves as well as combination with anti-calcification treatments to prevent
both degeneration and calcification. We show that neomycin based chemistry
significantly stabilize GAGs in the BHVs against GAG degrading enzymes and such
fixation would improve long-term durability of the prosthesis.
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CHAPTER ONE
INTRODUCTION
The heart, an important component of the circulatory system, can be compared to
two conjoined pumps, the right side pumping blood to the lungs and the left side pumping
blood to the peripheral organs [29]. Average human heart beats more than 2.5 billion
times in a 70-year lifetime. In one day, the heart beats approximately 100,000 times,
pumping about 2000 gallons [30]. The heart has four valves to allow one way blood flow.
To properly regulate the blood flow, these valves should possess the necessary
mechanical properties to withstand the cyclical fatigue during valve function.
A heart valve is considered defective if it either doesn’t close fully (insufficiency)
or doesn’t fully open (stenosis) [31]. The causes for the heart valve failures are rheumatic
fever, bacterial endocarditis, stenosis, insufficiency, congenital heart valve defects and
degeneration of the valve due to old age, high blood pressure, hyperlipidemia or
calcification [31, 32]. Valve replacement surgery, recommended when failure occurs due
to one or more of the abovementioned reasons, replaces the diseased valve with a
cryopreserved valve from a human cadaver heart (homograft), or a metal or a plastic
valve (mechanical valve), or a specially treated valve from porcine aortic valve or bovine
pericardium (xenograft – bioprosthetic heart valve (BHV)) or tissue-engineered heart
valve [31].
Approximately 85,000 heart valve replacement surgeries are performed every
year in United States and about 300,000 surgeries worldwide. It is estimated that half of
them are mechanical valve replacements and the other half bioprosthetic valve
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replacements [1-3]. Mechanical valves are extremely durable, but are prone to thrombosis
due to synthetic nature of the valves and non-physiologic hemodynamics. Thus, patients
need to be on chronic anti-coagulation therapy, which is contraindicated in many cases.
Bioprosthetic heart valves are preferred compared to mechanical valves as patients do not
need anti-coagulation therapy. Bioprosthetic heart valves made from porcine aortic
valves or bovine pericardium are usually stabilized using glutaraldehyde. Though
stabilized, they fail due to structural dysfunction or calcification within ten to twenty
years of use [2].
This research investigates methods to stabilize and improve the longevity of
BHVs by crosslinking the glycosaminoglycans present in the valves. The GAGs are
hypothesized to provide improved biomechanical function to the valve and reduce
calcification. Any strategy developed to preserve GAGs would result in improved
durability. Thus the quality of life of the patients receiving these implants would be
considerably improved due to increased longevity.
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CHAPTER TWO
LITERATURE REVIEW

2. 1. Native heart valve and its function
2.1.1 Function:
The heart has four chambers, the upper two are called atria or auricles and the
lower two are called ventricles. The apex of the heart is slightly inclined towards the left
side. There are four valves in the heart which open and close in order to allow the
unidirectional flow of blood when the heart is beating. Two of the valves lie between
atria and the ventricle and so they are called atrio-ventricular (AV) valves. They are the
tricuspid and mitral valve respectively. Two other valves called semi-lunar valves; one
between the left ventricle and the aorta called the aortic valve and the other between the
right ventricle and the pulmonary artery called the pulmonary valve. All valves except the
mitral valve have three cusps and mitral valve has two cusps. Under normal conditions,
the valves allow only unidirectional flow of blood. The difference in pressure on either
side of the valves makes the valves open and close. The AV valves have tendon like
structures called chordae tendineae that link them to the papillary muscles of the
ventricles. As the papillary muscles relax and contract, the resulting force is transmitted
through the chordae tendineae to the valves, causing the valves to open and close.
Contraction of papillary muscles opens the valves and relaxation closes the valves. Cusps
are attached individually through a dense fibrous tissue called annulus. This dense
connective tissue plays a major role as a load bearer during the opening and closing of the
valves [29, 31].
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2.1.2. Structure / architecture of the heart valves:
The heart valve cusps are multi-layered structures with complex architecture.
They possess specialized functionally adapted cells and anisotropic arrangement of
extracellular matrix (ECM) [2]. The heart valve cusps have three major layers, each
enriched with different and specific ECM for unique function. The layers are:
•

Ventricularis - on the inflow side of blood, consists of predominantly radially
arranged elastin fibers.

•

Fibrosa – on the outflow/backward flow side, consists of macroscopic collagen
bundles arranged in a circumferential manner where the collagen fibers run parallel to
the cuspal free edge.

•

Spongiosa – the centrally arranged layer between fibrosa and ventricularis consists of
loosely arranged collagen fibers along with abundant glycosaminoglycans (GAGs).
There are two general cell types seen in the valves (and their subtypes). A

covering layer of valvular endothelial cells (VEC) line the cusp on both outer sides and
valvular interstitial cells (VIC) are within the cusp matrix, which have features of both
fibroblasts and smooth-muscle cells. They synthesize, remodel and replenish the local
connective tissue matrix in the cusp [2]. The fibrosa and ventricularis are preloaded by
virtue of their attachment to each other; the fibrosa under compression and ventricularis
under tension. The valve cusp contains about 50% collagen, 13% elastin, and 3.5 %
GAGs of its dry weight [33].
The fibrosa with circumferentially arranged type I and type III collagen fibers acts
as the major load bearing layer. The arrangement of these fiber bundles gives rise to
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macroscopic crimps which causes corrugations in the heart valve cusp, when it is open
during systole (Figure 2.1A). These corrugations disappear during diastole, allowing
elongation of the layer with minimal stress [2]. When the heart valve closes, the elastin
present in the ventricularis expand and stretch the cusps to enlarge the coaptation area.
These elastin fibers recoil during the valve open phase to make the cusps contract [2, 33,

34].
Figure 2.1: (A) Section of the cusp showing the three different layers of the aortic cusp
with the free edge [33]. (B) Notations and nomenclature of the edges and portions of the
cusp [33, 35]. Histological sections of the cusps showing the three distinct layers of the
cusps with fibrosa on top and ventricularis with elastin (el) in the bottom [2].
The glycosaminoglycans (GAGs) present in the spongiosa layer help in absorbing
the shock during valve closure and also the shear stresses due to the differential
movement of the layers. This is due to the hydrophilic nature of GAGs which gives this
layer hydrogel like property to resist compressive forces [2].
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2.1.3. Glycosaminoglycans (GAGs):
GAGs are linear anionic acid mucopolysaccharides. They have repeating
disaccharide subunits made up of an amino sugar (either N-acetyl glucosamine or Nacetyl galactosamine) and a uronic acid (either D-glucuronic acid or L-iduronic acid)
[36]. These GAGs are typically attached to a core protein with a glycosidic bond and
these macromolecules are called as proteoglycans [36]. GAGs are highly hydrophilic in
nature as they contain carboxylic and sulfonic acid groups. There are a total of five types
of GAGs found in the body. They are hyaluronic acid (HA), chondroitin sulfate (CS),
dermatan sulfate (DS), keratin sulfate (KS) and heparan sulfate (HS) [36, 37]. Hyaluronic
acid does not contain sulfate esters and it is not bound to a protein core [36]. Hyaluronic
acid, chondroitin sulfate and dermatan sulfate are the types of GAGs present in the aortic
valve cusps [38].
GAGs are primarily found in the connective tissue especially the cartilage and in
heart valves. The primary functionality of GAGs is to maintain a hydrated environment
and thus providing high viscosity and low compressibility. Due to the anionic nature of
GAGs, they become well hydrated extended structures at physiologic pH and occupy
large hydrodynamic volume. They are reversibly compressible in solution [39].
Glycosaminoglycans are discussed in detail in section 2.11.

2.1.4. Cardiac valvular interstitial cells:
The valvular interstitial cells (VIC’s) posses properties similar to that of both
fibroblasts and smooth muscle cells. They have matrix secretion properties like
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fibroblasts and contractile properties like smooth muscle cells [40]. Similar to fibroblasts,
VIC’s do not have a basal lamina thereby establishing close contact with collagen fibers,
elastin microfibrils and proteoglycans of the matrix [40, 41]. These cells were known to
be responsible for the secretion of valvular matrix, including collagen, elastin and
proteoglycans [42]. Structural analyses of the VIC’s have shown that they have cellular
microfilaments for contractile properties. They are also found to be rich in smooth
muscle-specific α-actin [40]. VICs serve to maintain the structural integrity of the tissue
by remodeling via protein synthesis and enzyme degradation. When the VICs are myolike, they are found to be actively remodeling the ECM. They are probably known to be
maintaining the cuspal tissue homeostasis [42-46]. The VICs have a strong attachment to
the ECM of the tissue and it was found that the VICs alter their stiffness based on the
local tissue stresses [42-47].
Valvular endothelial cells (VECs) are much different from the aortic ECs and that
they are known to be regulating the vascular tone, inflammation and remodeling. There is
a feedback mechanism between the VECs and the vascular interstitial cells (VICs), which
transmits the information regarding the cytokines released from VECs. Valvular response
to shear with and without endothelium is much different. Collagen synthesis is found to
be enhanced in intact valves under shear stress but unchanged in endothelium-denuded
cusps. Conversely sulfated glycosaminoglycan (GAGs) content was found to be
enhanced in denuded cusps but constant in intact cusps [43, 44]. Circumferential cyclic
stretch was known to mediate aortic valves’ remodeling activity. Figure 2.2 shows the
effect of cyclic stretch on collagen, GAG and elastin synthesis in aortic valve cusps [48].
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Figure 2.2: Effect of cyclic stretch on collagen, sGAG and elastin content [48]

2.2. Heart valve disease or valvular heart disease (VHD)
Coordinated action between all the components of the system is very important
for the functional integrity of a normal valve. The key structures in case of the
atrioventricular valves (mitral and tricuspid valves) include cusps, commissures, annulus,
chordae tendineae, papillary muscles and ventricular myocardium. In case of semilunar
valves, they are the cusps, commissures and their supporting structures in the valve root
[49].
Valve surgery is required when dysfunction is caused by calcification, fibrosis,
fusion, retraction, perforation, rupture, stretching, dilation, or congenital malformations of
the valve cusps or associated struts [49]. A heart valve is found defective if the valve
either does not close fully (insufficiency) or does not open fully (stenosis) [31]. Valvular
stenosis is caused by a primary cuspal abnormality and a chronic disease process. In
contrast, valvular insufficiency may result from either intrinsic disease of the valve cusps
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or from damage to or distortion of the supporting structures. Stenosis and insufficiency
can coexist in a valve [49].
Degenerative aortic valve disease is the most common cause of aortic stenosis;
calcification of congenitally bicuspid aortic valves comprises the second most common
cause. The leading cause of chronic aortic insufficiency is aortic root dilation, causing
stretching and outward bowing of the commissures and a lack of cuspal coaptation. Post
rheumatic deformity remains the leading cause of mitral stenosis. Moreover, myxomatous
mitral valve disease and ischemic mitral regurgitation are the leading causes of pure
mitral valve regurgitation [49].
Heart valve disease results in a major complication of congestive heart failure,
where the blood engulfs the veins in the lungs and other parts of the body causing
congestion of fluid in body tissues [50]. Breathlessness is therefore a major symptom of
congestive heart disease along with other symptoms of fatigue, fainting, palpitations and
chest pain. Figure 2.3 shows the increasing trend in the number of congestive heart
failure in the United States for the period 2004 to 2014. Heart valve disease can cause
heart muscle disease and heart valve murmur. Valve diseases take up to 20 to 30 years to
develop and by the time the patient realizes and gets diagnosed for the problem, the
disease is already in an advanced stage.
Valvular heart disease is responsible for nearly 20,000 deaths each year in the
United States and is a contributing factor in about 42,000 deaths. The majority of these
cases involve disorders of the aortic valve (63%) and the mitral valve (14%). Deaths due
to pulmonic and tricuspid valve disorders are rarer (0.06% and 0.01%, respectively) [51].
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Figure 2.3: Trend in prevalence of VHD in US from 2004 to 2014 [51]

2.2.1. Causes of heart valve disease:
The major causes of heart valve disease are listed below [50]:
•

Rheumatic fever – an inflammatory condition which results in an autoimmune
response which starts with a strep throat.

•

Infective endocarditis (bacterial endocarditis) – an inflammatory condition that leads
to infection of the endocardium, the inner lining of the heart valves and heart
chambers.

•

Myxomatous degeneration – a dysfunction where the valve tissue looses its elasticity,
becomes weak and flabby. This condition is prevalent in the elderly people.
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•

Calcific degeneration – another common disease prevalent in the elderly people,
caused by calcium deposits on the valve.

•

Congenital anomalies – a condition that is due to abnormalities from the time of birth,
a most prevalent example of this being a bileaflet aortic valve instead of a trileaflet
valve.

•

Other causes – VHD could be sometimes due to coronary artery disease (CAD) or
heart attack, both of which might result in injury to papillary muscles that support the
valves.
The mitral and aortic valves are the most often affected valves due to valvular

disorders. This is because these valves are constantly exposed to high pressures and
mechanical stress that can lead to valve damage. Generally there is a normal pressure
gradient above and below the valve. However, as valvular dysfunction develops and
progresses, abnormal pressure gradients develops resulting in further valve deformation
or ventricular remodeling [51].

2.2.2. Heart valve diseases and their treatments:
The major types of heart valve diseases or VHD include stenosis and regurgitation
in all four heart valves and mitral valve prolapse [50].
The current available treatments for valvular heart disease are [50]:
•

Drugs – Drugs prescribed are generally not curative but reduce severity of symptoms.
They can be classified into vasodilators, diuretics, anticoagulants and antiarrythmics.
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•

Balloon valvuloplasty – A deflated balloon attached at the end of the catheter is
positioned at the center of the valve and then inflated. This clears up the block in the
valve and is mostly used in stenotic mitral valve and in elderly patients.

•

Surgical treatment – This is performed only under severe cases and here the surgeons
may open up a block or may suture up a torn or a leaky valve cusp.

•

Valve replacement surgery – When the problem is potentially life-threatening, the
valves are replaced by surgery. The valve prosthesis is either a mechanical valve or
biological valve.

2.2.3. Brief history of valvular heart repair / replacement:
In the era before 1950, rheumatic fever was the major cause of VHD and Jones
established diagnosis criteria for rheumatic fever [52]. AHA then played an important
role in communicating the importance of penicillin prophylaxis, which helps in reducing
the rheumatic fever and also the symptoms of VHD. The commonly affected mitral valve
was operated using closed-chest mitral commissurotomy. The understanding of VHD
pathogenesis, its diagnosis for effective treatment slowly started to increase. The need for
improved diagnostic precision for a better open-heart surgery was also realized [52].
In the era after 1950, the surgeons standardized the equations to determine the
pressures acting on the aortic valve and the mitral valve. Now, they have become
standard for the assessment of valve stenosis.
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In the above equations AVA is aortic valve area (cm2), CO is cardiac output
(L/min), HR is heart rate (bpm), SEP is systolic ejection period (sec), DEP is diastolic
ejection period (sec) and MVA is mitral valve area (cm2) [35, 53]. In AVA equation the
gradient refers to the mean systolic aortic gradient (mm Hg) and in MVA equation the
gradient refers to the mean diastolic aortic gradient (mm Hg) [35, 53].
Heart valve replacement started in the 1960’s, the brief history of valve
replacement is discussed here and a detailed review of valve replacement is dealt in the
next section. The replacement valve could be an autograft, allograft (homograft) and
xenograft (prosthetic valve). The prostheses could be a mechanical valve or a
bioprosthetic valve. Harken et al [54] followed by Starr and Edwards [55] used
mechanical valves in 1960. Allografts were first used by Ross [56] and then by BarrattBoyes [57] in the year 1962 and 1964 respectively. Carpentier was the first to use
heterografts (xenografts) in the year 1969 [58] and he called them bioprostheses.
Autografts and its use was described by Ross in 1967 [59].

2.3. Heart valve replacements and its types
While selecting a heart valve replacement, it should be chosen based on six-valve
related issues. The six factors are durability, risk of thromboembolism and need for
anticoagulation, technical ease of insertion, infectibility, availability, and valve-related
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noise. The modified form of the “Ten commandments of Satisfactory Prosthetic Aortic
Valve [60]” as published by Schoen et al is shown in Table 2.1 [2].
Nonobstructive
Closure is prompt and complete
Nonthrombogenic
Infection resistant
Chemically inert and nonhemolytic (does not damage blood elements)
Durable for extended intervals
Easily and permanently inserted into an appropriate site
Interface between the patient and the prosthesis heals appropriately
Not annoying to the patient
Table 2.1: Desirable characteristics of a heart valve substitute [2]
Not all valves have the above mentioned characteristics and the surgeons have to
choose the appropriate valve for the desired patient after analyzing which would be best
suited for the patient. The major valves available for replacement, autograft (cadaver
valve), mechanical valve and bioprosthetic valve are discussed here. Future tissue
engineered valves are also discussed.
Cadaver valves are very limited in their availability. Mechanical valves are made
from pyrolytic carbon discs/cusps or with a polymer ball mounted onto a metal cage.
Though these mechanical heart valves have extremely good durability, due the synthetic
nature of the valve and the non-physiologic hemodynamics of the valve they encounter
thrombosis and thromboembolism [2]. Life-long anti-coagulation treatment is needed for
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the recipient of mechanical valve and such treatment could be contraindicated in certain
patients such as young child or women of child bearing age. Bioprosthetic heart valves
(BHVs) are used for last 40 years due to their excellent hemodynamics and compatibility.
The rates of failure of the mechanical heart valves and the BHVs are similar because
though BHVs have better hemodynamics, they fail due to structural dysfunction and
calcification. Different types of heart valves are discussed in detail in the ensuing
sections. We will briefly discuss tissue engineered heart valves at the end as they are still
in the research stage of development and testing and not used clinically.

2.4. Mechanical heart valves
2.4.1. Ball Valves:
There was a long pressed need for invention of prosthetic heart valves.
Development of a prosthetic heart valve involved the search of a biologically compatible
materials and hemotologically tolerant designs [61]. Dr. Charles Hufnagel made the
impossible dream true by clinically introducing a ball-valve in the descending thoracic
aorta for treating valvular insufficiency in the year 1952 [61], though experimentation
began in 1946 [62]. It seemed to improve the cardiac functions and prevent regurgitant
blood flow below the prosthesis [63]. In 1951, he described the use of a methacrylate ball
contained in a methacrylate tube [61]. Since this valve was noisy due to the clicking
sound of the valve opening and closing, this was replaced by a nylon ball covered with
silicone rubber enclosed in a Plexiglas chamber making the valve mechanism quiet. The
ball was made of a critical weight so that it functioned by minimal changes in pressures
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[62]. Figure 2.4 shows the modified mechanical valve designed by Dr. Hufnagel. Dr.
Hufnagel’s efforts opened up the field of cardiac valve replacement and started to provide
significant hemodynamic improvements to patients with valve associated problems [64].
Dr. Hufnagel also started developing other types of valves like the caged non-tilting disc
valve, a biconical disc valve, coated flexible cusp valves, helical coil spring valve [62].

Figure 2.4: Modified quiet type of aortic ball valve [62]
In the year 1953, Dr. John Gibbon performed the first successful closure of an
intracardiac defect with a heart lung machine [65]. Flexible fabric valves were further
tried out by Dr. Bahnson, where he used Teflon aortic cusps or a nylon fabric
impregnated with silicone rubber. These models were disappointing as they failed due to
thrombus formation, stiffening and ingrowth of connective tissue [61, 66]. Dr. Dwight
Harken, a renowned heart surgeon, devised a caged ball valve using a silicone rubber
ball. He used a larger cage surrounding the primary cage as he was concerned that the
ball might impinge on the aortic valve. This valve was called as the Harken-Soroff ball
valve. The silicone ball used here appeared to have no deterioration. The use of the larger
cage was later discontinued as Dr. Starr proved that it was unnecessary [61, 65].
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Starr-Edwards caged ball valve was made using a methacrylate cage and a
silicone rubber ball. Success with canine surgery prompted them to use this valve in
clinical trials. Later this methacrylate cage was replaced with a stellite-21 metal cage.
Stellite-21 is an alloy of cobalt, chromium, molybdenum and nickel [61]. The caged ball
valve took a world of evolution in the next decade. They finally ended up using heat
curing of the silicone balls at high temperatures to eliminate the variance [61, 65]. Figure
2.5 shows the evolution of the Starr-Edwards ball valve from 1961 to 1980.

Figure 2.5: Evolution of Starr-Edwards Ball Valve from 1961 to 1980
Smeloff-Cutter ball valve was the first prosthetic valve to employ the “full-flow”
orifice concept. This was achieved by using a double closed-cage design. The smaller
cage help the ball at its equator during diastole and the larger cage retained the ball
during systole. The cage was machined from a single bar of titanium. The ball variance
was eliminated by changing the curing method of the silicone ball [61, 65]. Dr. Michael
DeBakey and Harry Cromie of Surgitool developed a ball valve similar to Starr-Edwards
valve. The initial model had a polyethylene poppet which was replaced later with a
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pyrolytic carbon poppet. This was the first use of the pyrolytic material in heart valves
and was because of the variance problem encountered with other materials. But
unfortunately, due the harder ball, the titanium struts encountered more wear and
eventually led to discontinuation of the valve [61, 65]. Dr. Nina Braunwald worked with
Cutter Laboratories to develop a cloth covered ball valve. The metal struts were enclosed
in Dacron tubing and the inflow ring in an ultra thin polypropylene mesh fabric [65, 67,
68]. Years after clinical use, it was reported that there was wear of the fabric and the ball
causing the ball escaping the cage. This resulted in discontinuation of the valve use and
production [67].
The discovery of pyrolytic carbon by Dr. Jack Bokros was an important landmark
in the making of mechanical heart valves. This material, originally developed for the
encapsulation of nuclear fuel rods, was used in the previously mentioned DeBakeySurgitool valve for the hollow ball. This highly polished pyrolytic carbon was found to be
the most thromboresistant material. This eventually led to its use in DeBakey’s ball valve
and all the other mechanical disc valves.

2.4.2. Non-tilting Disc Valves:
There are three landmark non-tilting disc valves that need to be mentioned. KayShiley disc valve was one of the foremost disc valves used. It was made from a stellite
housing which houses a silicone elastomer disc. Due to wear related problems this disc
was replaced by a delrin disc which remarkably improved the valve properties. Also Dr.
Kay added a muscle guard assembly to prevent disc impingement [61, 69]. Beall-
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Surgitool was a non-tilting disc valve that used a teflon disc valve with the annular apron
made out of velour fabric. The teflon disc notched on the parallel struts and so was
substituted later with a pyrolytic disc. The production of this valve was finally stopped
because of the fabric wear on the annular ring [70, 71]. Cooley-cutter biconical disc
prosthesis was a low-profile silicone rubber disc valve enclosed by four open ended
titanium struts with a dacron covered orifice. This valve was however discontinued due to
thrombosis and embolization. The valve was modified later by a pyrolyte carbon disc as
silicone disc was eroding [72]. Figure 2.6 shows the major landmarks in non-tilting disc
valves.

Figure 2.6: Three landmark non-tilting disc valve
From the use of ball valve and disc valve scientist understood an important
pattern. A soft ball (silicone rubber) was eroded by a harder strut (titanium), whereas a
harder disc/poppet (pyrolyte) erodes the softer (titanium) strut.

2.4.3. Tilting Disc Valves:
There are five landmark tilting disc valves that need to be mentioned. Figure 2.7
shows the major landmarks in tilting disc valves. Bjork-Shiley flat tilting disc valve was
made as a collaborative effort between Dr. Viking Bjork and Dr. Donald Shiley. The
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tilting disc valve that they developed used disc retainer which were two U-shaped wire
struts which were welded to the stellite orifice [73]. Initially, the disc was made of delrin
polymer. Later it was found that the polymer absorbs water and the disc looses its shape
and so the delrin polymer disc was replaced with a pyrolytic carbon disc. Also the welded
joint of the disc retainer seems to affect the longevity of the valve and so was replaced
with a single piece monostrut and it was machined as a part of the orifice ring [73].

Figure 2.7: Five landmark tilting disc valves
Bjork-Shiley also came out with a convexo-concave tilting disc valve where the
pyrolyte disc was concave and the inlet and outlet struts were modified so that the disc
could slide forward and down for about 2 mm. It was later reported that there was a high
incidence of fracture on these valves at the weld site of the small C-shaped outflow strut
[74]. It was unfortunate that the minor design change led to the failure of the valve. Later
these struts were replaced by machined monostrut and so far no case of failure has been
reported in more than 100,000 patients [75]. Dr. Kaster when working in Dr. Lillehei’s
laboratory developed a tilting disc valve, which has distinctive valve containment using
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two prominent side prongs. Distribution of this valve ceased as the valve was not
approved by FDA. These valves were manufactured and distributed by Medical
Incorporated and by the time the valves were approved they started marketing another
approved valve called the Omniscience valve. Dr. Kaster further modified the LilleheiKaster valve by reducing the profile of the prominent prongs into earlike guards. Also the
flat disc earlier was given a curvilinear profile. These valves are still in production and
have been implanted in nearly 100,000 patients [76]. This valve was almost reproduced
by Medical CV Inc, and was called as Omnicarbon valve [77]. The only slight
modification was the titanium housing in omniscience disc was replaced by pyrolyte
housing in Omnicarbon valves. Both the Omniscience and Omnicarbon valves
demonstrated extreme durability with essentially no failure [65]. Dr. Karl Victor Hall
worked with Dr. Kaster to develop a tilting disc valve which contained a pyrolyte disc
with a central perforation. It was designed such that the disc will slide over a guidewire
through its central perforation [78, 79]. Hall-Kaster valve has been widely used
worldwide and in 1987, after a minor modification, the valves were manufactured and
marketed by Medtronic and hence the name was changed to Medtronic-Hall valve. More
than 300,000 valves have been implanted so far with no reported failure [80, 81]. This
valve was found to be better than bileaflet prosthesis for aortic valve replacement [82].

2.4.4. Bileaflet Valves:
There are four important bileaflet valves that revolutionized the valve industry.
Dr. Vincent Gott and Dr. Ronald Daggett developed a bileaflet valve in 1963. The valve
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was made from a polycarbonate rings containing a disc of teflon fabric impregnated with
silicone rubber [83]. This material was coated with colloidal graphite and sterilized in
benzalkonium chloride and rinsed in heparin [61, 83]. This valve was developed to have a
lower profile design compared to the bulky caged-ball design. One disadvantage of this
valve was that there was a relatively stagnant blood flow in the area of the superstrut and
occasionally it becomes the site of thrombus formation [65]. But, there was no clinical
evidence of thromboembolism or valve deterioration in these valves.
Lillehei-Kalke bileaflet valve had the leaflets positioned in such a way that their
hinging axis lie towards the periphery of the metal annulus [84]. Since this did not work
well, the pivot of the axis was moved away towardss the retaining ring. This valve had a
central opening mechanism like the tidal floodgates. Surgitool manufactured only one
such titanium valve in 1968 and was implanted into a woman with unsuccessful result.
The valve was discontinued as the inventors thought the valve needed a better
biocompatible material [65, 84]. St. Jude Medical bileaflet valve, the most widely
accepted and used prosthetic valve, was thought to be an imitation of Kalke-Lillehei
bileaflet valve [85-87]. The central flow design was used making sure that the hinge for
the leaflets was in the center of the valve. The inventors made the valve completely from
pyrolytic carbon and they modified the initial design with a concept of leaflet-tab rotating
in the “butterfly-recess” in the inner wall of the housing [85, 87]. There has been no
change in the valve design since this design in 1977. The sewing ring has been changed
though through the years.
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Dr. Jack Bokros, who developed pyrolytic carbon, formed a company called
Carbomedics in 1979 [65, 88]. Carbomedics specialized in designing pyrolytic carbon
material for over 14 different valve manufacturing companies. In 1986 he developed a
valve which is similar to St Jude valve but its housing can be rotated within the sewing
ring [65]. Figure 2.8 shows the landmark bileaflet valves.

Figure 2.8: Four landmark bileaflet mechanical valves

2.5. Biological Valves
2.5.1. Autografts and allografts:
Autografts refer to the transplantation of an organ or a part from one place to
another place of the same individual. In case of heart valves, pulmonary valve is
predominantly used as autograft [89, 90]. Allograft or homograft refers to the grafting of
organ/tissue between donors of same species. The predominant allograft is cryopreserved
cadaveric valves [56] as shown in Figure 2.9. Cadaver valves have been transplanted
since 1960’s [56]. These valves, derived from fellow humans, have better hemodynamics,
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low risk of thromboembolism, no need for long-term anti-coagulation and are resistant to
bacterial infection [56-59, 91]. There are many factors that limit the use of allograft. The
availability of cadaveric valves, the age of the donor, the age of the patient, the
implantation site and the implantation technique used, implant preparation technique,
immunogenicity of the implant etc., are some of the limiting factors [2, 49, 91-93].

Figure 2.9: Cryopreserved allograft aortic valve [94]
Due to the reasons mentioned previously such as availability, age etc., autografts
and allografts are used sparingly. Mechanical or bioprosthetic valves are used in most of
the valve replacement surgeries. But given the availability and the advantageous
conditions, natural aortic valve is the “gold standard” because of the biocompatible
nature and proper extracellular matrix assembly [2].
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2.5.2. Bioprosthetic heart valves (BHVs):
The bioprosthetic valves, obtained either from porcine aortic valve or bovine
pericardium, have been in use since the early 1970’s [1-3, 95]. The use of bioprosthetic
valves has increased from 20% in 1995 to 40% in 2000 and is believed to be more than
60% currently [96]. The bovine pericardial valves are made from a sheet pericardium and
are mounted on a flexible frame. Both bovine and porcine valves are fixed with
glutaraldehyde for tissue preservation. Currently, more porcine aortic valves are being
used compared to bovine pericardial valves [95, 97].
The modern BHVs are classified into either stented or stentless varieties. Figure
2.10 shows the three major kinds of bioprostheses. BHVs generally are either stented
bovine pericardium, or stented porcine aortic valves or stentless porcine aortic valves.
The stents for these BHVs consists of typically three polymeric struts and sewing ring at
the base onto which the valve is sutured. The edges of the valves are sutured along with a
dacron cloth to the stents [95-99]. First generation stented BHVs used rigid struts
inducing more stresses resulting in cuspal tear and creep of the struts. Due to this reason,
the struts used in the next generation valves were made from flexible materials [100].

a

b

c

Figure 2.10: Bioprosthetic heart valve types (a) Stented bovine pericardial valve,
(b) stented porcine aortic valve and (c) stentless porcine aortic valve.
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In stentless bioprostheses, the stent and the sewing ring are eliminated, which
results in higher orifice area for a given size of a valve [95]. The stentless BHVs have
excellent hemodynamics, with nonturbulent flow and low transvascular gradients [100].
Left ventricular mass (LVM) regression occurs after aortic valve replacement, which may
lead to improved long-term durability. Stentless BHVs were found to improve LVM,
while leads to improved hemodynamics [101]. One minor disadvantage of stentless
BHVs is that the valve size is 1 or 2 sizes larger than the stented ones. They require more
skill and maneuvering time to insert them during surgery and more care has to be taken
[97].
Typically, these heterograft tissues were treated with chemicals to “fix” the tissue
to prevent immune rejection and tissue degeneration. In first generation BHVs,
formaldehyde was used as a fixative. Since it was found to be ineffective in properly
stabilizing ECM, it was replaced with glutaraldehyde. Glutaraldehyde, a water-soluble
cross-linker, almost completely reduces tissue antigenicity. Glutaraldehyde devitalizes
the tissue and kills the host cells thereby preventing degradation through enzymes and
sterilized the tissue for implantation [102].
2.5.2.1. Bovine pericardial heart valves:
The BHVs are made from calf pericardium (the fibrous sac that encloses the
heart) treated with glutaraldehyde, which are cut and mounted on flexible stents and
sutured to the sewing cuff with a dacron cloth [103]. These valves have large effective
orifice than the porcine BHVs, which makes them have better hemodynamic properties at
smaller diameters [100, 104]. Superior hemodynamics of this valve even in small sizes
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makes this valve suitable for patients with narrow aortic root and in children [104]. The
better hemodynamics also comes from the symmetric opening. The other advantages
include greater percentage of collagen in the tissue and availability of extra tissue to
accommodate shrinkage [95]. The Ionesco-Shiley bovine pericardial valves, implanted
from 1971 to 1975, were the first heterograft heart valve implant [103]. Since they proved
to be less durable due to accelerated degeneration, their manufacture and implantation
was halted [100]. This valve was later modified with improved design and introduced
into market by Edwards Lifesciences. This valve was called the Carpentier-Edwards
Perimount valve [98, 100]. In this valve, the pericardial tissue is anchored behind the
stents rather than using stitches through the tissue as it was found to be detrimental in
case of Ionescu-Shiley valve [98]. Due to change in tissue mounting design, the shear
stresses were reduced and due to the anchoring the cuspal tears were reduced [98, 100].
The first generation of pericardial valves (Ionesco-Shiley, Mitroflow and Hancock
valves) failed due to non-calcific cuspal perforations and tears [2, 105, 106]. The tears
happen especially at the cuspal commissures and the sutures around the commissures
[105, 106]. Collagen fibers (Type I) oriented randomly in pericardium makes its structure
not very adaptive for valve function. Unlike aortic cusps where the stresses are
transferred to the aortic wall, the pericardium has stresses concentrated at the
commissures [2]. The second generation pericardial valves (Carpentier-Edwards
Perimount, Baxter Health Corporation valves) are designed such that the tissue is
suspended from the inside of the flexible, low-profile stent. These valves though found to
have better performance and durability than the first generation valves, were found to fail
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ultimately due to the same mode of cuspal tears [107-109]. Pericardial valves are
fabricated with the rough side towards the inflow, to keep the surface washed and
minimize thrombosis [2].
2.5.2.2. Porcine aortic heart valves:
The porcine heart valves have many similarities in the shape, size and pressure
requirements of the human aortic valve and are available easily. Porcine aortic heart
valves also have the similar architecture like the human valves with fibrosa, spongiosa
and ventricularis layers. These factors make the porcine heart valves a very good choice
as bioprosthetic heart valves [2, 110]. Figure 2.11 shows a low-profile BioImplant
porcine BHV.

Figure 2.11: Low-profile BioImplant porcine bioprosthesis
In the late 1960s, homograft aortic valves were rapidly replaced by
“manufactured” porcine aortic valves as they have a longer “shelf life” and varied sizes
were available [110]. The Carpentier-Edwards and Hancock I Medtronic valves were
among the “first generation” porcine aortic heart valves, which were introduced in the
1970s. The valves are mounted on a flexible stent in case of Carpentier-Edwards to
compensate for the restricting muscle shelf. In case of Hancock modified orifice valves,
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the previous design with low optimal hemodynamics was replaced such that the right
cusp is replaced by a non-coronary cusp from a second valve [100].
The “first generation” porcine BHVs were treated with glutaraldehyde under
pressure, where they are exposed to about high back pressure equal to diastolic pressure
(~80 mm Hg) during fixation, giving the valves a smooth, closed and a pleasing
configuration. However it led to a very stiff, noncompliant cusp material with high
internal stresses, local curvatures and kinks [99]. Due to this reason, the “second
generation” porcine aortic valves were treated with low-pressure fixation technique.
These valves supposedly had better durability, good tissue mechanics and lower internal
stresses as a result of shift to low-pressure fixation. Clinical data also showed that
Hancock II valve was found to be better than Hancock I [99, 111].
The low-pressure fixation led to invention of physiologic fixation or “zeropressure fixation”, where valves are fixed at zero transmural pressure e.g., Medtronic
“Intact” valves. One disadvantage of this is that there is excess cuspal tissue. This
problem was solved by predilating the aortic root during fixation e.g. Medtronic Freestyle
and Mosaic valves. In these valves, the aortic root is fixed at ~40 mmHg pressure and the
cusp is fixed at zero pressure. The inflow and the outflow pressure are maintained at 40
mmHg, thus maintaining the pressure gradient across the cusps to be zero [99]. This
preserved the cuspal structure and function and made it behave like fresh aortic valve
[112]. Figure 2.12 shows the physiologic zero pressure fixation process. Zero-pressure
fixation or low-pressure fixation compared to high pressure fixation was found to
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maintain the tissue in its native state though studies have found that the tissue becomes
less stiffer and have reduced tensile strength [113, 114].

Figure 2.12: Zero-pressure fixation of porcine aortic valve [112]
The recent bioprosthetic heart valves are called as the “third generation” BHVs,
which are pretreated with anticalcification agents to prevent calcification in the valves
after implantation. In these strategies, the sites of nucleation of hydroxyapatite crystals
are removed or altered. In some cases, the ability of the calcium ions to diffuse and
penetrate the tissue is inhibited thereby preventing calcification. The anticalcification
treatments are discussed in detail in a later section.

2.5.3. Tissue engineered heart valves:
Tissue engineered heart valves are newest generation of prosthetic valves that are
being currently researched. The approach of heart valve tissue engineering through
regenerative medicine uses patient’s own cells placed on synthetic or biologic scaffolds
to replace the failed valves [115]. Tissue engineered valve would be a living organ, able
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to respond to growth and other physiological forces in the same way like a native aortic
heart valve. Some of the important approaches in this field include (a) the use of
decellularized tissues as scaffolds for in situ regeneration, (b) construction of tissue
equivalents in the laboratory before implantation and (c) use of scaffolds preseeded with
stem cells. Two major approaches attempted over the years have been regeneration and
repopulation. Decellularized valves from processed human or animal tissue are implanted
in the host patients to infiltrate the scaffold, remodel and regenerate valvular tissue [116].
Immune rejection is avoided as the tissue is decellularized and antigenic determinants are
removed. The explanted valves had good repopulation of cells looking like fibroblasts
and almost complete re-endothelialization was also seen. Despite initial success, clinical
results in children were catastrophic with this approach [116-118].
The approach to develop tissue engineered heart valves was initially pioneered by
Hoerstrup et al [119]. Nonwoven polyglycolic acid (PGA) mesh was coated with a thin
layer of poly-4-hydroxybutyrate (P4HB). Trileaflet scaffolds were made out of
PGA/P4HB material by using heat-application welding technique. Myofibroblasts were
seeded onto the scaffolds for 4 days and then ECs were seeded and the valve was
transferred to a pulse duplicator reactor. The valve was grown under gradually increasing
nutrients, flow, and pressure conditions. After 14 days of maturation in the bioreactor the
valves were removed and implanted into lamb from 1 day to 20 weeks. The polymer was
resorbed and degraded, and at the same time ECM was formed. The biomechanical
profile of the tissue engineered (TE) heart valve will ultimately depend on the
organization of the formed matrix [119]. One disadvantage with this type of valve was
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that PGA constructs were thick in nature. It was tedious to form a complex 3D matrix
like a trileaflet valve. Also after implantation into sheep it was found that these valves
had mild regurgitation due to central non-coaptation. It was eventually found after 20
weeks that the TE valves had similar mechanical properties and were undistinguishable
from native aortic valves. Figure 2.13 shows the bioreactor setup and the TE heart valve
after 14 days of maturation in the bioreactor.

Figure 2.13: (A) Pulse duplicator bioreactor system consisting of two major chambers
(B) Bioreactor setting and (C) TE heart valve after 14 days of maturation in the
bioreactor [119, 120]
Collagen base scaffolds with entrapped cells were also used as a model for
making TE valves. The cells interact with the fibrils causing the matrix to contract which
mimics the in vivo wound healing. Tranquillo et al made a collagen scaffold to make a
bileaflet valve and Figure 2.14 shows the image of the mold and the bileaflet valve made
from the mold [118]. Vesely also tried making a hybrid heart valve from collagen fibers,
elastin sheaths and hyaluronan as the glycosaminoglycan component of the valve.
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Figure 2.14: Tranquillo’s original mold and the bileaflet valve fabricated by casting a
collagen gel
The big question now in everyone’s mind is “When will TE heart valves be ready
for clinical use?”. With the only clinical experience from Synergraft being disastrous it
may take upto 20 years at the least for solving the complex problems in the TE heart
valves and also test it for long-term compared to glutaraldehyde fixed valves [118]. TE
heart valves, with growth and remodeling capacity, could be more useful and beneficial
when implanted in children compared to elderly patients. Also, it has been tried so far
only in pulmonary position as it has low pressure and not in high pressure aortic or mitral
positions.

2.6. Advantages and disadvantages of various heart valve prostheses
Cardiac valve replacement with prosthetic valves enhances patient survival and
quality of life [121]. It was also reported that prosthesis associated problems necessitate
re-operation or death in 50-60% of patients with prosthetic valve. The rates of failure of
the mechanical and bioprosthetic valves are fairly similar [2, 121]. Majority of the valves
failed due to one of the four reasons (a) thromboembolism, thrombosis and
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anticoagulation-related hemorrhage; (b) valvular endocarditis; (c) structural dysfunction
(degeneration and calcification); and (d) nonstructural dysfunction (e.g., tissue
overgrowth, paravalvular leak, hemolysis etc). The failure can vary with prosthesis type,
size, mode, site of implantation and patient characteristics like age and activity level [2,
121]. Mechanical prosthesis is generally associated with failure due to thromboembolism
and thrombotic occlusions requiring anticoagulation. However contemporary mechanical
valves are durable and structurally reliable [2, 3].
Tissue valve prostheses have low rates of thromboembolism and they do not
generally require chronic anticoagulation. They also have a major advantage with regard
to the central flow pattern and are found to be more thromboresistant than synthetic
materials. These valves without anticoagulation regime are found to have
thromboembolism similar to the mechanical valves with anticoagulation treatment. The
tissue valves fail by mean of two mechanisms: structural dysfunction owing to
progressive tissue deterioration and calcification (devitalized cell mediated calcification
and calcification at sites of damaged collagen) [2, 3, 121]. It has also been found that the
loss of glycosaminoglycans has been detrimental to the durability of the tissue valves
[27]. The modes of failure of the bioprosthetic valves are discussed in detail later.
Though mechanical and tissue valves have their own pros and cons, it is better to
judge as to which valve should be used based on individual patients, their characteristics
like age, other complications etc., in order to best suit them.
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2.7. Glutaraldehyde fixation of bioprosthetic heart valves
The homograft or the xenograft obtained from humans or animals are treated with
chemicals to crosslink the tissue to avoid any tissue degeneration and deterioration. This
process maintains the materials original structure, mechanical integrity, and removes or
neutralizes the antigenic properties of these BHV materials [122, 123].
The fixation of BHVs involves a chemical agent or a physical process resulting in
irreversible and stable intra and inter molecular chemical bonds within the components of
the tissue. The chemical fixatives generally form bonds between the functional groups of
amino acids or carboxyl groups to stabilize the tissue [123]. Heart valves, vascular grafts,
elastic cartilages, tendon xenografts, artificial skin are some of the bioprostheses that
generally go through the fixation process [122].
From invention of biological valves in the 1960’s, there was a hard pressed need
to stabilize these tissues before implanting them into humans. Formaldehyde, a common
preservative of biological substances, was initially used and it was found to provide the
desirable tissue stability. However, the long-term durability of bioprostheses fixed in
formaldehyde was found to be inferior compared to glutaraldehyde. Ever since the
introduction of glutaraldehyde in 1969, it has been used successfully for fixing BHVs and
has reigned the fixation of bioprosthetic heart valves and is the major FDA approved
fixative for these valves. Glutaraldehyde is a cheap, readily soluble in water, which when
used as a fixative has a low incidence of valve-related complications, though the harmful
effects of glutaraldehyde are being researched by many scientists. Glutaraldehyde makes
tissue non-viable, non-biodegradable, and non-thrombogenic while preserving the
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anatomic integrity, cuspal strength and flexibility [122, 123]. The fixation chemistry of
glutaraldehyde and how it is superior to formaldehyde is discussed in the ensuing section.

2.7.1. Fixation chemistry:
Glutaraldehyde is highly soluble in water and in aqueous solutions it occurs either
as free aldehyde, monohydrate and dihydrate glutaraldehyde, monomeric and polymeric
hemiacetals and various unsaturated polymers [123]. Figure 2.15 shows the different
forms of glutaraldehyde in aqueous medium. Commercially available BHVs are usually
treated with a low concentration of glutaraldehyde solution (typically around 0.5%) for
more than 24 hrs to ensure optimum fixation. Glutaraldehyde is a five-carbon aliphatic
molecule (1,5-pentanedialdehyde) with an aldehyde at each end of the chain makes it
bifunctional.

Figure 2.15: Different forms of glutaraldehyde in an aqueous medium [123]
Glutaraldehyde chemically interacts with the collagen molecules in the tissues
especially with the amino groups of lysine to form a chemical bond. It can bind two
collagen molecules together as it is bifunctional. It is presumed that the cross-linking is
by inter and intra molecular manner by formation of covalent bonds.
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The bond formation occurs in two major ways: (a) Schiff bases are formed by the
interaction of an aldehyde group with the amino groups of lysine or hydroxylysine
residue of the collagen molecule or (b) By aldol condensation between the two adjacent
aldehydes. Figure 2.16 shows the schematic of the formation of Schiff’s base using a
simplified representation of monomeric glutaraldehyde with amino groups of collagen.
The Schiff base linkage is not a very stable bond but the aldol condensation product is
very stable. Glut, apart from interacting with the amino group of collagen, also interacts
with the carboxyl, amide groups of proteins. The order of reactivity of glutaraldehyde
with different compounds is as follows: primary amines > peptides > guanidines >
secondary amines > hydroxyl groups.

Figure 2.16: Schiff base formation between monomeric glutaraldehyde and amine
groups of collagen
Glutaraldehyde stabilizes tissue better than other aldehydes and formaldehyde.
Also, lower concentration of glutaraldehyde is found to be better than higher
concentration for bulk tissue fixation. When using higher concentrations of
glutaraldehyde, the surface cross-linking increases rapidly and so it causes further
penetration of the fixative difficult and thus tissue may not be properly fixed [122-125]. It
has also been found that GLUT fixation alters the internal shear properties of porcine
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aortic valves [126]. Due to these changes, the valve tissue flexing during opening and
closing is altered thereby resulting in valve fatigue [126].
Glutaraldehyde had been used for fixation despite changes to tissue properties.
Formaldehyde was used as fixative even before glutaraldehyde and it was found that the
formaldehyde fixed tissue had desired tissue stability. Long-term durability was affected
due to the reversible fixation by formaldehyde. Also being mono-functional, it can react
with only one collagen molecule. The initial stability of fixation was lost when exposing
the fixed tissue to dynamic conditions which reversed the formaldehyde formation.
Figure 2.17 shows a schematic of the reversible reaction of formaldehyde. The crosslinks
were susceptible to dissociation when stored at 37°C in normal saline over 10 months. It
was also found that the treatment with formaldehyde resulted in cusp stretching,
deformations, reduction in collagen matrix and increased immune response. Due to these
reasons, formaldehyde was discontinued and glutaraldehyde has been used since then
[122, 123].

Figure 2.17: Formaldehyde cross-linking reversible reaction
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2.7.2. Harmful effects and shortcomings of glutaraldehyde crosslinking:
Glutaraldehyde is known to depolymerize and tissue treated with glutaraldehyde
released by-products into the recipients. The toxic effects of glutaraldehyde though being
minimal and tolerable, may be detrimental for the patients in long-term [96, 123]. Three
major detrimental effects of glutaraldehyde crosslinking are as follows: (a) Residual
glutaraldehyde and its reaction products have known pro-calcific effects and exacerbate
tissue calcification, (b) The inability of the crosslinking mechanism to block or mask the
antigenicity and the calcium nucleation sites, and (c) The mechanical damage attributed
to the tissue stiffness from this crosslinking procedure [96].
Residual or unstable glutaraldehyde remaining in the interstices of the crosslinked
tissue has been implicated for the inflammatory response, cytotoxicity, calcification, and
lack of endothelialization [122]. The concentration of glutaraldehyde used for
crosslinking determines the intensity of the biological response. Low concentration of
glutaraldehyde (0.2 – 0.5%) was found to have very little response as compared to high
concentration of glutaraldehyde (3 - 5%) [127]. The use of glutaraldehyde in
bioprosthetic heart valves can be beneficial or detrimental. It may be advantageous when
the glutaraldehyde fixation hinders the cellular ingrowth due to its cytotoxic nature
reducing macrophage activity. It is detrimental for the same reason that it hinders the
growth of endothelial cells on the surface. Endothelialization may impart better blood
compatibility to BHVs. It has also been found that longer duration of glutaraldehyde
crosslinked tissue showed the least antigenicity [115, 122, 128, 129].
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Modifications to the tissue to overcome the abovementioned shortcomings are
discussed here. It has been shown that thorough rinsing of the glutaraldehyde fixed tissue
extensively in normal saline for three times 10 to 20 mins, prior to implantation reduces
cytotoxicity [122]. Also these tissues were found to be least toxic when they were stored /
treated in propyl- and methylhydroxybenzoate or glycine [130]. Residual glutaraldehyde
can be removed by treating the tissue with bisulphate washing [131]. Amino Oleic Acid
(AOA) treatments, has been found to neutralize the residual glutaraldehyde as well as
hinder calcification by reducing the calcium diffusion through the tissue [115]. AOA with
its amino groups binds to the free aldehyde in the tissue. This treatment not only allowed
endothelial cell growth but was found to reduce and mitigate calcification [96].
Neutralization of free aldehydes has been done by reactive amine rich compounds such as
glutamine, glycine, lysine and homocysteic acid [115]. Urazole (1,2,4-triazole-3,5-dione)
was found to be a better neutralizing agent by Zilla et al [96]. Most importantly,
glutaraldehyde only stabilizes the collagenous component of the bioprosthetic heart
valves and it fails to stabilize other extra cellular component matrices such as
glycosaminoglycans and elastin. It has been found that loss of these components may
result ultimately in valve failure [21, 27, 38, 132-134]. The detailed section regarding the
loss of glycosaminoglycan and its stabilization is discussed later. Also nonglutaraldehyde based and other fixatives for biological heart valves are discussed later.
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2.7.3. Alternative fixatives:
In order to solve the problem posed by treating valvular tissue by glutaraldehyde,
various different alternative fixation chemistries were proposed by researchers. Physical
methods of crosslinking include ultraviolet irradiation [4] and dye mediated photooxidation (PhotoFix®, Carbomedics, Austin, TX) [5]. Alternative chemical fixatives
include stabilization using epoxy compounds [6, 7], diphenylphosphorylazide [8], acyl
azides [9], cyanamide [9], diisocyanates [10], diglycidyl ether [11], polyethylene glycol
(PEG) [12], carbodiimide (Ultifix®, Medtronic, Minneapolis, MN) [1, 13, 14], diamine
bridges [15] [16], triglycidylamine [17-19], periodate [20-22], reuterin [23, 24] and
genepin [25].
Epoxy treatments to bioprosthetic tissue are gaining interest as the tissue retains
its pliability and appearance after treatment. Though considerable research and
experimental success has gone into most of these alternative fixation strategies, there has
been only little translation of this success into clinical environment. Dye-mediated photo
oxidation and carbodiimide treatments have made their way into clinical trials. In dyemediated photo oxidation the bioprosthetic tissue is immersed in a dye which is photooxidative and this is followed by exposing the tissue to light of specific wavelength
thereby resulting in crosslinking of the tissue [2].
Also tissues that are treated with most of these alternative fixatives exhibit
reduced calcification than the conventional glutaraldehyde treatment. However, the
mechanisms behind the calcification of tissue using these alternate fixatives need to be
further investigated [135].
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2.7.3.1. Triglycidylamine (TGA)
Triglycidylamine (TGA) is a novel polyepoxide crosslinker that is used as an
alternative fixative to glutaraldehyde. TGA is used to crosslink porcine heart valve cusps,
bovine pericardium and type I collagen. It is found that the materials treated with TGA
had similar shrinkage temperature like glutaraldehyde treated tissue, improved
compliance and increased resistance to collagenase. Also, TGA treated tissue showed
significantly lower calcification after rat subdermal implantations, and reduced
expressions for matrix metalloproteinase - 9 (MMP-9) and tenascin – C. TGA
crosslinking also resulted in the bioprosthetic tissue with improved biomechanical
properties than GLUT treated tissue [17]. TGA crosslinking has also been implicated for
reduced alkaline phosphatase activity [18].

2.8. Biomechanics of heart valves
Heart valves are complex cardiac structures that ensure unidirectional blood flow
during the cardiac cycle. HV biomechanics can be approached in a multi-length-scale
approach as the mechanical stimulus has a biological impact on the organ, tissue and the
cellular level as shown in Figure 2.18. The hemodynamic environment surrounding the
heart ensures the way in which the heart valve behaves and functions. Proper
understanding of the hemodynamic conditions is necessary to understand the functions of
a normal and a diseased valve [47].
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Figure 2.18: Schematic of biomechanics of heart valves at multi-levels [47]
Mitral valve and aortic valve control flow of oxygenated blood whereas, tricuspid
and the pulmonary valve control flow of deoxygenated blood to the lungs. When the
ventricles are contracting during systole, the aortic valve opens and the pulmonary valve
closes. During the diastolic phase, the ventricles get filled through the open mitral and
tricuspid valves. The valves present in various locations of the heart experience varied
pressures. The tricuspid and the pulmonary valve withstand about 30 mmHg, aortic valve
about 100 mmHg and mitral valve about 150 mmHg. Because of the extreme pressures
acting on the valves present on the left side of the heart, they are more prone for cyclical
fatigue and failure [136]. The biomechanics at the organ and tissue levels are discussed
here.
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2.8.1. Biomechanics at organ level
The flow velocities through the aortic valve reach peak values of about 1.35 ±
0.35 m/s during systole. During end of systole, due a very small reverse flow, it become
zero. Due to adverse pressure difference in the axial direction, a low inertial flow is
created along the aortic wall causing reverse flow with small vortices in the sinuses of the
aortic valve. The action of the vortices help the valves close in a better coapted manner,
as studies have shown that axial pressure difference alone is enough for the closing of
valves but not as efficient when coupled with the vortices. The pulmonary valve has
similar velocity profile like aortic valve but much less peak velocities (0.75 ± 0.15 m/s).
Valve geometry determines the flow patterns through the valve and flow patterns can be
found using Doppler anemometry. This can be used to evaluate the function of the heart
valves [47, 137-139].
When mitral valve opens, blood flows from left atrium to left ventricle with a
flow velocities of about 50 to 80 cm/s. After ventricular relaxation, the mitral valve
closes partially. In late diastole, the atrium contracts more, pushing blood at lower
velocity of about 1.5 to 1.7 cm/s through the valve. The tricuspid valve flow parameters
are similar to mitral valve although it has much lower velocities due to its higher orifice
area. Also it has been found that the pressure gradient plays an important role in the
closing of the mitral valve and only slight contribution comes from the vortices during
closing [137-141]. The valves have to provide an efficient unidirectional flow of blood
with minimal fluid loss or regurgitation. Due to the interaction of the blood with the
valves during flow, extreme shear stresses are developed in the valvular cusp surfaces.
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Figure 2.19 shows the typical pressure and flow curves of mitral and aortic valves [47,
136].

Figure 2.19: Typical flow and pressure curves of aortic and mitral valves [136]

2.8.2. Biomechanics at tissue level
Heart valve cusps have a unique architecture composing of three major layers:
ventricularis, fibrosa and spongiosa. Fibrosa is rich in collagen fibers and they are
arranged in a circumferential manner and are known to be the major load bearing layer of
the cusps. Ventricularis with its elastic fibers provides the elastic nature of the cusps.
Collagen fibers are well known to withstand high degree of tensile stresses but have poor
torsional or flexural stiffness. Therefore by determining the directional orientation of
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these fibers we can determine the direction where the valves can withstand maximum
tensile stresses. Small angle light scattering (SALS) was used to quantify the fiber
architecture of the valve cusps and in a study, valves with varying transvalvular pressures
were used. Increasing the transvalvular pressure changed the fiber architecture until a
certain pressure (~4 mmHg) after which there was no detectable improvement in the fiber
alignment Figure 2.20 (a-d) shows the architecture of the valves and collagen fiber
orientation at various transvalvular pressure [47, 136, 142-144].
Collagen fiber architecture gives macroscopic crimps on the fibrosa side of the
valvular cusps. Also the fibers have microscopic crimps varying with different pressure
and the forces acting on the valves. Sacks et al, quantified these collagen crimps as
percentage of the histological cross sectional area. It was observed that there were about
60% of undulations present at a transvalvular pressure of 0 mmHg which was
straightened at 1 mmHg. At 4 mmHg, the undulations were very rarely seen and at 90
mmHg they were completely absent. Figure 2.20e shows the collagen crimp percentage
with respect to the varying transvalvular pressures [142-144].
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Figure 2.20: Cuspal nomenclature, collagen fiber orientation by SALS and collagen fiber
crimp % at various transvalvular pressures [47, 142-144]
The tissue level functions were predominantly dominated by the tensile strength
to resist the transvalvular pressures. This leads to large rapid directional strain during
opening and closing of the valves. The unique structural layers of the cusps provide the
ability to perform various functions at tissue level. The type I collagen present in the
fibrosa helps to withstand most of the tensile load acting on the cusps. It also allows for
modest strains in the circumferential direction followed by rapid stiffening and they
rotate towards the stretch axis. The elastic fibers in the ventricular do not allow rapid
retraction of the fibers in the radial direction during valve opening [47, 136].
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Biomechanics of heart valves occurs in two modes: in-plane stretch and flexural
deformation. Flexure occurs when the valve opens and closes, tension when the valve is
fully loaded and in coaptation position, and shear stress on the surface due to blood flow
[47]. The biomechanical behavior of the heart valves is much more complex: they have
highly non-linear stress-strain relationships, large deformations and complex viscoelastic
properties. Due to this nature, it was difficult to model valve biomechanics. The
conventional uniaxial testing can only provide the information of the stiffening of the
valve cusps after fixation. It will not be very effective as uniaxial testing cannot mimic
the stress acting on varying axes at the same time. Equibiaxial testing however
overcomes this problem. Billiar et al developed the first biaxial testing for aortic valve
cusps necessary for constitutive modeling of the heart valve cusps [143, 144]. The cusps
demonstrated a highly anisotropic behavior and exhibited a strong mechanical coupling
between the radial and circumferential directions. Due to the mechanical coupling, it can
be seen from Figure 2.21 that there are negative strains produced in the circumferential.
Figure 2.21 shows the setup of the biaxial tensile testing system, the biaxial mechanical
data from fresh and fixed tissue, and mechanical data depicting the dependence of strain
on the anisotropic nature of the samples [47, 136, 142-144].
Flexural response measurements are advantageous because even minor changes in
stiffness at low stress-strains as well as the contributions of the individual layers can be
detected. The valve sections were subjected to flexure with and against the curvature.
This helps in applying alternate states of tension or compression to fibrosa or
ventricularis of the cusps. During flexion with curvature, there was tension in
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ventricularis and compression in fibrosa. During flexion against curvature, there was
compression in ventricularis and tension in fibrosa as depicted in Figure 2.22. Using this
experiment the bending moment is calculated with respect to change in curvature [47,
136, 141-144].

Figure 2.21: (a) Schematic of biaxial mechanical test of heart valve cusp, (b) fresh and
fixed tissue biaxial mechanical data and (c) biaxial data from tissue with varying
anisotropies [47, 136, 142-144]
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Figure 2.22: (A) Schematic of direction of bending with respect to different layers, V –
ventricularis, S – Spongiosa and F – Fibrosa, (B) Schematic of the pre-stressed nature of
the heart valve cusps [26, 47, 145]

2.9. Modes of failure of bioprosthetic heart valves
Some of the major failure modes of bioprosthetic heart valves are progressive
structural valve deterioration, dystrophic calcification, and inflammation / immune
reaction response. Other modes of common valve failure include infective endocarditis,
thrombosis, paravalvular leaks and pannus or tissue growth [2, 96, 110, 135, 146]. The
major modes can be classified into calcific and non-calcific failure modes. Table 2.2 lists
the failure modes of bioprostheses [110].
Structural (tissue) failure modes
With calcification
Without calcification
Infection
Thromboembolism
Paravalvular leak
Tissue Overgrowth
Hemolysis
Table 2.2: Failure modes of bioprostheses [110]
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2.9.1. Calcification
BHV failure due to calcification is a predominant mode of failure in tissue treated
with glutaraldehyde. Calcification is accelerated when these bioprostheses are implanted
in children and young adults. Calcification occurs as an intrinsic mineralization process
and begins deep within the cuspal tissue, where in poorly crystalline hydroxyapatite
crystals are deposited within the valve structure. Calcium deposits are found to
predominate at cuspal commissures and the basal region of the cusp belly, although they
may occur at any other site in the cusp [2, 96, 110].
It has been found that the prosthetic heart valves calcification has the following
determinants [147]:
•

Host factors (e.g. immature subjects calcify bioprosthetic tissue more rapidly than
adults)

•

Fixation conditions (e.g. glutaraldehyde crosslinking aggravates tissue calcification)

•

Mechanical effects: deposition of calcium phosphates occurs more rapidly at regions
of maximum stress concentration in BHVs
The pathogenesis of calcification involves an interaction of these various

determinants. Calcification is initialized in the devitalized connective tissue intrinsic to
the bioprosthetic tissue, subsequently to the calcification of ECM, more prominently
collagen in cusps and elastin in aortic wall. The determinants of the calcification process
are explained in Figure 2.23C.
Commercially available bioprosthetic heart valves are all fixed with
glutaraldehyde (GLUT). Unfortunately, GLUT is found to be a major contributor and
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exacerbates calcification in BHVs. Glut causes devitalization of cells resulting in
calcification [135, 146, 148-150]. Also the free aldehyde residue causes cytotoxicity and
induces cell / tissue necrosis and eventually calcification. Devitalized cell mediated
calcification occurs in two major phases: nucleation and propagation. Calcium derived
from plasma reacts with organic phosphorus in the crosslinked, non-viable cells. Living
cells have energy dependent pumps to maintain low levels of intercellular calcium where
as non-viable cells cannot extrude the calcium out of the cells. This results in high
concentration inside the cells resulting in calcium phosphate crystals nucleation.
Propagation of the crystal formation further depends on the concentrations of the Ca2+
and PO43- and the balance of calcification accelerators and inhibitors. The crystal
formation is largely associated with the cell membranes [2, 110].
Mechanism of calcification of collagen and elastin are still poorly understood. In
collagen, calcification occurs at areas of damaged collagen and free aldehyde groups
attached to collagen after crosslinking. In case of elastin, calcification occurs whether or
not it is crosslinked. In the native arteries, disruption of elastin has been implicated
directly to elastin specific calcification [2, 146]. Since elastin is not stabilized by GLUT,
it is more prone for degeneration in glutaraldehyde fixed bioprosthetic valves. Elastin
degradation would be detrimental in case of stentless valves as the aortic wall is more
prone for elastin calcification [146]. Stented BHVs should also be researched more in this
regard, even though the elastic aortic wall is covered in Dacron cloth, as it might be only
a matter of time before these valves begins to fail due to the cascade of calcification [2,
146].
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Early calcification in the cusps is grossly seen as small, yellow-white or pinkwhite mass and can ulcerate as they grow larger. Spongiosa of the porcine valve has been
found to be the greatly calcified layer through histology. Histological and ultrastructural
examination of human and animal explanted valves has shown deposits localized in
connective tissue cells and also extracellular collagen fibers as shown in Figure 2.23 [2,
110]. Figure 2.23 also shows the schematic of calcification and an image of a valve
failed due to calcification.

Figure 2.23: (A) Calcification of a native valve in an aged individual, (B) Calcification
in collagen fibers as seen by ultrastructural examination and (C) Schematic of
calcification process and its determinants [2, 147, 151]
Vascular calcification and bioprosthetic valve calcification resembles bone
formation. In case of bone, calcification is regulated by (a) osteopontin, (b) osteonectin,
(c) osteocalcin and matrix GLA protein. Osteopontin has been shown to inhibit
calcification of vascular SMC’s and has been demonstrated in case of calcified
bioprostheses explanted from humans [2].
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2.9.2. Degeneration and structural dysfunction
Degeneration and structural dysfunction occurs to valves due to mechanical injury
and damage occurring to the collagen fibers. Transmission electron microscope evidence
suggests that collagen is damaged and also separation occurs at the end of the fibers.
Tearing occurs on these BHV cusps, localized mainly at the stressed regions of the cusps,
such as valvular commissures and points of maximum flexion [96, 110]. Figure 2.24
shows the image of a bioprosthetic heart valve damaged due to cuspal tear.

Figure 2.24: Structurally damaged bioprosthetic heart valve
Various reasons for the structural matrix damage occurring to the valve include
abnormal valve motion, inhibition of structural rearrangements which occur during
normal valve function, loss of cell-mediated remodeling and replenishment of ECM,
local buckling of tissue, and damage due to chemical and possibly mechanical
determinants. The native aortic valve functions on the combination of micro and macro
mechanics, which helps in avoiding acute bending angles. In native aortic valve, the
annulus dilates during systole resulting in a triangular shaped valve opening avoiding
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bending less than 60°. In BHVs, either stented or stentless, the dilation of the annulus is
either limited or eliminated due to fixation or presence of stent. This results in acute
bending of the valve cusps, reverse curvature and buckling. This process is depicted in
Figure 2.25, which shows the native valve in closed position (top left), open position (top
right) and the BHV in open position (bottom) [2, 110].

Figure 2.25: Root mechanics of native aortic and bioprosthetic valves [96]
Chemical treatment of the cusps for fixation results in increased flexural stress
that causes damage to cuspal collagen fibers in regions subjected to compressive stresses.
The biochemical and molecular changes caused to collagen due to fixation also contribute
to progressive damage and the propensity of the BHVs to calcify. The damage to
collagen not only triggers macrophage activity but also facilitates protease and matrix
metalloproteinase (MMP) digestion [2]. Since GAGs are important for absorbing the
shear and compressive forces acting on the cusps, loss of GAGs may be important in
mechanically mediated valve failure [2]. The mitral valves were seen to be more prone
for mechanical damage and tears. This could be because the increased closing pressure of
the mitral valve [96, 110].
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The functional life and durability of bioprosthetic heart valves seems to be 12-15
years, after which failure is either through structural deterioration / degeneration or tissue
mineralization. It has been seen that mineralization occurs in areas of structural
degeneration, although degeneration has been reported to occur independently. Failures
due to calcification and degeneration either combined or isolated have been reported on
explanted valvular shows that the two modes have failure occur distinctively at different
regions (Figure 2.26) [2, 152, 153].

Figure 2.26: (a, b) Areas of damaged collagen and calcification in explanted valve
imaged using SALS, (c, d) X-ray image of the valve cusps showing calcification
It has been found that fatigue causes degeneration in the valvular cusps especially
in the collagen fibers. Type I collagen fibers present in the valvular cusps are found to be
damaged due to fatigue and rearranged. ATR-FTIR spectroscopic images of control
uncycled glutaraldehyde fixed cusps and 5 million cycled cusps showed an additional
peak in the amide I region (1645 cm-1). This suggests that the collagen fibers are
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damaged and rearranged due to fatiguing of valves [27]. Figure 2.27 shows the
rearrangement and the appearance of the new peak in the FTIR spectra.

Figure 2.27: FTIR spectra for type I collagen films (a) uncycled glutaraldehyde
crosslinked collagen and (b) 5 millions fatigued glutaraldehyde fixed film [27]

2.9.3. Inflammation and immunologic degradation
Inflammatory cells were found to cover the surfaces at either monolayer density
or infiltrate into the tissue. “War formations” of macrophages are serious culprits of
destruction, due to severe potential of macrophages and giant cells to degrade even
synthetic materials. Remnant tissue immunogenicity was found to be mitigated, not
completely eradicated, by using diamine extensions of glutaraldehyde linked tissue [96,
129, 154]. Destructive macrophages were primarily found only in the fibrosa of the cusps
[154, 155]. The inflammatory process could be eradicated by using higher concentrations
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of glutaraldehyde. When cusps were fixed with higher concentrations of glutaraldehyde
cusps were completely free of inflammation [15]. But using higher concentration of
glutaraldehyde would bring in a whole gamut of toxicity problems.
Widespread evidence today demonstrates that the immune reaction from the host
damages the implanted tissue through immune mechanisms [96]. It has been found that
(a) crosslinking reduces tissue antigenicity but does not eliminate it, (b) experimental
animals are sensitized by both fresh and crosslinked valve tissue, (c) Antibodies to valve
components can be seen in patients diagnosed following valve dysfunction and (d)
mononuclear inflammation is seen sometimes in failed tissue valves [2]. Therefore,
BHVs are more prone to inflammation mediated failure.
Though only low concentrations of glutaraldehyde are used, the tissue
crosslinking just reduces the remnant tissue antigenicity by many folds. It does not
completely eliminate and abolish the immunologic reactions from the host tissue. The
crosslinking by low-dose glutaraldehyde fails to alter certain components such as the cell
receptors, and glycoproteins that can elicit cellular and humoral response [96, 154]. The
possibility of immunologic reactions damaging the valvular implants should never be
excluded. These reactions may lead to increased fibrosis resulting in valve failure. Host
tissue overgrowth also known as pannus growth results from immune reactions and
consequently results in progressive cuspal stiffening. This pannus may extend from the
valvular tissue flow side into the sinuses area and can eventually block the coronary sinus
orifices leading to more severe consequences [110]. Pannus overgrowth is dealt
separately in the other modes of failures of BHVs in the next section.
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There are conflicting hypothesis posed by researchers with respect to
immunogenic process resulting in either calcific or non-calcific failure of bioprosthetic
heart valves. But the extents to which the BHVs are damaged either by calcific or noncalcific manner through immunologic mechanisms are still unknown, uncertain and need
to be researched [2]. None the less, Zilla et al, found that there is a link between
calcification and immune response by demonstrating that there is a threefold higher
calcification in the aortic-wall tissue which was pre-incubated in serum containing high
levels of graft-specific antibodies. This provided the direct immune-calcification link
[96]. There is also evidence that proves otherwise, it was found that the valvular
endothelium may uniquely resist immunological reactivity. They have also found that
regional endothelial cell properties prevent leukocyte adhesion to the aortic valves [2].
Until we have more thorough evidence as to whether the immunologic response is
affecting the valve failure through either calcific or non-calcific manner, this area is
highly debatable and controversial.

2.9.4. Other common modes of failure
2.9.4.1. Pannus overgrowth
Overgrowth of tissue across the sewing ring, suture material, dacron fabric, or the
valve itself especially in case of bioprosthetic valves can lead to orifice narrowing and
cusp immobilization. Inflammation greatly bears responsibility for this growth of
hyperplasic tissue causing sustained growth signals. Inflammation causes a chronic
foreign-body reaction against the sewing-ring material. Macrophages and the giant cells
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are the dominant cells causing this reaction and they secrete a wide range of cytokines
and growth factors such as interleukin-I (IL-1), platelet-derived growth factor (PDGF)
and basic fibroblast growth factor (bFGF) [96, 154].
Inflammation here may be due to insufficient antigen masking of the bioprosthetic
tissue itself. Diamine crosslinking at 3% glutaraldehyde, followed by thorough
glutaraldehyde detoxification, resulted in near abolition of inflammatory response and
also in significant suppression of pannus growth [96, 154]. It has also been noted that the
manner of the surgical procedures especially in the mitral site leads to a greater degree of
pannus formation. The prostheses become stenosed or incompetent due to pannus growth.
Also, pannus formation happens on the inflow side in aortic position and occurs both on
the atrial and ventricular side in mitral position [110, 154].
2.9.4.2. Infective endocarditis
Infective endocarditis is rare yet life threatening complication associated with the
prosthetic valves occurring in about 1-6% of the patients, especially within the first 2
years of surgery. It can also occur sporadically throughout the lifespan of the prosthetic
valve [110]. It has been reported even after 15 years of surgery which is fairly uncommon
[156]. This disease is characterized by the colonization of the endocardium by bacteria or
other microorganisms, leading to formation of vegetation on the valvular tissue or
material. Large majority cases are due to common microorganisms seen in hospitals and
even on patient’s skin. Early infections were due to such kind of bacteria present in the
skin like Staphylococcus epidermis, gram negative bacteria [157, 158]. Later causes
might be due to infection by Staphylococcus aureus which results in acute endocarditis
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leading to valvular damage within days to a week. Subacute endocarditis is caused by
Staphylococcus viridans and can sometimes persist from weeks to months without
detection. Some of the major complications due to endocarditis are incompetence or
insufficiency, embolization of the infected vegetations, paravalvular abscess leading to
paravalvular leaks, tissue necrosis and hematomas at site of surgery and pericarditis.
These vegetations often lead to obstruction of the prosthesis as can be seen Figure 2.28
[110, 156-159].

Figure 2.28: Large central vegetation occluding the orifice due to infective
endocarditis [156]
2.9.4.3. Thrombus
Thrombosis is one of the most severe complications of cardiac valve replacement,
having 0.5% incidence in aortic and mitral valve positions and about 20% in tricuspid
position. Despite the varied changes in the valve designs and improvements in the
operating technique, thromboembolic complications remain a major cause of postoperative morbidity and mortality. Major contributing factors for thrombosis remains to
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be the surgical technique used and the inadequate anticoagulation therapy. Pannus growth
and fibrous tissue formation also contribute to the generation of thrombi.
Thrombus formation could be due to direct consequence of thrombogenic surface
of the prosthesis, altered transprosthetic blood flow or inadequate anticoagulation, left
atrial geometry and function, including atrial fibrillation or a loss of active atrial
contraction. Thrombus formation is divided in to four classes from I to IV. I and II are
usually incidental echocardiographic findings in patients with evidence of stroke or
embolism. Class III and IV corresponds to obstructive forms with hemodynamic
repercussions, including cardiac shock often associated with cerebral or peripheral
embolism. Common modes of detection are using fluoroscopy, Doppler evaluation,
transthoracic echocardiography (TTE) or a transesophageal echocardiography (TEE).
Treatments for thrombosis formation usually are generally the replacement of the
prosthetic valve, though sometimes it can be just a thrombectomy (removal of thrombus
by surgery) or thrombolytic treatments and therapies [110, 160, 161].
2.9.4.4. Paravalvular leak
Paravalvular leaks are usually associated with and caused by infective
endocarditis. Initially, paravalvular leaks were due to poorly placed sutures, failure of the
suture knots, “cutting through” of sutures (suture tearing adjacent tissue) and significant
calcification of valve annulus. Late paravalvular leaks are caused by gaps between
sutures resulting in small paravalvular leaks. Even the smallest of these leaks may
increase hemolysis and may be associated with congestive heart failure and increase the
risk of infection and therefore have to be treated surgically [110].
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2.9.4.5. Hemolysis
Hemolysis is generally seen with older generation mechanical valves and rarely in
the new generation prosthetic valves. Bioprosthetic heart valves generally have very little
hemolysis. However, in damaged, calcified and torn valves, hemolysis can be clinically
significant. Paravalvular leak associated with prosthesis also tends to increase hemolysis
along with increased potential for endocarditis [110]. The next section deals with anticalcification treatments.

2.10. Anti-calcification treatments
Calcification being a major mode of BHV failure, various strategies were
developed in order to prevent calcification. The three basic strategies are: (a) systemic
therapy with anticalcification agents; (b) local therapy with implantable drug delivery
devices; and (c) biomaterial modifications either by removal of calcifiable component or
by chemical modification [2, 3]. Systemic methods were found to have a major
drawback. They were found to interfere with physiologic calcification (i.e., bone growth)
and often resulted in shunted growth, and so they cannot be effective for valvular
calcification. This drawback was overcome by using controlled drug delivery at the local
site [3]. However this approach is yet to be used and implemented clinically. The best
approach though would be to modify the substrate by chemical treatment or remove
calcifiable compounds or by binding an inhibitor [2, 3]. Various agents have been studied
in detail for anti-calcification. Table 2.3 lists some of the important agents and their
mechanism of anti-calcification.
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Diphosphonates such as ethane hydroxybisphonate (EHBP) inhibited calcification
by poisoning the growth of calcium crystals. Trivalent ions such as iron and aluminum
prevent calcification as these cations complexes with phosphates and prevented calcium
phosphate formation and nucleation [2, 3]. Amino oleic acid (AOA) binds to
bioprosthetic tissue by amine linkage and prevented calcium flux into the tissue [115,
162]. Surfactants and detergents such as sodium dodecyl sulfate (SDS) extracted the
phospholipids resulting in reduced calcification [146]. Ethanol preincubation especially
greater than 80% is known to extract almost all the phospholipids and cholesterol from
the cusps thus preventing calcification of cusps. Also ethanol treatment was found to
cause permanent alteration to the collagen conformation and also it enhances cuspal
resistance to collagenase, thus preventing collagen associated calcification [3, 146].
Decellularization of the heart valve tissue also resulted in reduced calcification [3].

Table 2.3: Anticalcification agents and their mechanisms [2]
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The above said agents would fall in one of the three major categories for anticalcification as described below. BHV calcification is mainly due to three important
implant factors: GLUT residual toxicity, devitalized cells, and ECM components in BHV.
Several approaches and agents have been used to target one or more of these problems.
•

Anticalcification targeted towards GLUT
Since glutaraldehyde (GLUT) is considered and portrayed as “villain” causing

calcification, attempts are made to replace it with “mild” fixatives. Zero length fixatives
that do not leave any residue in the tissue has been used, such as dye mediated
photooxidation (PhotoFix®, Carbomedics, Austin, TX), carbodiimide based fixation
(Ultifix®, Medtronic, Minneapolis, MN) and UV light crosslinking. Also other
crosslinkers like epoxy based materials, acyl azides, diisocyanates and genepin have been
used. Edwards Life Sciences used a technology called Thermafix® which uses heat
treatment to mitigate calcification. The hypothesis behind this technique being that the
heat treatment denaturing the proteins and phospholipids involved in calcification. But no
further evidence is proposed to this hypothesis [135, 146, 163-165].
Several other treatments are used to neutralize the aldehyde handles and residues
present in the BHV tissue. This is done using agents such as glutamine, glycine, lysine,
homocysteic acid and amino-oleic acid. AOA is found to be a good anticalcification
agent by Chen et al [166]. They demonstrate that AOA binding reduces the calcium
diffusion across the tissue. AOA may act as detergents to remove the phospholipids from
the tissue. Secondly, bound AOA might chelate calcium and inhibit nucleation of calcium
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phosphate crystallization and finally retards the calcium flux across the tissue. However,
AOA does not to prevent aortic wall calcification [166].
•

Anticalcification targeted at phospholipids and devitalized cells
Detergents and surfactants such as SDS, poylsorbate 80, Triton X-100, organic

solvents such as ethanol, ether, chloroform / methanol mixtures and other
Decellularization methods were found to remove cellular remnants and phospholipids
from the BHV tissue. Combination of ethanol (~40% by volume) and ~1.2% Tween-80
for phospholipids extraction has been used by Edwards Lifesciences and termed as
XenoLogix® [167]. Another major treatment used for extraction of phospholipids is
ethanol treatment (more than 60% volume)which is marketed by St Jude Medical Inc in
their Linx® and BiLinx® treated valves [148]. This treatment was found to be effective in
porcine cusps, bovine pericardium and partially effective in case of aortic wall
calcification. 80% aqueous solution of ethanol was found to extract almost all
phospholipids, cholesterol thereby preventing devitalized cells mediated calcification
[146].
•

Anticalcification targeted towards extracellular matrix components
Extracellular matrix components are damaged during chemical modification and

it is unfortunate that only little attention is given towards, collagen and elastin damage. It
has been shown that collagen component in cusps and elastin component in aortic wall
calcifies in BHVs. Ethanol treatment was found to beneficially alter collagen
conformation such that the collagen becomes calcification resistant. However, ethanol
treatment was only partially effective in aortic wall as elastin is the major ECM
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component. Elastin specific calcification is a problem in both stented and stentless heart
valve implants. The only treatment for elastin specific aortic wall calcification is that St.
Jude uses BiLinx technology which uses differential treatment of ethanol for cusps
coupled with aluminum chloride treatment for aortic wall [168]. Aluminum ions were
found to inhibit alkaline phosphatase activity thereby preventing calcification. Aluminum
is shown to tightly bind to elastin and prevents its calcification. Preventing elastin
calcification in heart valves has the potential to increase the durability of valves in the
clinical setting [146].
In summary, one of the anti-calcification treatments could be used to prevent the
calcification in BHVs, which might potentially improve the durability of these valves.
Glycosaminoglycans comprise another important component of bioprosthetic
heart valves and they are discussed in detail in the ensuing section.

2.11. Glycosaminoglycans and its importance in valves
The extracellular matrix (ECM) in heart valves is composed primarily of collagen,
elastin and proteoglycans. The principle polysaccharides of the matrix are termed as
proteoglycans. Proteoglycans consist of a core protein and one or more covalently
attached glycosaminoglycan (GAG) side chains. GAGs are linear polysaccharides, whose
building blocks (disaccharides) consist of an amino sugar (either glucosamine or
galactosamine) and an uronic acid (glucuronic acid or iduronic acid). Each disaccharide
usually contains carboxylate and/or sulfate esters which make the glycosaminoglycans
highly negatively charged molecules. All mammalian cells produce proteoglycans and
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secrete them into ECM. The ECM determines the physical characteristics of tissues and
many of the biological properties of cells embedded in it [26, 169-171]. It has been
evident from electron microscopy images that the aggregates of proteoglycans have a
bottle brush structure, with a hyaluronic acid core as shown in Figure 2.29. The central
HA core is tightly associated to link proteins [169].

Figure 2.29: (a) Electron microscopy image of proteoglycan aggregate
demonstrating a bottle brush structure. Scale bar equal 0.5 µm [172], (b) Schematic of
proteoglycan aggregate structure [26]
There are five major GAGs present in the body. They are hyaluronic acid (HA),
dermatan sulfate (DS), keratan sulfate (KS), chondroitin sulfate (CS) and heparin sulfate
(HS). HA lacks any sulfated groups, but the rest of the GAGs are all sulfated and they
have sulfates at various positions. GAGs are anionic and hydrophilic in nature due to
presence of carboxylic and sulfate groups [169, 170, 173].
The proteoglycans structure shown in Figure 2.30 depicts explicitly the regions in
the core protein for different GAGs and how the core protein binds to HA backbone

68

[173]. Biosynthesis of glycosaminoglycans occurs in the Golgi apparatus except for
hyaluronic acid, which is synthesized in the cell membrane [174].
Nearly all animal cells synthesize GAGs; HA, CS and HS are synthesized in
prokaryotes. GAGs are highly charged anions that interact with hundreds of different
proteins. GAGs bind to proteins primarily through the interaction of their sulfo and
carboxyl groups with basic amino acid residues present in shallow pockets or on the
surface of GAG binding proteins. In the past decade GAGs have been shown to play a
role in the regulation of a large number of important cellular processes including cell
growth and cell–cell interaction [170, 173].

Figure 2.30: Tentative model for proteoglycans structure [175]
GAGs are found to serve four important functions in the body [176]. They are:
•

As barriers to diffusion across the basement membranes
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•

As sources of mechanical repulsive forces for lubrication and cushioning in joints

•

As anticoagulant coatings of blood vessels, and finally

•

As reservoirs for specific binding to proteins in order to regulate or stabilize their
activity

2.11.1. GAGs in heart valves
Native heart valves experience extreme pressures and stresses when they open
and close during systole and diastole. They are subjected to strenuous and highly
complex mechanical forces [2, 38]. To withstand such higher pressures and stresses and
dissipate them, they need highly specialized structure in their ECM. Proteoglycans and
GAGs carry this responsibility of dissipating the stresses. The glycosaminoglycans attract
counter ions and water molecules. This endows a unique physical property of tissue
hydration and thus making them resilient to compressive forces [171]. By hydrating the
central layers of the heart valve cusps, the GAGs help reduce the internal shear stresses
acting on the cusp [2].
GAGs have the ability to support compression, and help minimize the cuspal
buckling during the opening of the valves. GAGs can be compressed to only ~20% of
their maximum dimension and they tend to repel each other due to the negatively charged
nature and behave like a compressed spring. This nature of the GAGs helps them absorb
the compressive forces acting on the valves [2]. GAGs are found to have rod-like
structure giving them this property and Figure 2.31 [39] shows the effect of unit cell
compression on randomly oriented GAG rods. As a result of compression, the inter-GAG
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rods distance becomes smaller in the direction of compression and larger in the
perpendicular direction.
The primary GAG types seen in the heart valves are hyaluronic acid (HA),
chondroitin sulfate (CS) and dermatan sulfate (DS). GAG biosynthesis has been found to
be highest in the cardiac valves among all cardiac tissue tested and they have a very high
turn over rate. Degradation of GAGs is found to occur at a rapid rate. The half-life of
hyaluronic acid in skin is about 12 hours. Also, one third of HA has been found to be
replenished every day [38, 177, 178]. Native aortic valve cusps are found to have ~3.5%
of GAGs by dry weight. Despite their minute quantities, they are far more significant for
the functionality of the valves, especially bioprosthetic heart valves [38]. Very little is
known about GAGs and their functionality in BHVs. The ensuing section talks about why
the stabilization of these GAGs is important and the different fixatives targeted towards
GAG fixation.

Figure 2.31: Effect of uniaxial compression on randomly oriented GAG rods [39]

2.11.2. Role of GAGs in BHVs and importance of GAG stabilization
Glycosaminoglycans present in the spongiosa layer of the cusps provide a “sliding
gap” between the ventricularis and fibrosa. Glutaraldehyde, the commercially used
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fixative for the BHVs is known to be an excellent fixative for the collagenous component
of the BHVs. However, it does not stabilize the other important components of the heart
valve cusps [96, 154]. Though researchers found out that GAGs form an integral part of
the framework of the heart valve tissue in the 60s and 70s, it was not until the 90s that
researchers found out the loss of GAGs is playing an important role in the failure of
tissue valves.
Beaty et al published an extensive review on glycosaminoglycans in 1987
mentioning the important diseases associated with glycosaminoglycans. It mentioned
other diseases such as mucopolysaccharidosis, periodontal disease, osteoarthritis and
rheumatoid arthritis [169]. It never mentioned about loss of GAGs involved in the failure
of heart valves. It was pointed out only later that the loss of GAGs was partly responsible
for the failure and degeneration of bioprosthetic heart valves [27]. Also, failed porcine
BHVs were analyzed and found to have degreased amount of GAGs [28].
GAGs were found to provide a hydrating environment between the cuspal layers.
They help absorb the different forces and the pressures acting on the valves. They also
were found to reduce tissue buckling during the opening of the valve by providing the
“sliding gap” [2, 96, 154]. Stabilization of GAGs might significantly improve the
durability of the bioprosthetic valves by helping to prevent the risk associated with the
cuspal tears at the areas of maximum flexion during fatigue. It might also improve the
longevity of the valves by precluding the buckling forces acting on the BHVs. Various
researchers and also research from our lab has suggested that GAGs are vital for the
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proper functioning of the bioprosthetic valves and for improving the durability of these
valves [21, 26-28, 38, 134].

2.11.3. The need for alternative fixative and its importance
Bioprosthetic heart valves used commercially are fixed with glutaraldehyde.
GLUT is known to be a good fixative for only the collagenous component of the heart
valve tissue. The other two major components, glycosaminoglycans (GAGs) and elastin
are not stabilized by GLUT fixation. Having known the importance and the functions of
GAGs, it is important to develop alternative fixation strategies specifically targeted
towards GAG fixation. Moreover, glutaraldehyde is known to cause more harmful effect
such as calcification. Glutaraldehyde crosslinked tissue is found to be susceptible to
enzymatic degradation by GAG degrading enzymes. Therefore a better strategy and
fixation chemistry is needed in order to preserve the extracellular matrix components
such as GAGs [38, 132, 133, 135]. The ensuing section will describe in detail the GAGtargeted fixation chemistries.

2.11.4. GAG-targeted fixation chemistries:
Some of the important strategies specifically target GAGs during fixation. They
are discussed in detail below:
2.11.4.1. Sodium Meta-periodate
Sodium metaperiodate is another fixative which has been used previously from our lab as
an alternative fixative. Periodate mediated crosslinking is used to stabilize
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glycosaminoglycans. The geminal diols present in the structure of HA would react with
the periodate ion allowing the formation of aldehyde groups in the GAG chain. These
aldehyde groups would then react with other molecules in the valve tissue, particularly
the amine groups found in the lysine residues of collagen molecules, achieving GAG
fixation [20]. The schematic of the crosslinking chemistry can be seen in Figure 2.32. It
can be used to crosslink major components of ECM such as type I collagen and
hyaluronic acid. Fixation using periodate showed 36% reduction in the amount of
unbound GAG disaccharides as compared to GLUT fixed tissue. Also it has been shown
to have reduced calcification that GLUT fixed tissue after 21 days of subdermal
implantation [20]. In another study, it is found that periodate resulted in reduced
calcification even after 6 weeks of subdermal implantation and resulted in higher
amounts of GAGs even after enzymatic degradation as compared to GLUT [21].
Periodate is used for stabilizing ostrich pericardium in an interesting study and they have
found that the GAGs are stabilized better compared to GLUT. They have also used
exogenous chondroitin sulfate along with periodate in the fixation process and found to
have better stabilization due to the exogenous addition of chondroitin sulfate [22].
2.11.4.2. Carbodiimide
Another GAG-targeted fixative that is of interest is a carbodiimide based fixative.
1-ethyl-3-3-dimethylaminopropyl carbodiimide (EDC) is used in conjunction with nhydroxy succinimide (NHS). Figure 2.32 shows the steps by which EDC helps crosslink
collagen with GAGs. EDC activates the carboxyl group of the GAGs. This further forms
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a stable intermediate with NHS. This intermediate further forms an amide crosslinks with
the free amine groups of collagen [13, 21].

Figure 2.32: Schematic of crosslinking using EDC/NHS (ENG) and periodate (PG) [21]
Various researchers have found that use of carbodiimide crosslinking stabilizes
GAGs in tissue better as compared to GLUT crosslinking. They also were found to have
reduced calcification compared to GLUT. Also, it had been found to dramatically
potentiate the anti-calcific effects of alpha-amino oleic acid on GLUT fixed aortic wall
[1, 14, 21].
EDC/NHS as well as periodate are GAG targeted fixatives which stabilize GAGs
better than GLUT. However, they do not prevent the enzyme mediated degradation of
GAGs completely. Despite several fixatives available for BHV fixation, complete GAG
stabilization and inhibition of enzyme mediated GAG-degradation is yet to be achieved.
We aim to achieve improved valve stability by achieving complete GAG stability.
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CHAPTER THREE
PROJECT RATIONALE

3.1. Rationale
Despite various advancements in the field of cardiovascular engineering,
glutaraldehyde (GLUT) remains the major fixative approved by FDA for stabilization of
bioprosthetic heart valves over the past four decades. While GLUT fixation sterilizes the
tissue, reduces tissue antigenicity and decreases implant rejection, it has various
disadvantages [102]. Residual glutaraldehyde remaining in the interstices of the
crosslinked tissue has been implicated in the inflammatory response, cytotoxicity,
calcification and the lack of endothelialization [122]. In addition it is unable to stabilize
glycosaminoglycans (GAGs) and elastin present in these bioprostheses [27, 132].
GAGs are very important for the proper functioning of the native heart valves.
GAGs are anionic in nature thus absorb water and help to keep the valves hydrated. They
also mediate the shear stresses and compressive forces acting on the valves [2, 27, 179].
The loss of the GAGs has been reported in previous research during the fixation, storage,
in-vitro fatigue cycling and in-vivo implantation of BHVs [21, 38, 133, 134]. This loss of
GAGs may make tissue stiff by increasing the flexural rigidity resulting in premature
valve failure. The goal of this project is to treat the tissue valves with a fixative
stabilizing the valvular GAGs, and improving the biomechanics and functioning of these
BHVs, thus extending the functional life of these valves beyond their current limits.
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3.1.1. Hypothesis:
Durability of the bioprosthetic heart valves (BHVs) is increased by stabilizing the
glycosaminoglycans present in the cuspal tissue. This could be achieved by GAGtargeted fixation chemistry coupled with an enzyme inhibitor. Stabilization of GAGs by
enzyme inhibition strategy along with anti-calcification treatments may eventually
prevent both calcific and non-calcific degeneration of valves thus extending their
functional life.

3.2. Specific Aims
Aim 1: There exists an optimal bound concentration of neomycin to stabilize
valvular GAGs.
Approach:
a) Porcine aortic heart valves will be fixed with a GAG-targeted fixative (carbodiimide),
supplemented by the addition of neomycin trisulfate, an enzyme inhibitor, to the
crosslinking chemistry.
b) Neomycin concentration will be optimized to prevent GAG loss from the BHVs.
Innovative features: The results of this research would demonstrate for the first time that
the carbodiimide crosslinking coupled with a GAG degrading enzyme inhibitor
(neomycin trisulfate) improves GAG retention in BHVs. Furthermore, the current
crosslinking strategy is compatible with the conventional and commercially used
glutaraldehyde crosslinking.
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Aim 2: Neomycin treatment with carbodiimide fixation will improve the
stabilization of valvular GAGs against in-vitro enzymatic degradation and in-vivo
subdermal implantation.
Approach:
a) The in-vitro biochemical stability of porcine BHVs will be analyzed after
treatment with GAGases, collagenase and elastases in-vitro.
b) In-vivo degradation of GAGs will be tested after the subdermal implantation of
the cusps into juvenile rats. The explanted tissue will subsequently be analyzed
for the amount of GAG retained in the cusps and for the extent of calcification.
Innovative features: This approach demonstrates for the first time that neomycin
treatment improves GAG stability in BHVs after in-vivo implantation.

Aim 3: Neomycin treatment for GAG preservation will enhance the stabilization of
glycosaminoglycans after long-term storage and in-vitro cyclic fatigue.
Approach:
a) Valvular cusps will be stored for various time points with the GAG content being
estimated at each time point.
b) In-vitro cyclic fatigue testing will be performed on the valves using Dynatek
Dalta M6 tester to determine the effect of fatigue cycling on GAG stability.
Innovative features: Valves have a shelf life of upto 3 years before being implanted
where in vivo digestion could take place. So it becomes essential to analyze the GAG loss
due to storage, and storage followed by enzymatic degradation. Our results would
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demonstrate the GAGs loss due to storage, and storage followed by enzymatic
degradation for upto 1.5 years of storage.

Aim 4: GAG-targeted fixation coupled with anti-calcification treatments will help
reduce the calcification of the BHVs along with enhanced GAG stability.
Approach:
a) Valves will be treated with sodium borohydride to neutralize residual
glutaraldehyde after GAG fixation chemistry.
b) Valves will be pretreated with ethanol to reduce calcification in valves after GAG
fixation chemistry.
Both in vivo calcification and GAG retention will be tested by subdermal implantation of
the valve cusps.
Innovative features: This unique GAG stabilization uses both an enzyme inhibition
strategy and ethanol anti-calcification treatment to address both the modes of valve
failures, calcification and structural dysfunction. This could help prevent valve failures
thereby improving the overall durability and functional life of BHVs.

Aim 5: GAG stabilization using neomycin fixation will result in improved
biomechanics of BHVs than glutaraldehyde fixation.
Approach: Valves fixed in neomycin and glutaraldehyde will be subjected to biaxial
mechanical testing with and without GAGase digestion to determine the biomechanical
properties of these BHV tissues.
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a) Uniaxial tensile testing will be performed on the valves. The biomechanical
properties obtained from uniaxial and biaxial testing will be compared and
analyzed for similarities and differences.

3.3. Significance of current research
Despite several improvements in the bioprosthetic heart valve, an ideal
bioprosthetic heart valve has yet to be achieved. Currently, BHVs fail within 10 – 15
years due to degeneration. Thus they are only used in older patients who can outlast the
implant life. In child bearing women, children, and young adults, 2nd surgery is more
complicated than the 1st surgery. The long-term objective of this research is to create
BHVs that would last for 25 years or more by maintaining all its structural and functional
attributes. This will be achieved by stabilizing the GAGs present in the BHVs using
GAG-targeted fixation coupled with an enzyme inhibitor to eliminate the degradation of
cuspal glycosaminoglycans. GAGs are found to play a major role in both the modes of
failure in BHVs; degenerative and calcific failure. Degenerative failure of valves is often
overlooked. Stabilizing the GAGs has the potential to reduce the non-calcific mode of
degeneration. This can be coupled with anti-calcification treatment to reduce calcification
in valves. As a result, the research on GAG stabilization in combination with anticalcification, would help improve the valve durability and longevity.
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3.3.1. Alternative fixation - Significance of carbodiimide fixative:
Since glutaraldehyde fixation is not effective in stabilizing all ECM components
in BHVs, an alternate fixative is needed. This fixation should not alter the normal valve
function and performance, such as its hemodynamics and durability. In addition, this
fixative ideally should have the ability to inhibit the calcification of valve tissue.
Carbodiimide fixation of BHVs has been investigated as an alternative to glutaraldehyde.
Subdermal implantation studies in rats have shown that calcification is reduced by
crosslinking the bioprosthetic tissue with carbodiimides [2, 3]. Furthermore studies have
shown, carbodiimide fixed tissue to have better collagen stability and less calcification
than glutaraldehyde fixed tissue [14, 165, 180, 181]. Previous studies have focused on
collagen fixation and have overlooked GAG retention strategies. 1-ethyl-3-(3dimethylaminopropyl)-carbodiimide (EDC) activates the carboxyl group of the GAGs
and collagen. This conjugate further forms a stable intermediate with nhydroxysuccinimide (NHS), which forms amide crosslinks with the free amine groups of
collagen [13]. The chemistry behind the fixation of the GAGs in the BHVs by EDC has
received little attention and is still poorly understood. To address this issue, this study
will help in the understanding of the efficacy and efficiency by which EDC fixes GAGs
and how the properties of other components such as collagen and elastin in the tissue are
altered. However, EDC crosslinking alone was not pursued as it does not completely
prevent the enzymatic degradation of GAGs, and it does not stabilize BHVs as good as
GLUT. Clinical trials with EDC currently were also not so successful.
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3.3.2. GAG stabilization using enzyme inhibitors – Neomycin as a hyaluronidase
inhibitor:
Previous studies have shown that EDC, though an effective GAG-targeted
fixative, does not completely inhibit the enzymatic degradation of GAGs [21]. Therefore,
to inhibit the degradation of GAGs effectively, a GAGase inhibitor along with the GAGtargeted fixation chemistry is needed.
As a next step we chose an inhibitor which can effectively inhibit the degradation
of GAGs as well as help in the crosslinking process. Hyaluronic acid (HA) forms the
backbone of GAGs; therefore hyaluronidase (HAase) inhibitors are short listed (Figure
3.1). The ideal inhibitor should be permanently fixed to the tissue and function
effectively as a hyaluronidase inhibitor for preserving GAGs in the valves. Based on the
available literature, possible HAase inhibitors and their chemical structure are analyzed to
determine if they might be used for crosslinking along with inhibition (Figure 3.1). Since
EDC and glutaraldehyde both utilize amine groups for crosslinking, ideally the inhibitor
should have amine groups. Hyaluronidase can be inhibited by sulfated oligosaccharides
such as verbascose, planteose and neomycin in biological tissues [182]. Apigenin [183],
a flavone, marimastat [183], Vcpal (6-palmatoyl-L-ascorbic acid) [183-185], tetradecyl
sodium sulphate [186], indomethacin [187], hesperidin phosphate [188], sodium
aurothiomalate [189, 190] and glycyrrhizin [191] are other known hyaluronidase
inhibitors that can be utilized.
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Figure 3.1: Structure of hyaluronidase inhibitors (A) Neomycin, (B) Apigenin, (C)
Indomethacin, (D) Marimastat, (E) L-Ascorbic acid, (F) Glycyrrhizin, and (G) Tetradecyl
sodium sulfate.

After careful analysis, neomycin was chosen as the hyaluronidase inhibitor and
crosslinker for our studies due to the following reasons.
I. Neomycin has six amine groups in its structure and can be utilized in covalent
crosslinking to the tissue. EDC can activate these amine groups to form amide
crosslinks [13] or glutaraldehyde can activate them to form Schiff base bonds.
II. It contains a combination of hydrophilic moiety with an affinity-conferring
lipophilic residues that bind to hyaluronidase there by blocking the enzymatic
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degradation [182]. Previous research has shown that compounds having a
hydrophilic and lipophilic groups exhibit increased inhibition [183].
III. Neomycin exhibits inhibition comparable to all hyaluronidases and more than that
of the widely accepted apigenin [182].
This study represents the first time neomycin being used as a GAG stabilizing
agent for bioprostheses. Therefore this technology was patented by Clemson University
(CXU-523, filed on Nov 2007, filing number 11/934,844). Crosslinking and preserving
GAGs through this fixation chemistry could help in improved durability and longevity of
BHVs.
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CHAPTER FOUR
EXTRACELLULAR MATRIX STABILIZATION IN BIOPROSTHETIC HEART
VALVES

4.1 Introduction
Glycosaminoglycans (GAGs) compose the majority of the spongiosa layer of the
porcine bioprosthetic heart valves (BHVs). They play a significant role in the functioning
of native valves by providing hydration and minimizing the stresses acting on the valves.
Previous research has shown that GAGs are lost from GLUT crosslinked porcine aortic
tissue valves during fixation, storage, in vitro fatigue testing, and after in vivo
implantation [21, 27, 133, 134]. We believe that cuspal GAGs are important components
for valvular biomechanics and loss of GAGs may in part be responsible for degenerative
failure of BHVs. GLUT fixation also does not stabilize elastin, another major component
of the heart valve tissue. As GAGs and elastin, two of the major components of the heart
valve tissue, not stabilized properly, it becomes clearly evident that native heart valve
architecture is not preserved in GLUT fixed BHVs. For BHVs to be durable and have
enhanced longevity, the native matrix components need to be preserved properly.
Therefore, we conducted several experiments using neomycin as a targeted GAG fixative
to show that neomycin stabilization is superior to GLUT fixation in preserving the matrix
components.
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4.1.1. Motivation behind the research: Preliminary studies:
The preliminary motive of our studies was to demonstrate the shortcomings of
GLUT fixative and develop an alternative fixative to preserve matrix components. The
outlined study demonstrated the drawbacks of GLUT fixation. The porcine aortic valves
freshly harvested from the slaughter house were rinsed in saline and fixed in
glutaraldehyde (GLUT). The valves fixed in GLUT were stored in 0.2% GLUT until
further usage. To study the effect of GAG loss due to storage in GLUT, porcine aortic
cusps obtained were fixed in 0.6% GLUT. These fixed cusps were stored in 0.2% GLUT
for upto 6 months. Fresh porcine aortic cusps obtained right after harvestation were used
as controls. Valve half cusps were digested in-vitro in 1.2 ml of 5 U/ml of hyaluronidase
and 0.1 U/ml of chondroitinase ABC (HAase + CSase) in 100 mM ammonium acetate
buffer at 37°C and was vigorously shaken at 650 rpm for 24 h. Hexosamine assay was
used to quantify the tissue hexosamine content. GAGs were lost due to fixation, due to
storage and also after enzyme digestion (Figure 4.1). Therefore, it becomes very
imperative to preserve these GAGs. These results were in agreement with the previous
results from our lab as well as other researchers as mentioned in the background.
Therefore GAG targeted fixation and stabilization of GAGs became a very important
goal and motivation for us.
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Figure 4.1: GAG loss due to GLUT fixation, storage and enzyme digestion

4.2. Methods
4.2.1. Tissue Preparation and fixation:
Porcine aortic heart valves were obtained at the time of slaughter from a local
abattoir (Snow Creek Meat Processing, Seneca, SC). The aortic root was cut along the
cuspal commissures and the cusps were left attached to the base of the aortic sinuses. The
aortic valves were transported to the laboratory in saline on ice. The valves were rinsed in
buffered saline for three rinses of 10 minutes each in the orbital shaker. The aortic valves
and the cusps were chemically crosslinked within 3-4 hours of harvesting in order to
minimize the amount of GAGs lost during collection and transportation. They were fixed
in different groups as described in Table 4.1. For storage studies, the valves and cusps
fixed in 3 different groups were stored in 0.2% GLUT depending on the timeframe of the
study. For valves obtained for accelerated fatigue testing and biomechanical testing the
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aortic valves were kept intact. Fixation of these valves was done by stuffing the valves
with cotton balls wetted with the fixative essentially to keep them in closed position.
Usually 100 ml of fixative was used for a whole valve and about 30 ml of fixative for a
single cusp. For all studies six samples per group (n=6) were used unless otherwise
mentioned.
Group ID

Acronyms
Fresh porcine

Treatment Conditions
Fresh aortic valve cusps after harvesting were rinsed

FRESH

non-crosslinked

and used for weight loss studies and fresh tissue

aortic valve tissue

hexosamine content
0.6% glutaraldehyde (in 50 mM HEPES buffered

GLUT

Glutaraldehyde

saline , pH 7.4) for 24 hrs followed by 0.2%

fixation

glutaraldehyde (in 50 mM HEPES buffered saline, pH
7.4) for 6 days
30 mM EDC and 6 mM NHS (in MES hydrate, pH

ENG

EDC / NHS

5.5) for 24 hrs followed by 0.6% glutaraldehyde (in 50

followed by Glut

mM HEPES buffered saline , pH 7.4) for 24 hrs

fixation

followed by 0.2% glutaraldehyde (in 50 mM HEPES
buffered saline, pH 7.4) for 5 days
1 mM neomycin trisulfate (in 50 mM MES hydrate,

Neomycin
NEO

fixation followed
by EDC/NHS and
Glut fixation

pH 5.5) for 1 hr followed by 30 mM EDC and 6 mM
NHS (in MES hydrate, pH 5.5) for 24 hrs followed by
0.6% glutaraldehyde (in 50 mM HEPES buffered
saline, pH 7.4) for 24 hrs followed by 0.2%
glutaraldehyde (in 50 mM HEPES buffered saline, pH
7.4) for 5 days

Table 4.1: Crosslinking conditions and treatments used for stabilizing porcine aortic
heart valve cusps
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The flow charts here show the design of in vitro and in vivo experiments.

Flowchart 4.1: Design of experiments – In vitro Studies

Flowchart 4.2: Design of experiments – In vivo Studies

89

4.2.2. Immunohistochemistry (IHC) for neomycin:
Immunoperoxidase staining was performed on cuspal sections to visualize the
effectiveness of specific binding of neomycin to the cusps. Vectastain elite ABC kit for
rabbit IgG and diaminobenzidine tetrahydrochloride (DAB) peroxidase substrate kit were
used to visualize the specific staining (Vector Laboratories, Burlingame, CA). The
sections were incubated overnight in rabbit anti-neomycin primary antibody (1:500
dilution). To minimize cross reactivity, rat-adsorbed biotinylated anti-rabbit IgG was
used in place of biotinylated secondary antibody provided with the staining kit. Omission
of the primary antibody was used as the negative control. The sections were finally
counter stained using hematoxylin.

4.2.3. GAG quantification by hexosamine assay:
Total tissue hexosamine contents were determined by previously published
methods [21, 134, 192]. In brief, pre-weighed lyophilized cusps were hydrolyzed in 2N
HCl for 20 h at 95°C in a vacuum dessicator and HCl was evaporated under nitrogen gas.
The residues were dissolved in 2 ml of 1M sodium chloride solution and then reacted
with 2 ml of 3% acetyl acetone in 1.25M sodium carbonate. Then 4 ml of 100% ethanol
and 2ml of Ehrlich’s reagent (0.18M p-dimethylaminobenzaldehyde in 50% ethanol
containing 3N HCl) were added and solutions were left at room temperature for 45 min.
The pinkish-red color product was indicative of the tissue hexosamine quantities and the
absorbance was read at 540nm in a microplate reader (µQuant, Biotek Instruments Inc.,
Winooski, VT) [192]. A set of D(+)-glucosamine solutions (0 – 200 µg) were used as a
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standard curve. Total tissue hexosamine content was measured and further normalized to
dry tissue weight for comparison.

4.2.4. GAG quantification by DMMB assay:
The GAGs released into the enzyme solutions (HAase + CSase, or papain) were
quantified by DMMB assay as described previously [193-195] with minor modifications.
In a 96 well-plate, 20 µl of enzyme solution along with 30 µl of PBE buffer (100 mM
Na2HPO4, 5 mM EDTA, pH 7.5) and 200 µl of DMMB Reagent Solution (40 mM NaCl,
40 mM Glycine, 46 µM DMMB, pH 3.0) were added into each well and absorbances
were read at 525 nm in a microplate reader. Chondroitin sulfate (0 – 1.25 µg) standards
were used. As additional controls, the chondroitin sulfate standards were also treated with
20 µl of the enzyme mixture (HAase + CSase) for comparisons. The total GAGs released
into the enzymes were normalized to the initial dry weights of the tissue.

4.2.5. Optimization of neomycin concentration:
To determine the optimum concentration of neomycin for GAG fixation, cusps
were incubated in 1 mM, 500 µM, 100 µM and 10 µM concentrations of neomycin in
MES hydrate (pH 5.5) for 1 hr followed by standard EDC/NHS and GLUT fixation.
GLUT crosslinking alone was used as control. Samples were subjected to hexosamine
and DMMB assays prior to or after GAG digestion using chondroitinase/hyaluronidase
mixture to determine the efficacy of GAG fixation.
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4.2.6. De-oxystreptamine as a control for neomycin:
2-deoxystreptamine dihydrobromide (DOS) was used as a control for neomycin.
It has similar structure and amine functionalities for carbodiimide based linking to the
tissue but it lacks GAGase enzyme inhibition activity of neomycin. Figure 4.2 shows the
structure of 2-deoxystreptamine dihydrobromide (DOS). For this study, 1 mM of DOS
was used followed by EDC/NHS and GLUT similar to neomycin. Hexosamine assay and
DMMB assays were performed to determine the amount of GAGs present in the cusps
and GAGs released into the enzyme/buffer liquid respectively.
H 2N

NH2

OH

HO
OH

Figure 4.2: Structure of 2-deoxystreptamine dihydrobromide

4.2.7. GAG stability studies - Determination of cusp stability against GAG
degrading enzymes:
The cusps, cut from their respective sinuses, were dissected symmetrically along the
radial direction and washed thoroughly in 100 mM ammonium acetate buffer at a pH of
7.0 for 3 x 5 minutes. One half of the cusp was incubated in 1.2 ml of 5 U/ml of
hyaluronidase and 0.1 U/ml of chondroitinase ABC (HAase + CSase) in 100 mM
ammonium acetate buffer at 37°C and was vigorously shaken at 650 rpm for 24 h. The
other half was incubated in ammonium acetate buffer alone as a control. The optimum
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concentration of these enzymes was chosen as described previously [134]. For papain
digestion studies the cusps were digested in 1ml of Papain digestion buffer per cusp
(5mM L-cysteine, 100 mM Na2HPO4, 5 mM EDTA, pH 7.5) containing 125 µg/ml of
Papain at 60°C for 24 h. The enzyme-digested cusp samples were thoroughly washed in
deionized water, lyophilized, and used for GAG quantification using hexosamines assay.

4.2.8. Measurement of thermal stability of collagen crosslinks:
Differential Scanning Calorimetry (DSC) (Model DSC 7, Perkin-Elmer, Boston,
MA) was used to determine the thermal denaturation temperature (Td), which is an
indicator of the extent of collagen crosslinking stability [13, 21, 134]. A 2 mm X 2 mm
sample was cut from the belly region of the cusps and the samples were placed in
hermetically sealed pans. The sample pan and reference pan (empty) were placed into the
pan holders of the DSC and sealed securely. The temperature of the DSC was raised by a
computer program at a rate of 10°C/min from 20°C to 110°C. Td, the temperature at the
endothermic peak, symbolized the denaturation of collagen triple helix. This temperature
was noted as the denaturation temperature (n=6 per group).

4.2.9. Weight loss studies: determination of weight loss of cusps after collagenase
and elastases digestion:
Effectiveness of elastin and collagen stabilization in the cusps was determined by
treating cusps with elastase and collagenase respectively. The cusps were rinsed,
lyophilized and weighed to measure the initial dry weight. The lyophilized cusps were
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then treated with porcine pancreatic elastase or type VII collagenase as described
previously [196-198]. Briefly, the cusps were treated with 1.2 ml of elastase (5 U/ml) in
100mM Tris buffer, 1mM CaCl2, 0.02% NaN3 (pH 7.8) and incubated at 37°C for 24 hrs
with shaking at 600 rpm. For collagenase studies, samples were treated with 1.2 ml of
type VII collagenase (75 U/ml) made in 50 mM Tris buffer, 10 mM CaCl2, 0.02% NaN3,
pH 8.0, and incubated at 37°C with orbital shaking at 650 rpm for 48 hrs. The samples
were then rinsed, lyophilized and weighed for final dry weight. The percentage weight
loss due to elastin or collagen degradation is calculated from the initial and final dry
weights before and after treatments of elastase or collagenase respectively.

4.2.10. Immunohistochemistry (IHC) for elastin:
To test the effectiveness of elastin stability, cuspal sections from GLUT and NEO
groups with and without elastase treatment were immuno-stained for elastin. Vectastain
elite ABC kit with rabbit IgG and diaminobenzidine tetrahydrochloride (DAB)
peroxidase substrate kit were used (Vector Laboratories, Burlingame, CA). The sections
were incubated overnight at 4 °C in rabbit anti-elastin primary antibody (1:200 dilution).
Rat-adsorbed biotinylated secondary anti-rabbit IgG antibody was used to minimize cross
reactivity. Negative staining control was performed with the omission of the primary
antibody. The sections were finally counter stained using hematoxylin.
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4.2.11. Hydroxyproline assay to determine collagen content:
Tissue hydroxyproline content was measured for cusps fixed in NEO, ENG,
GLUT and FRESH before and after collagenase treatment. This was done to analyze the
stability of cuspal tissue against collagenase treatment. In brief, pre-weighed lyophilized
cusps were hydrolyzed in 2N HCl for 20 h at 95°C in a vacuum dessicator and further
dried under nitrogen gas. The residues were dissolved and reconstituted in 500 µl of DI
H20. 20 µl of reconstituted sample was taken and this was reacted with 250 µl of
chloramine-T reagent for 20 minutes. This was followed by the addition of 250 µl of
aldehyde-perchloric acid solution. The samples were heated in an oven at 60°C for 15
minutes and vortexed to mix well and allowed to cool. The absorbance of these samples
was measured by taking 250 µl aliquots in 96-well plate. The absorbance was measured
at 558 nm. A set of trans-4-hydroxy-L-proline solutions (0 – 6 µg) were used as a
standard curve. Total tissue hydroxyproline content was measured and further normalized
to dry tissue weight for comparison.

4.2.12. Desmosine assay to determine elastin content:
Tissues fixed in NEO, ENG, GLUT and FRESH were treated with elastase as
mentioned before in Section 4.2.9. These tissues were lyophilized and weighed before
hydrolysis using 6N Ultrex hydrochloric acid for 8 hours at about 95°C. The samples
were dried in nitrogen gas and further reconstituted using 0.01N HCl. These samples
were sent to our collaborator Dr. Barry Starcher for desmosine analysis. Desmosine, an
amino acid unique to elastin, can be used to express elastin content. A radioimmunoassay
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was performed on the reconstitutes to express desmosine as picomoles desmosine / mg
protein [199]. Comparison of desmosine content on different groups after elastase
treatment could be used to determine the stability of various groups against elastases.

4.2.13. Subdermal implantation studies:
Cusps fixed with GLUT, ENG and NEO (n=10 per group) were rinsed in sterile
saline prior to implantation. Male juvenile Sprague-Dawley rats (35-40g, Harlan
Laboratories, Indianapolis, IN) were anesthetized by inhalation of 3% isoflurane gas and
two subdermal pockets were created in the dorsal side. Cusps were implanted into the
pocket (one cusp per pocket, 2 cusps per rat) and the incision was closed using surgical
staples. Cusps and the capsule tissue surrounding the cusps were explanted after three
weeks. All animals received humane care in compliance with protocols approved by
Clemson University Animal Research Committee as formulated by NIH (Publication No.
86-23, revised 1996). Cuspal explants were further used for hexosamine, calcium, and
histological analysis. Cuspal explants for GAG quantification were immediately frozen
on dry ice and lyophilized.

4.2.14. Histological evaluation:
For histological evaluation using paraffin sections, samples were placed in 10%
alcoholic acid formalin at room temperature for 24h prior to infiltration and embedding.
Following fixation, samples were dehydrated, infiltrated with paraffin wax in a tissue
processor. Radial cuspal sections were embedded into paraffin blocks after processing the
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tissue. 5 µm sections were cut using a microtome and scooped onto microscope slides.
These sections were used for various histological analyses.
Generally cuspal morphology was analyzed by hematoxylin and eosin staining.
GAGs were visualized in the samples using an Alcian Blue staining with Brazilliant!®
nuclear fast red as a counter stain (Anatech Ltd., Battle Creek, MI) [134]. In order to
visualize the presence of calcium deposits after implantation, Dahl’s alizarin red stain for
calcium was used with light green counter stain.

4.2.15. Calcium and Phosphorous analysis from explanted samples:
In order to determine the extent of calcification, a portion of the sample from the
explants was used for calcium and phosphorous quantification. Calcium analysis was
performed using atomic absorption spectroscopy and phosphorous quantification was
done using a molybdate complexation assay.
The portion of the explanted cusps were lyophilized, weighed and hydrolyzed
using 6N Ultrex II pure hydrochloric acid (J. T. Baker, Philipsburg, NJ) for 8h in a
boiling water bath. This was followed by evaporating the HCl under nitrogen gas and
reconstitution of the residue in 1 ml of 0.001 N Ultrex II HCl. This reconstituted sample
is used for further analysis of calcium or phosphorous.
A portion of the reconstituted sample is diluted using atomic absorption matrix
(0.5% Lanthanum oxide in 3N Ultrex HCl) to bring the samples near the standard curve
range (usually 50X dilutions). Flame atomic absorption spectroscopy (Perkin-Elmer 3030
Atomic Absorption Spectrophotometer, Norwalk, CT) was used to measure the calcium
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content of the samples [148]. The absorbance is measured at a wavelength of 422.7 nm
and the total tissue calcium content is further normalized to the dry tissue weight.
For phosphorous analysis, samples are usually diluted twice that of which was
used for calcium analysis in deionized water to make a final volume of 1 ml. 1 ml of
reagent C (2.5% ammonium molybdate with 6N sulfuric acid and 10% L-ascorbic acid)
was added and reacted at 37 °C for 2 hours. Samples were cooled for 15 minutes and 250
µl aliquots from each samples was placed in a 96 well plate. Sample absorbance was
measured at 820 nm and phosphorous content determined from the standards used. The
total phosphorous content was finally normalized to the tissue dry weight.

4.2.16. Gel electrophoresis (zymography):
To determine the presence of GAG degrading enzymes in vivo and the inhibitory
effect of neomycin trisulfate on hyaluronidase, a substrate gel electrophoresis
(zymography) was performed as previously described [21, 38] on tissue capsules
surrounding the cusps after 3 weeks of implantation. Briefly, 10% polyacrylamide gels
containing 170 µg/ml of hyaluronic acid were prepared. The capsules were homogenized
and 20 µg of soluble protein (quantified by BCA assay) were loaded into each lane. The
gels were then run at 90 V for 150 min in running buffer (25 mM Tris, 2 mM Glycine,
1% SDS and pH 8.3). Protein molecular weights standards (10 – 150 kDa) were used to
identify the molecular weight. The gels were then incubated in a developing buffer (50
mM citric acid, 50 mM dibasic sodium phosphate, 8 g/l sodium chloride, 0.02% sodium
azide, pH 3.75) for 20 h at 37°C. For studying inhibitory effect of neomycin trisulfate, 1
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mM of neomycin trisulfate was added to the developing buffer. After developing, the gels
were stained with 0.5% Alcian blue in 20% methanol and 10% acetic acid. GAGdegrading enzyme activities appeared as clear bands on a blue background of undigested
GAGs. Images were taken with a digital camera and the lanes were analyzed using
densitometry.

4.3. Results
4.3.1. Immunohistochemistry (IHC) for neomycin:
Immunohistochemical staining for cusps crosslinked in presence of neomycin
(NEO) showed neomycin staining throughout the cusp tissue (Figure 4.3-A) suggesting
that neomycin was bound uniformly throughout the cusp tissue. The staining was
negative in control ENG group where neomycin was not linked to the tissue (Figure 4.3B). Negative controls with omission of primary antibodies were also negative (data not
shown).
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Figure 4.3: Immunoperoxidase staining for Neomycin sulfate; (A) Cusps in the NEO
group showed uniform brown stain for neomycin, (B) Cusps in the ENG group where
neomycin was not added showed no staining.

4.3.2. Optimization of neomycin concentration:
To determine the optimum concentration of tissue-bound neomycin necessary to
prevent enzyme-mediated GAG degradation, crosslinking was performed with various
concentrations of neomycin. Neomycin concentrations of 1mM to 100 µm exhibited
similar GAG stability (Figure 4.4). At a lower concentration (10 µM) of neomycin,
GAGs were lost after enzyme digestion, indicating inadequate GAG stability. DMMB
assay showed that at 1mM and 500 µM neomycin concentrations, no GAGs were
released in enzyme solutions (Figure 4.5). 1 mM of neomycin was chosen as the
concentration for use in this study as we wanted to completely prevent GAG loss.
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Figure 4.4 – Concentration Study: Hexosamine content of cusps fixed using various
neomycin concentrations (1 mM, 500 µM, 100 µM and 10 µM) along with GLUT control

Figure 4.5 – Total GAGs released in enzyme by DMMB assay for various fixation
groups. UD denotes undetected amounts.
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4.3.3. De-oxystreptamine as a control for neomycin:
In an attempt to establish that neomycin prevents GAG loss from cusps due to its
hyaluronidase inhibitor property, 2-deoxystreptamine dihydrobromide (DOS) was chosen
as control (Figure 4.2). It has amine groups like neomycin to link to the tissue during
chemical crosslinking process, but lacks hyaluronidase inhibitor property. Figure 4.6
shows that DOS linking was only partially effective in GAG stabilization in cusps against
enzymatic degradation (p<0.05). DMMB assay on enzyme solutions also showed similar
trend and complemented the hexosamine results (Figure 4.7).

Figure 4.6 – Hexosamine content of cusps fixed in DOS, NEO, ENG, and GLUT. Deoxystreptamine (DOS) was chosen as control for NEO.

102

Figure 4.7 – DMMB assay showing total GAG content of cusps fixed in DOS, NEO,
ENG, and GLUT. UD denotes undetected amounts.

4.3.4. GAG stability studies - stability of cuspal tissue to GAG degrading enzymes:
To assess the effectiveness of bound neomycin in preventing enzyme digestion of
cuspal GAGs, crosslinked cusps were treated with a chondroitinase and hyaluronidase
mixture. The hexosamine data showed that GAGs were lost from GLUT group (Figure
4.8). NEO group retained more GAGs after digestion as compared to the other groups
(p<0.05). There was no significant difference (p<0.05) between the digested and
undigested values in NEO and ENG groups. It is to be noted that there were significantly
lower GAGs in cusps in GLUT and ENG group before enzyme digestion suggesting that
GAGs were unstable. The enzyme solutions were analyzed for released GAGs by
DMMB assay (Figure 4.9). Insignificant amounts (p<0.05) of GAGs were released in to
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the enzyme solution from cusps in NEO group while significantly higher (p<0.05) GAG
contents were seen in enzyme solutions from GLUT and ENG groups, clearly suggesting
that binding of neomycin sulfate to the cusps lead to almost complete resistance to GAGdegrading enzymes.
To further test the stability of crosslinked GAGs against enzymes, cusps were
treated with papain enzyme. This is harsher GAG digestion method and it has been used
to remove GAGs from tissues for GAG analysis [193-195]. The cusps after papain
digestion were used for hexosamine assay. The cusps in NEO group retained most GAGs
after papain digestion followed by ENG (p<0.05). GLUT showed the least resistance to
papain digestion and retained the least amount of GAGs (Figure 4.10). The amount of
degraded GAGs released into the papain digested solution was analyzed using DMMB
assay. Cusps from NEO group released least amount of GAGs into papain digestion
buffer (Figure 4.11). These results were complementary to the hexosamine assays on the
cusps.
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Figure 4.8: Hexosamine content of cusps fixed in NEO, ENG and GLUT with and
without GAGase digestion

Figure 4.9: DMMB analysis on enzyme / buffer solution for released GAGs in NEO,
ENG and GLUT groups
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Figure 4.10 – Hexosamine content of cusps fixed in NEO, ENG and GLUT following
papain digestion (p<0.05).

Figure 4.11 – DMMB assay for total released GAGs performed on papain digested
solution from cusps fixed in NEO, ENG and GLUT (p< 0.05).
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4.3.5. Measurement of thermal stability of collagen crosslinks:
Thermal denaturation temperatures (Td) of the fixed aortic valve cusps from the
three groups were measured to ensure that the targeted GAG-fixation chemistry does not
alter the collagen stability. Td values were similar for all groups (NEO: 92.26 ± 0.43,
ENG: 91.94 ± 0.36, GLUT: 91.37 ± 0.35, °C, p<0.05) suggesting that the targeted GAGfixation chemistry did not alter collagen stability in the valve cusps.

4.3.6. Weight loss studies: determination of weight loss due to collagenase and
elastases:
Percent weight loss of the cusps after subjecting them to elastase was determined.
Percent weight loss was least for NEO group, followed by ENG group (p<0.05). GLUT
and FRESH groups lost significant weight after elastase (Figure 4.12) suggesting that
GLUT does not stabilize the elastin present in the cusps. Neomycin bound cusps were
resistant to elastin degradation, so this chemistry was also effective in elastin
stabilization.
Percent weight loss of cusps after subjecting to collagenase also followed a
similar trend as in the case of elastase digested tissue. NEO group lost least weight
followed by ENG, GLUT and then FRESH groups (Figure 4.13). There was a significant
difference among all the 4 groups (p<0.05). Since GLUT stabilizes collagen and all
fixation groups were terminally fixed with GLUT, we observed less than ten percent
weight loss for all the fixation groups. FRESH on the other hand lost about 65% of
collagen as it is not chemically crosslinked.
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Figure 4.12 – Percent weight loss of cusps from NEO, ENG, GLUT and FRESH groups
following elastase treatment showing NEO losing the least weight.

Figure 4.13 – Percent weight loss of cusps from NEO, ENG, GLUT and FRESH groups
following collagenase treatment showing NEO losing the least weight.
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4.3.7. Immunohistochemistry (IHC) for elastin:
Immunohistochemical staining showed the presence of elastic fibers in NEO and
GLUT groups without elastase (Figure 4.14A and 4.14C respectively). However, after
elastase enzyme treatment, cusps in NEO group retained elastic fibers as seen in IHC
stain whereas GLUT cusps lost elastin and were sparingly stained for elastic fibers
(Figure 4.14B and 4.14D). Negative controls with the omission of primary antibody also
did not show any staining (data not shown). Thus, IHC data further confirmed the weight
loss data showing better elastin stabilization in the NEO group.

Figure 4.14 – Immunohistochemical staining for elastin fibers (A) NEO, (B) NEO with
elastase, (C) GLUT and (D) GLUT with elastase. Presence of elastin is indicated by
brown staining for the elastin fibers. The arrows indicate the presence of elastin fibers
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and their location. The insets in figures are higher magnification (100X) image of the
desired region in the figures.

4.3.8. Hydroxyproline assay to determine collagen content:
Tissue hydroxyproline content before and after collagenase treatment showed that
all groups fixed using a fixative (NEO, ENG and GLUT) stabilized collagen effectively
after collagenase treatment (Figure 4.15). There was no significant difference (p<0.05)
between the undigested and collagenase digested cusps in those groups. In contrary,
FRESH tissue had significant collagen loss after collagenase treatment (p<0.05). Also,
NEO hydroxyproline content seemed to be more than other groups. This we believe could
be due to interference of the NEO fixed tissue during hydroxyproline absorbance
measurements. All other undigested groups including FRESH had the same basal level
hydroxyproline content.
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Figure 4.15 – Hydroxyproline content of cusps from different groups before and after
collagenase treatment.

4.3.9. Desmosine assay to determine elastin content:
Desmosine content of cusps from different groups suggested that there was
significant elastin loss in all groups after elastase treatment (p<0.05) (Figure 4.16).
Though, NEO showed significantly improved stability than GLUT in weight loss studies
and IHC after elastase treatment, there was no significant difference in their desmosine
content (p<0.05). This suggested the fact that elastin could still be vulnerable to
degradation in fixed prosthesis and could be supplemented with other treatments for
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further stabilization. FRESH tissue desmosine content after elastase was significantly
lower than other fixed groups after elastase (p<0.05).

Figure 4.16: Desmosine content of cusps from different groups before and after elastase
treatment

4.3.10. Subdermal implantation studies:
The cusps in the NEO group retained significantly more GAGs as compared to ENG and
GLUT groups after three weeks of subdermal implantation (p<0.05), (Figure 4.17).
Calcium assay showed that cusps from NEO and ENG groups had significantly (p<0.05)
lower calcification compared to GLUT (Figure 4.18). However the GAG stabilization
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did not lead to inhibition of calcification. As all groups were terminally fixed with
glutaraldehyde, which is known to exacerbate calcification [2, 3, 135], it is possible that
glutaraldehyde effect was dominant in the calcification process. The phosphorous
analysis indicated that there was no significant difference between the different groups
(Figure 4.18). The calcium: phosphorous molar ratios were calculated for each group;
NEO = 1.42, ENG = 1.49, GLUT = 1.64.

Figure 4.17 – Hexosamine content of cusps fixed in NEO, ENG and GLUT groups
following 21 days of implantation.
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Figure 4.18 – Quantitative calcium and phosphorous content of cusps fixed in different
groups and explanted after 21 days subdermal implantation.

4.3.11. Histological evaluation:
Qualitative amounts of GAGs present in the cusps in the three groups were
determined by Alcian Blue staining with Brazilliant!® nuclear fast red as counter stain.
Cusps crosslinked with GLUT retained the least amount of GAGs as seen by the least
amount of blue stain, while cusps in ENG group and in NEO group retained more GAGs
as seen by the higher intensity of blue stain (Figure 4.19). Alcian blue staining for GAGs
was also performed on cuspal sections implanted for 21 days to visualize the presence of
GAGs. NEO retained more GAGs compared to ENG and GLUT after explantation. Also,
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Dahl’s Alizarin red staining was performed to visualize the presence of calcium deposits
on the explanted cusps (Figure 4.20). There was no significant difference in the intensity
of alizarin red staining for cusps explanted from different groups .

Figure 4.19 – Alcian Blue staining for GAGs with nuclear fast red counter stain of cusps
fixed in NEO, ENG and GLUT

Figure 4.20: Explant tissue histology using alcian blue staining (A to C) and alizarin red
staining (D to F). NEO: Panels (A and D), ENG: Panels (B and E) and GLUT: Panels (C
and F)
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4.3.12. Gel electrophoresis (zymography):
Tissue capsules surrounding cusps were analyzed for HA-degrading enzymes by
HA zymography. This assay showed similar band intensities for active hyaluronidases in
all groups. Thus hyaluronidase activity (migrating at ~ 55 kD) was similar in all the
groups (Figure 4.21). It confirmed that, presence of more GAGs in the NEO group was
not due to lower enzyme activity in this group as compared to other groups. When
neomycin trisulfate was added to the development buffer it inhibited enzyme activity
(Figure 4.21). This suggests that incorporation of neomycin trisulfate into cuspal
structures could prevent enzyme-mediated degradation of GAGs in BHVs.

Figure 4.21 – HA gel zymography on soluble proteins extracted from the capsule
surrounding the three weeks explanted cusps. Addition of 1mM neomycin trisulfate to the
developing buffer inhibited enzyme activity (lanes DN1 and DN2).
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4.4 Discussion and Conclusions
Glycosaminoglycans are high molecular weight, hydrophilic, and anionic
polysaccharides that are able to support large compressive loads [200]. These molecules
are present extensively in cartilage, heart valve cusps and other cardiovascular connective
tissues. It has been shown previously that GAGs play an important role in cartilage
lubrication and biomechanical function [39]. Also it has been shown that GAGs are
responsible for the water storage capacity that gives the articular cartilage its unique
property of hydration and compressibility [201]. GAGs are present in the spongiosa layer
of heart valve cusps and prevent local compressive buckling during valve function.
Glutaraldehyde crosslinking of porcine aortic valves does not stabilize GAGs present in
the cusps and these GAGs leach out during storage, in vitro cyclic fatigue, and in vivo
implantation [21, 38, 134]. Such loss of GAGs may be partly responsible for valve
deterioration [2].
Our previous attempts to chemically stabilize GAGs were only partially
effective in preventing GAG loss. Enzyme mediated GAG degradation could not be
abolished by chemical GAG stabilization [21, 38, 134]. The purpose of the present study
was to evaluate the effectiveness of a hyaluronidase inhibitor coupled with carbodiimide
based crosslinking chemistry as a targeted GAG stabilization strategy for improved valve
function.
We chose neomycin trisulfate as a GAG enzyme inhibitor for several reasons. It
has been shown that sulphated neomycin possess comparable inhibition for all
hyaluronidases and much more than the widely accepted hyaluronidase inhibitor apigenin
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[182]. Our HA zymography studies also showed that neomycin trisulfate has an
inhibitory effect on hyaluronidase. Neomycin trisulfate also has amine functionalities that
could be utilized to chemically attach it to the cusps with carbodiimide chemistry. Thus,
binding of neomycin to the cusps was achieved by this chemistry. IHC studies clearly
showed that such binding of neomycin was effective and it was uniformly bound
throughout the cusp tissue.
Chemically bound neomycin significantly inhibited enzyme-mediated
GAG degradation in the cuspal tissue. This, to our knowledge, is the first time that bound
neomycin was shown to be effective in preventing GAG degradation in BHVs. Sulphated
oligosaccharides such as neomycin trisulfate have a combination of hydrophilic moiety
with an affinity-conferring lipophilic residues that bind to hyaluronidase thereby blocking
the enzymatic degradation [182]. It has been shown previously [13] that EDC activates
the carboxyl group of the GAGs and collagen and this further forms a stable intermediate
with NHS. This intermediate forms an amide crosslinks with the free amine groups of
collagen thereby crosslinking the GAGs effectively. Carboxyl groups of GAGs are the
active sites for enzyme-mediated degradation [178, 202]. Thus, ENG crosslinking was
partially effective in preventing GAG degradation as some of the carboxyl groups were
utilized in GAG crosslinking. However, EDC crosslinking does not crosslink all
carboxyls present in the structure of GAGs and some of the carboxyl residues are still
prone to enzyme-mediated degradation. Additional binding of neomycin trisulfate along
with ENG crosslinking (NEO group) inhibited enzyme-mediated degradation and thus
further prevented GAG loss. Our data showed that binding of neomycin inhibited
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GAGases as well as papain mediated degradation. Hexosamine values in the cusps in
GLUT and ENG groups after papain digestion were much lower than after GAGase
digestion. This may be because papain digests non-GAG related hexosamines from the
tissue. Binding of neomycin also significantly prevented degradation of non-GAG related
hexosamines. Whether this has any clinical implications is uncertain at this time.
Because carboxyl groups of GAGs are the active sites for enzyme-mediated
degradation [178, 202], we investigated whether neomycin’s binding with the carboxyl
groups of GAGs could be the cause of its effectiveness in preventing GAG loss. We used
DOS control as a substitute for neomycin. Since the structure of DOS is similar to that of
neomycin, yet DOS does not inhibit GAGases, we compared GAG stability. DOS-linking
only partially prevented GAG loss. These results suggest that the inhibitory action of
neomycin on GAG loss is due to a combination of binding to GAGs’ carboxyl groups and
inhibiting GAGase activity within the cusps.
Collagen fibers impart the framework and provide mechanical strength to the
heart valve cusps [135]. To minimize valve degeneration, it is essential to maintain the
stability of collagen [2, 21, 134]. Thermal denaturation temperature Td, also called as
shrinkage temperature is used as a measure of collagen crosslinking [1]. Results from our
studies for Td values showed that the denaturation temperature of tissues treated with
NEO, ENG and GLUT are in the comparable range as reported previously by our group
[20, 21, 134]. Thus, additional binding of neomycin did not affect collagen crosslinking
in the cusps. Our results showed that neomycin binding prior to glutaraldehyde
crosslinking improved the resistance of BHV cusp collagen to collagenase as compared
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to GLUT crosslinking alone. Thus, collagen crosslinking by glutaraldehyde was further
enhanced by neomycin linking.
In native cusps elastic fibers in the ventricularis layer, arranged radially, are
believed to contribute to recoil of cusps, minimizing surface area during systole (when
the valve opens), and to stretch during diastolic back pressure to form large coaptation
areas [203]. The role of elastin in BHVs is not clear, and no studies have focused on
elastin stabilization in BHVs. It is believed that elastin forms a matrix and surrounds the
collagen fiber bundles that help to return the collagen fibers to their undeformed state,
maintaining rest geometry [33, 204]. In the same studies, damage to elastin fibers was
found to distend the cusps, resulting in reduced extensibility and increased stiffness.
Elastases were also found to remove proteoglycans nonspecifically [205]. We found that
neomycin linking increased cusp resistance to elastases in weight loss studies. Immunohistochemistry for elastin after elastase digestion showed intact fibers in neomycin
(NEO) group and completely degraded elastin in GLUT crosslinked cusps. However,
desmosine content of cusps from neomycin and glutaraldehyde were found to be similar
after elastase treatment. Further studies are warranted to prove that neomycin is more
effective in preserving elastin compared to glutaraldehyde.
The ultimate test of any fixative is to prevent in vivo enzyme mediated
GAG degradation. We have shown earlier that chemical crosslinking of GAGs was only
partially effective in preventing GAG loss in vivo when the cusps were implanted
subdermally in rats [21, 38, 134]. In the present study, neomycin binding to the cusps
significantly abolished in vivo enzyme mediated GAG degradation. Chemical linking of
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GAGs with carbodiimide chemistry alone was not effective in preventing GAG loss and
GAG loss in ENG group was comparable to glutaraldehyde crosslinked cusps. The
overall values for hexosamines normalized to dry weight of the tissue were lower after
implantation as the cusps gain little weight after implantation probably due insudation of
proteins.
It has been hypothesized that GAGs might act as inhibitors of calcification in
cartilage [38]. However, role of GAGs in preventing bioprosthetic heart valve
calcification is still unclear. Recently, Herrero and colleagues have shown increases in
calcification of bovine pericardium when GAGs were selectively removed from the tissue
[206]. Additionally, others have demonstrated the ability of utilizing added exogenous
GAGs to successfully mitigate calcification of BHV tissue [207]. Furthermore, distinct
losses in GAGs have been observed in clinically explanted calcified BHVs [28, 208]. In
present study, cusps from GAG-fixation groups NEO and ENG, showed lower
calcification than GLUT fixed cusps, but the calcification was not completely inhibited
despite the fact that NEO group had considerable amounts of GAGs. Initial calcification
deposits in BHVs occur in devitalized cells. As cusps from all groups were crosslinked
with glutaraldehyde, it may be possible that GAG stabilization had very little effect in
preventing cell-mediated calcification. Thus, GAG stabilization chemistries need to be
combined with well known anti-calcification strategies to prevent calcification and
degeneration of BHVs.
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The following conclusions could be drawn from our studies
•

GAG stability studies using GAG degrading enzymes suggested that neomycin
fixed

tissue

prevented

complete

enzymatic

degradation

compared

to

glutaraldehyde fixed tissue.
•

GAG fixation was only partially effective in tissues fixed with carbodiimide, deoxystreptamine and glutaraldehyde.

•

GAG digestion using GAGase mixture or papain digestion, both resulted in GAG
loss in glutaraldehyde stabilized cusps. Neomycin was effective in preserving
GAGs after both methods of digestion.

•

Chemically bound neomycin significantly inhibited enzyme- mediated GAG
degradation in the cuspal tissue. This, to our knowledge, was the first time that
bound neomycin was shown to be effective in preventing GAG degradation in
BHVs.

•

HA gel zymography suggested that neomycin had comparable inhibition of
hyaluronidase.

•

1 mM concentration of neomycin was used for fixation of cusps in all studies.
Optimum concentration needed should be further found by other methods such as
using radio labeling the neomycin used for fixation.

•

Thermal denaturation temperature and percent weight loss study using
collagenase suggested that neomycin fixation stabilized collagen better than
glutaraldehyde.

122

•

Hydroxyproline studies suggested that collagen is adequately preserved in fixed
tissue compared to fresh tissue.

•

Immunohistochemistry and percent weight loss suggested elastin being stabilized
using neomycin crosslinking better than other fixatives. Quantitative elastin
content by desmosine analysis yielded no significant different between various
groups. Further studies are warranted to prove neomycin fixation could stabilize
cuspal tissue elastin.

•

Subdermal implantation studies suggested that neomycin retains more GAGs
compared to other groups.

•

Neomycin fixation did not result in complete inhibition of calcification. Further
anticalcification treatments are required to inhibit calcification in neomycin fixed
valves.
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CHAPTER FIVE
CHARACTERIZATION OF GLYCOSAMINOGLYCAN LOSS AFTER
STORAGE AND IN VITRO CYCLIC FATIGUE

5.1. Introduction
Glycosaminoglycans (GAGs) have been shown to be an integral part of the heart
valve cusps for its proper function and working. GAGs present in the spongiosa layer,
resist compressive forces acting on the valve during the opening and closing of the valves
and thereby prevent tears at the point of maximum flexion. GAGs were also found to
chelate calcium by binding to them thereby avoiding the calcific valve failure. The
commercially available GLUT fixed valves were found to not stabilize the GAGs due to
absence of amine groups in GAGs. The aim of this study was to determine the
vulnerability of GAGs by quantifying the GAGs lost during storage, enzyme digestion
and after accelerated cyclic fatigue.

5.2. Methods
5.2.1. Tissue Preparation:
The aortic valves obtained at the time of slaughter were fixed as detailed in
section 4.2.1 using NEO, ENG and GLUT as shown in Table 4.1.

The flowchart 5.1 shows the overall design of experiments for long-term storage studies
and in vitro cyclic fatigue testing studies.
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Flowchart 5.1: Design of experiments for long-term storage studies as well as in vitro
cyclic fatigue testing studies
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5.2.2. Storage Studies:
GAG content of cusps was monitored over time for about 1.5 years storage. Thus,
cusps treated with GLUT, ENG and NEO were stored for 4 months, 6 months, 12 months
and 18 months in 0.2 % GLUT. Effect of in-vitro enzymatic degradation of GAGs was
also determined at these time points by hexosamine content and DMMB assay. This
study was used to determine the GAGs lost due to storage as well as due to enzymatic
degradation after various time points.

5.2.3. Hexosamine assay:
The effect of storage as well as enzymatic degradation on cusps was determined
by performing hexosamine assay as mentioned in Section 4.2.4.

5.2.4. DMMB assay:
Dimethylmethylene Blue (DMMB) assay was used to determine the amount of
GAGs released into the enzyme / buffer liquids used for the storage studies as described
in Section 4.2.5.

5.2.5. Cyclic fatigue studies:
Bioprosthetic heart valves (BHVs) were subjected to in vitro accelerated cyclic
fatigue testing to test GAG stability during valve function. Fresh porcine aortic valves
were obtained from the local abattoir in saline on ice. Within 3 hours after harvesting, the
valves were fixed in fixatives (GLUT and NEO only for fatigue testing studies). During
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fixation, the valve cusps and the valves were stuffed with cotton balls in order for the
valves to give a diastolic morphology and also to avoid backflow during fatigue testing.
After fixation, the valves are carefully trimmed and sutured onto delrin stents and rings as
shown in Figure 5.1. Utmost care is taken during trimming as any cuts will result in
stress propagation and tearing of the valves during testing. The valves were then mounted
carefully onto Dynatek Dalta M6 accelerated fatigue tester. 0.2% GLUT is used as the
circulating fluid in the tester. The setup of the tester and its components are shown in
Figure 5.2.
Three valves per group were mounted and they were tested at a rate of ~700
cycles / minute. In this protocol, approximately 37 days of testing (~38 million cycles)
would be equivalent to 1 year of in vivo functioning of the normal cardiac cycle of an
adult. The testing includes daily stroboscopic checking of the valves and pressure
observations for any discrepancies. The valves were subjected to 10 million or 50 million
cycles. Also, in order to determine the effect of storage followed by fatigue, NEO fixed
cusps were stored for upto 8 weeks and further subjected to 10 million cycles of
accelerated fatigue testing.

Figure 5.1: Valve preparation for in vitro accelerated fatigue testing
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Figure 5.2: Setup of M6 Dynatek Dalta Accelerated Fatigue Tester
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5.2.6. Histology:
Histological assessment after accelerated fatigue cycling were performed on
paraffin embedded cuspal tissue sections. Alcian blue staining with Brazilliant!® nuclear
fast red (Anatech Ltd, Battle Creek, MI) as a counter stain was used to stain for GAGs.
Histological images were captured using a Zeiss Axioskop 2 plus (Carl Zeiss
MicroImaging, Inc., Thornwood, NY) coupled along with an image analysis software
(SPOT Advanced).

5.2.7. Data Analysis:
All data were expressed as a mean ± standard error of the mean (SEM). Statistical
analysis was performed using single factor analysis of variance (ANOVA). Differences
between the means were determined using least significant difference (LSD) with a pvalue of 0.05.

5.3. Results
5.3.1. Storage Studies:
GAGs have been previously found to be lost from BHVs after storage [21]. This
becomes an important issue as valves have up to 3 years of storage life prior to
implantation. We investigated GAG stability in BHVs that were stored for up to 18
months.
NEO group was found to be effective against GAG-degrading enzymes for up to
18 months of storage whereas GLUT group showed progressive loss of GAGs after
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enzymatic degradation as storage time increased (Figure. 5.3 – 5.6). GLUT fixed tissue
lost about 40.5% of GAGs after 1 year of storage in GLUT solution while NEO stabilized
tissue lost only about 2.25% of GAGs. In case of undigested valves, NEO lost only
0.42% of GAGs from 4 months to 18 months. In contrary, GLUT fixed undigested valves
lost about 13.05% of GAGs from 4 months to 18 months. This suggests that the GLUT
stabilization of cusps is very vulnerable to the GAGs degeneration due to storage. GAGs
leach out from these valves even without the action of GAG degrading enzymes. NEO
fixed valves on the other hand can be seen to inhibit the action of GAG degrading action
even after 18 months of storage and after enzymatic degradation (Figure 5.6).

Figure 5.3: Hexosamine content of cusps fixed in NEO, ENG and GLUT and stored in
0.2% GLUT for 4 months storage
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Figure 5.4: Hexosamine content of cusps fixed in NEO, ENG and GLUT and stored in
0.2% GLUT for 6 months storage

Figure 5.5: Hexosamine content of cusps fixed in NEO, ENG and GLUT and stored in
0.2% GLUT for 1 year storage
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Figure 5.6: Hexosamine content of cusps fixed in NEO, ENG and GLUT and stored in
0.2% GLUT for 1.5 years storage
DMMB assay was performed on the enzyme / buffer liquid used for digestion of
cusps to determine the amount of GAGs released into the enzyme solution. Better
crosslinking is depicted by lower amounts of GAGs in the enzyme solution. DMMB
assay results on enzyme solutions after 4, 6 and 12 months storage showed progressive
loss of GAGs from GLUT group with significant amount of GAGs loss at each time point
(p<0.05). Only negligible amount of GAGs was released from cusps in NEO group as
compared to GLUT group (Figure. 5.7 – 5.9) (p<0.05). These results suggest that NEO
crosslinking was significantly effective in preventing GAG loss due to storage.
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Figure 5.7: DMMB assay for total GAGs released from cusps fixed in NEO, ENG and
GLUT and stored in 0.2% GLUT for 4 months storage

Figure 5.8: DMMB assay for total GAGs released from cusps fixed in NEO, ENG and
GLUT and stored in 0.2% GLUT for 6 months storage
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Figure 5.9: DMMB assay for total GAGs released from cusps fixed in NEO, ENG and
GLUT and stored in 0.2% GLUT for 1 year storage

5.3.2. Cyclic fatigue studies:
In vitro cyclic fatigue experiments were conducted to assess whether neomycin
crosslinking is effective in GAG stabilization after cyclic fatigue testing for up to 50
million cycles. After 10 million cycles, cusps from GLUT group lost 9.5% GAGs while
NEO fixed tissue lost only 6.22% GAGs (Figure 5.10). There was no significant
difference between uncycled and 10 million cycled samples in NEO group (p<0.05)
suggesting complete GAG stability. Furthermore, GLUT group continued the trend of
losing more GAGs at 50 million cycles (Figure 5.11). NEO group on the other hand
experienced only a very slight decrease in the GAG content from 10 million to 50 million
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cycles, which was insignificant (p>0.05). After 50 million cycles, cusps from GLUT
group lost 42% GAGs while NEO fixed tissue lost only 7.12% GAGs (Figure 5.11).

Figure 5.10: Hexosamine content of NEO and GLUT fixed cusps following in vitro
fatigue cycling for 10 million cycles.

Since GAG loss occurs even during storage in GLUT solution, cusps fixed with
NEO and stored up to 2 months in 0.2% GLUT were fatigue tested for 10 million cycles
to evaluate the effect of storage coupled with fatigue on NEO cusps only. There was no
significant difference in GAG content between the uncycled control and the cycled
samples in the NEO group (Figure 5.12).
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Figure 5.11: Hexosamine content of NEO and GLUT fixed cusps following in vitro
fatigue cycling for 50 million cycles.

Figure 5.12: Hexosamine content of NEO fixed cusps stored upto 2 months and in vitro
fatigue cycled for 10 million cycles.
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Histological staining was performed on samples in an effort to qualitatively
visualize the presence of GAGs after fatigue. The presence of blue stain and its relative
intensity in alcian blue staining is related to GAG content. Cusps in NEO group showed
greater intensity of blue stain in the spongiosa layer than cusps in GLUT group
suggesting it retains more GAGs than GLUT group after 50 million fatigue cycles
(Figure 5.13). Moreover, cusps in GLUT group showed voids in the spongiosa layer after
GAG loss.

Figure 5.13: Alcian Blue staining of cusps after 50 million fatigue cycles (A) NEO, (B)
GLUT

5.4. Discussion
BHVs are approved by the FDA for a 3-year storage life; they are routinely stored
for a few months-to-a year before implantation. In the present studies, the effectiveness
of GAG stabilization after storage was determined for three time points: 4 months, 6
months, 12 months and 18 months. NEO treated cusps inhibited enzymatic degradation of
GAGs, for up to one year of storage; GLUT treated cusps progressively lost GAGs
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during storage, which suggests that GAGs are leaching into the storage solution due to
incomplete GAG fixation. Additional studies are needed to confirm whether GLUT-fixed
BHVs that are stored for extended period will degenerate earlier after implantation than
neomycin-linked BHVs.
Neomycin binding prevented GAG loss from cusps for up to 50 million cycles,
while significant GAGs were lost from GLUT crosslinked BHVs. Because of the risks
associated with both surgery and in vivo valve failure, the FDA Replacement Heart
Valves Draft Guidance, V.5.0., requires samples from every batch of bioprosthetic heart
valves to be cycled in vitro for 200 million cycles and to undergo performance analysis
before implantation [99, 209]. GLUT-fixed BHVs, first approved for human use four
decades ago, perform adequately for a minimum of 200 million cycles in vitro cyclic
fatigue experiments. Clearly, GAG loss during first 50 million cycles does not affect
biomechanical performance. In terms of years of functional life, a period of 200 million
cycles corresponds to only 5.years. Many BHVs fail due to degeneration after 10-15
years of implantation.

5.5. Conclusions and recommendations
The following conclusions could be drawn from the long-term storage and in vitro
cyclic fatigue testing studies:
•

Neomycin inhibited GAG degradation for upto 1.5 years of storage. Enzyme
mediated GAG degradation was also inhibited upto 1.5 years of storage
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•

Glutaraldehyde stabilized cusps progressively lost GAGs due to storage and after
enzymatic degradation as storage time point increased.

•

Neomycin also inhibited GAG degradation for upto 50 million cycles fatigue
suggesting GAGs were not lost in neomycin stabilized cusps due to valvular
function.

•

Glutaraldehyde fixed valves lost GAGs both after 10 and 50 million fatigue
cycles.

•

Further studies are warranted to prove the efficacy of neomycin fixation during
valve function for upto 200 million fatigue cycles and also for upto 3 years
storage time.

•

Valves could be cycled in fluids with physiological viscosity to assess the
shearing on the cusps. Structural morphology of cusps could be assessed by
scanning electron microscopy (SEM) to determine the microstructural damages
due to shear.
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CHAPTER SIX
ANTI-CALCIFICATION TREATMENTS AND QUANTIFICATION FOR
BIOPROSTHETIC HEART VALVES

6.1. Introduction
Bioprosthetic valve failure occurs either due to degeneration or calcification or
their combination. In our preliminary studies we showed that despite effective GAG
preservation, NEO treatment did not completely prevent cusp calcification after
subdermal implantation in juvenile rats. Ethanol pretreatment of glutaraldehyde fixed
cusps was shown to inhibit cusp calcification in animal studies including rat subdermal
and sheep mitral valve implants [149]. This anti-calcification pretreatment is currently
clinically used for BHVs as a Linx® technology by St. Jude Medical Inc. We have
observed that ethanol pretreatment is unable to stabilize GAGs in the cusps (unpublished
data). The goal of proposed experiments is to evaluate whether we can implement ethanol
pretreatment after NEO stabilization, without hindering GAG stability and without
reducing the anti-calcification potential of the ethanol treatment.
Also, it has been long known that the free aldehyde groups present in the
bioprosthetic tissue after glutaraldehyde fixation was a major culprit leading to the
bioprostheses calcification and ultimately failure [15, 96, 146]. Sodium borohydride had
been used as a reducing agent or Schiff quenching agent to reduce and eliminate the free
aldehyde groups of tissues processed with glutaraldehyde [210-213]. It has been
previously shown by Connelly et al that, sodium borohydride reduction followed by
ethanol pretreatment of the valves was very effective in inhibiting cuspal calcification
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[210]. Therefore, the eventual goal of this study was to study the anticalcific effects of
ethanol treatment and sodium borohydride treatment combined as well as separately. This
would help us achieve an ideal anti-calcific treatment for our novel NEO fixed valves.

6.2. Methods
6.2.1. Tissue preparation:
Porcine aortic valve cusps were obtained from a local abattoir in saline and
brought to the laboratory on ice. These cusps were fixed in NEO or GLUT fixation as
mentioned previously in Section 4.2.1. These tissue cusps were further used for
anticalcification studies using the protocol mentioned below.
Valve cusps fixed with NEO and GLUT were treated with sodium borohydride
and / or ethanol to evaluate their anticalcification effects. The anticalcification effects of
ethanol and sodium borohydride has been previously reported in the literature [148-150,
210, 214-216]. The treatment conditions for different groups used for this study are
shown in Table 6.1.
Group ID

NEO + EtOH

GLUT +
EtOH

Acronyms

Treatment Conditions

Neomycin fixation

NEO treatment followed by 80% ethanol in

followed by ethanol

HEPES (pH 7.4) for 24 hours

Glutaraldehyde
GLUT treatment followed by 80% ethanol in
fixation followed by
HEPES (pH 7.4) for 24 hours
ethanol
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NEO treatment followed by NaBH4
NEO +

Neomycin fixation

treatment (0.08 M) in carbonate buffer (0.1

NaBH4

followed by NaBH4

M NaHCO3, 0.1 M Na2CO3, pH 10.3) for 24
hours
GLUT treatment followed by NaBH4

GLUT +
NaBH4

Glutaraldehyde
treatment (0.08 M) in carbonate buffer (0.1
fixation followed by
M NaHCO3, 0.1 M Na2CO3, pH 10.3) for 24
NaBH4

hours
NEO treatment followed by NaBH4

NEO +

Neomycin fixation

treatment (0.08 M) in carbonate buffer (0.1

NaBH4 +

followed by NaBH4

M NaHCO3, 0.1 M Na2CO3, pH 10.3) for 24

EtOH

and ethanol

hours. This is followed by 80% ethanol
treatment in HEPES (pH 7.4) for 24 hours
GLUT treatment followed by NaBH4

GLUT +

Glutaraldehyde

treatment (0.08 M) in carbonate buffer (0.1

NaBH4 +

fixation followed by

M NaHCO3, 0.1 M Na2CO3, pH 10.3) for 24

EtOH

NaBH4 and ethanol

hours. This is followed by 80% ethanol
treatment in HEPES (pH 7.4) for 24 hours

Table 6.1: Group identification for anticalcification treatment followed by fixation
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The flowchart 6.1 shows the design of experiments for the anti-calcification studies

Flowchart 6.1: Design of experiments for the anti-calcification studies
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6.2.2. Stability of cusps against in vitro GAG degrading enzyme:
The cusps fixed in different fixatives as mentioned above are taken through the
similar protocol for GAG digestion as mentioned in Section 4.2.3. The

samples

after

digestion are lyophilized and weighed. The dried cuspal samples were analyzed for
cuspal tissue hexosamine content as mentioned in Section 4.2.4. The GAGs released into
the buffer / enzyme was quantified using DMMB assay as mentioned in Section 4.2.5.
The tissue hexosamine content or the total GAGs measured were finally normalized to
tissue dry weights. Number of samples used were n=6 per group in order to maintain
statistical significance.

6.2.3. Weight loss studies of cusps against collagenase and elastase:
Collagen and elastin are the two major extracellular matrix components in the
valvular cusps apart from GAGs. In order for a valve to function and mimic the native
valve, these ECM components should be preserved properly as well. Therefore, cuspal
tissue weight loss against elastase or collagenase was determined. This was done for the
cusps fixed in neutralizing or anti-calcification agents. Briefly cusps were dried,
lyophilized and weighed to measure the initial dry weights. The cusps were further
rehydrated and treated with porcine pancreatic elastase or type VII collagenase as
mentioned previously in Section 4.2.9. For elastase studies, samples were incubated for
24 hrs and for collagenase studies, samples were incubated for 48 hrs. The samples were
incubated at 37°C with orbital shaking at 650 rpm. The enzyme digested samples were
again dried, lyophilized and the final dry weights measured. The percentage weight loss
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due to elastin or collagen degradation was calculated from the initial and final dry
weights before and after treatments of elastase or collagenase respectively. In order to
have statistical significance (n=6) number of samples were used.

6.2.4. Measurement of thermal stability of collagen crosslinks:
Thermal stability of the collagen crosslinks were determined using differential
scanning calorimetry (DSC). The denaturation temperature (Td) denotes the temperature
at which the collagen triple helix is broken and is a direct indicative of the collagen
crosslink stability. Samples were heated in hermetically sealed pans from 20 to 110°C at
a rate of 10°C/min. Td, the temperature at the endothermic peak was determined and
compared for cusps fixed in different groups.

6.2.5. Subdermal Implantation Studies:
The cusps fixed in different groups as mentioned in Table 6.1 were treated with
ethanol and / or sodium borohydride (n=10 per group). Cusps were rinsed in sterile saline
prior to implantation to remove residual glutaraldehyde, ethanol or sodium borohydride.
Male juvenile Sprague-Dawley rats (35-40g, Harlan Laboratories, Indianapolis, IN) were
anesthetized by inhalation of 3% isoflurane gas and two subdermal pockets were created
in the dorsal side. Cusps were implanted into the pocket (one cusp per pocket, 2 cusps per
rat) and the incision was closed using surgical staples. Cusps and the capsule tissue
surrounding the cusps were explanted after three weeks (21 days). All animals received
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humane care in compliance with protocols approved by Clemson University Animal
Research Committee as formulated by NIH (Publication No. 86-23, revised 1996).
Cuspal explants were further used for hexosamine, calcium, phosphorous and histological
analysis. Cuspal explants for GAG quantification were immediately frozen on dry ice and
lyophilized.

6.2.6. Calcium and Phosphorous analysis:
In order to determine the extent of calcification, a portion of the sample from the
explants was used for calcium and phosphorous quantification. Calcium analysis was
performed using atomic absorption spectroscopy and phosphorous quantification was
done using a molybdate complexation assay.
The same protocols as mentioned in Section 4.2.15 were used for determination
of calcium and phosphorous content. Standard curve is obtained by using calcium and
phosphorous standards of known concentrations and was used to quantify the unknown
calcium and phosphorous content of the tissue. The calcium and phosphorous content
were finally normalized to the tissue dry weights.

6.2.7. Histological Analysis:
For histological evaluation using paraffin sections, samples were placed in 10%
alcoholic acid formalin at room temperature for 24h prior to infiltration and embedding.
Following fixation, samples were dehydrated, infiltrated with paraffin wax in a tissue
processor. Radial cuspal sections were embedded into paraffin blocks after processing the
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tissue. 5 µm sections were cut using a microtome and scooped onto microscope slides.
These sections were used for various histological analyses.
Generally cuspal morphology was analyzed by staining using hematoxylin and
eosin. GAGs were visualized in the samples using an Alcian Blue staining with
Brazilliant!® nuclear fast red as a counter stain (Anatech Ltd., Battle Creek, MI) [134]. In
order to visualize the presence of calcium deposits after implantation, Dahl’s alizarin red
stain for calcium was used with light green counter stain.

6.2.8. Specimen bending preparation:
For bending studies to measure the tissue buckling, cusps fixed in NEO and
GLUT followed by ethanol treatment alone (i.e., GLUT + EtOH and NEO + EtOH) were
bent against the native curvature. Cusps were excised from the aortic root and 5 mm
circumferential strips were obtained from the belly region of the cuspal tissue. These
strips were bent to desired curvatures to mimic physiological bending in the belly region
of cusps (Figure 6.1). In native valves, the annulus expands when the valve opens. In
bioprosthetic valves, since they are fixed or fixed and stented, the expansion of annulus is
restricted resulting in irregular folding of cusps [154]. This results in reverse bending
curvatures, characterized by the fibrosa on the outside of the bend [217, 218]. Stainless
steel pins were pierced through either ends of the strips and the ends were separated to a
desired radius of curvature. They were further held in place by using cork stoppers at
either ends of the pin for 24 hours in 0.2 % Glut solution. These samples were sectioned
with bent configuration for histological observations to determine tissue buckling.
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The radius of curvature was varied by changing the length of the tissue to satisfy
the following relationship:
s=r*θ radians
whereby s denotes the arc length of the curvature, r represents the radius of curvature,
and θradians is the radian angle of the arc.

Figure 6.1. Specimen bending preparation for tissue buckling studies

6.2.9. Tissue buckling quantification:
Zeiss Axioskop 2 plus (Carl Zeiss MicroImaging, Inc., Thornwood, NY) along
with SPOT Advanced software were use to quantify the extent of buckling. The actual
curvature of the bending, tissue thickness, and depth of buckling were measured using
measuring and drafting functions such as circular and linear dimension features of the
SPOT Advanced software. A circle was fitted visually to the semi-circular arc of the
tissue to determine the radius of curvature. The tissue thickness was measured by
averaging the local thickness of the tissue away from the sites of tissue buckling. Depth
of tissue buckling was quantified by measuring the distance between the deepest point of
buckling and the inner boundary of the tissue thickness (Figure 6.2). The fractional depth
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of buckling represents the ratio of buckling depth to the local tissue thickness. The
curvature was multiplied by the local thickness of tissue in order to normalize the
variation in tissue thickness between samples. Thus, the degree of buckling depth was
affected by both curvature and tissue thickness.
The extent of buckling increased as the radius of curvature decreased or as the
curvature of bending increased. This was demonstrated by plotting fractional depth of
buckling versus the product of tissue thickness and curvature of bending as described
previously by Vesely, I. et al [218, 219]. NEO was found to have lower depth of buckling
before and after GAG digestion compared to GLUT as shown previously [220].

Figure 6.2: Buckling depth quantification: Buckling depth was quantified by measuring
the deepest point of the buckling to the inner boundary of the tissue. Arc length is
measured by fitting a circle to the outer boundary of the tissue.
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6.2.10. Statistical Analysis:
All data were expressed as a mean ± standard error of the mean (SEM). Statistical
analysis was performed using single factor analysis of variance (ANOVA). Differences
between the means were determined using least significant difference (LSD) with a pvalue of 0.05.

6.3. Results
6.3.1. Stability against GAG degrading enzymes:
In order to determine stability of the cusps against GAG degrading enzymes,
cusps treated with sodium borohydride and / or ethanol were analyzed using hexosamine
and DMMB assays with and without GAG digestion, as previously mentioned.
After in vitro GAG digestion, all the NEO groups had no significant difference
between GAG digested and undigested samples (p<0.05) (Figure 6.3). There was
significant difference between GAG digested and undigested in all the GLUT groups
(p<0.05) (Figure 6.3). Also, NEO+EtOH and NEO+NaBH4+EtOH retained more GAGs,
before and after digestion, compared to other groups. Though NEO+NaBH4 resisted
GAG degradation, it retained significantly lower amount of GAGs compared to
NEO+EtOH and NEO+NaBH4+EtOH. DMMB assay results shown in Figure 6.4 also
correlated with the hexosamine results, showing lower amount of GAGs released into
enzymes / buffer in NEO groups.
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Figure 6.3: In Vitro hexosamine content for anti-calcification and neutralization studies
with and without GAG digestion. It can be seen that all NEO groups resisted GAG
degradation while there was significant GAG removal in case of GLUT groups.
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Figure 6.4: Total GAGs released into the enzymes / buffers measured using DMMB
assay for anti-calcification and neutralization studies.

6.3.2. Weight loss studies of cusps against collagenase and elastase:
Collagenase and elastase weight loss studies were performed by in vitro digestion
of these cusps in either elastase or collagenase. This was done to show that the improved
GAG stability followed by anti-calcification and neutralizing treatments did alter the
collagen and elastin stability. After elastase digestion, there was a significant difference
(p<0.05) between NEO and GLUT cusps in every group except ethanol treatment alone.
A similar trend was observed in the case of collagenase digestion (Figures 6.5 and 6.6).
This suggested that NEO treated cusps had superior stability against both collagenase and
elastase apart from GAG degrading enzymes.
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Figure 6.5: Percent weight loss for anti-calcification and neutralization studies after
elastase digestion

Figure 6.6: Percent weight loss for anti-calcification and neutralization studies after
collagenase digestion
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6.3.3. Measurement of thermal stability of collagen crosslinks:
Thermal denaturation temperature (Td), a measure of the stability of the collagen
crosslinks, was measured by using DSC on each fixation group to determine the
denaturation temperature. Table 6.2 shows that the denaturation temperature of cusps
fixed in different fixatives were in the acceptable range and there was no significant
difference between groups suggesting no adverse effects on collagen stability.

Table 6.2: Thermal Denaturation temperature of cusps fixed in different groups

6.3.4. Subdermal Implantation Studies:
The purpose of the subdermal implantation studies were two fold: (i)
determination of GAG retention following implantation on cusps that underwent
anticalcification and neutralization treatment and (ii) determination of calcification of
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cusps fixed in different groups after anticalcification and neutralization treatment. The
failure of the previous study to show a decrease in cuspal calcification after GAG
retention prompted this study utilizing ethanol pretreatment and sodium borohydride
neutralization to decrease the calcification potential of the implanted tissue. Data
obtained from the explanted cusps suggested that NEO+EtOH group retained most GAGs
after in vivo GAG digestion (p<0.05). NEO+NaBH4+EtOH and NEO+NaBH4 , though
resisting in vitro GAG digestion, did not resist in vivo GAG digestion compared to the
unimplanted control as can be seen from Figure 6.7. All the GLUT fixed groups also lost
GAGs after in vivo implantation significantly (p<0.05).

Figure 6.7: Hexosamine content of cusps fixed in different groups following 21 days
implantation in rats. Unimplanted cusps were used as control for comparison to
determine GAG loss due to implantation.
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Calcium and phosphorous data obtained from this experiment confirmed that
there is a decrease in calcium and phosphorous content in case of ethanol treated groups.
Sodium borohydride treatment by itself did not inhibit calcification as can be seen by
higher amount of calcium content in NEO+NaBH4 and GLUT+NaBH4 groups (p<0.05)
(Figure 6.8).

NEO+EtOH significantly calcified least compared to other groups

(p<0.05). GLUT+EtOH though calcifying less did not inhibit in vivo GAG digestion.
Although ethanol pre-treatment did serve to reduce the calcification potential of the
implanted cuspal tissue, it did not reveal any reduction in calcium content due to the
presence of cuspal GAGs. The calcium: phosphorous molar ratios were calculated as
shown in figure 6.8 above each group.

Figure 6.8: Calcium and phosphorous content of cusps fixed in different fixatives with
Ca: P molar ratios following 21 days implantation into Sprague Dawley rats
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Figure 6.9: Alcian blue staining for GAGs of cusps fixed in different fixatives after 21
days of implantation in male Sprague Dawley rats. (A) NEO+EtOH, (B) GLUT+EtOH,
(C)

NEO+NaBH4,

(D)

GLUT+NaBH4,

(E)

NEO+NaBH4+EtOH

and

(F)

GLUT+NaBH4+EtOH.

6.3.5. Histological Analysis:
Alcian blue staining for GAGs and Dahl’s alizarin red staining for calcium
deposits were performed on histological sections of cusps obtained after in vivo
implantation. Figure 6.9 shows the alcian blue staining of cusps explanted from various
groups. The blue areas represent the presence of GAGs. It can be seen from Figure 6.9
that NEO groups significantly has greater intensity of blue stain compared to GLUT
groups. Figure 6.10 shows the alizarin red staining of cusps explanted after 21 days in
Sprague Dawley rats where red deposits show the presence of calcium. Ethanol treated
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groups can be seen to not have red deposits confirming that ethanol works as a good
anticalcification treatment.

Figure 6.10: Alizarin red staining for calcium of cusps fixed in different fixatives after
21 days of implantation in male Sprague Dawley rats. (A) NEO+EtOH, (B)
GLUT+EtOH, (C) NEO+NaBH4, (D) GLUT+NaBH4, (E) NEO+NaBH4+EtOH and (F)
GLUT+NaBH4+EtOH.

6.3.6. Depth of buckling analysis:
Cusps fixed in NEO and GLUT and further incubated in ethanol for
anticalcification treatment were analyzed for the dept of buckling by bending the cusps
against the native curvature. Cuspal tissue fixed with NEO + EtOH experienced least
degree of buckling (p<0.05) when compared to their GLUT + EtOH counterparts bent to
similar configurations (Figure 6.11). GAG digestion of GLUT + EtOH cusps resulted in
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a significant increase in the depth of buckling (p<0.05). There was no significant change
in the depth of buckling of NEO + EtOH after GAG digestion (p<0.05). This suggested a
greater propensity of the GLUT + EtOH group to buckle locally and fail eventually when
compared to NEO + EtOH group. This study followed a similar trend compared to NEO
and GLUT fixed cusps as shown by Shah et al [220] suggesting that ethanol treatment
did not have any detrimental effect on NEO fixed cusps.

Figure 6.11: Depth of buckling analysis: Cusps fixed in NEO and GLUT followed by
ethanol treatment was analyzed for buckling depth measurement. Graph shows the
fractional depth of buckling plotted against the product of thickness and curvature.
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6.4. Discussions
Deterioration is a major cause of bioprosthetic heart valves (BHVs) dysfunction
which is synergistically caused by two major factors (i) calcification and (ii) non-calcific
degradation of the matrix elements [2, 221, 222]. Despite, more than four decades of
work in the field of BHVs, an ideal BHV free from degenerative and calcification is yet
to be achieved. Calcification occurs in the valves due to multi-factorial reasons. Age,
mitral or pulmonary implant position, prosthesis design (stented or non-stented), structure
(porcine or pericardium, aortic wall portion or cusp), and effectiveness of antimineralization treatments are some of the factors [223]. Deterioration of the matrix
elements such as GAGs are prevented by using a neomycin as a fixative, which might
prevent the degenerative mode of BHV failure [220, 224]. Previous attempts to show that
GAG retention using NEO stabilization before and after GAG digestion leading to
decreased calcification failed. Therefore studies were performed using proprietary Linx®
technology using ethanol treatment and / or neutralization of aldehyde groups using
sodium borohydride. Previous studies have demonstrated the effectiveness and efficacy
of ethanol pretreatment and sodium borohydride [148-150, 210, 214, 216]. We wanted to
potentiate the effectiveness of ethanol treatment and sodium borohydride further by
trying to achieve least / nil calcification on our neomycin fixed BHV cusps. The goal was
to eventually have least calcification on valve cusps as well as increased resistance to
degeneration. This would ideally improve the durability of the valves several folds and
reducing the need for re-operation in failed bioprosthesis.
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GAGs and matrix elements have been previously shown to be important for the
functioning of the valves. Leaching of GAGs from valves during fixation, storage and
implantation have been implicated in the failure of BHVs [21, 38, 132-134, 220, 224].
Previous works showed the stability of GAGs in valve cusps following neomycin fixation
[220, 224]. Since these valve cusps were further treated with ethanol for anticalcification, in vitro stability studies were necessary before showing the in vivo stability.
In vitro stability against GAG degrading enzymes showed that all NEO groups retained
more GAGs significantly compared to all GLUT groups. GLUT groups significantly lost
GAGs after enzymatic degradation (p<0.05).
Collagen and elastin are the other two major ECM components present in the
valve. Anti-calcification treatment should not hinder or harm the stability of these
components, for the valves to be durable. Therefore cusps were analyzed for collagen and
elastin stability. Cusps also showed adequate stability against collagenase and elastase in
vitro in case of NEO stabilized cusps. Neither ethanol treatment nor neutralization using
sodium borohydride had a detrimental effect on the collagen crosslink stability as can be
seen by DSC studies. Fractional depth of buckling studies also suggested that
GLUT+EtOH groups significantly buckled more when compared to NEO+EtOH before
and after GAG digestion.
Though all NEO fixed group retained GAGs after GAG digestion in vitro, only
NEO+EtOH retained more GAGs after 21 days of subdermal implantation on male
Sprague Dawley rats (p<0.05). Also, NEO+EtOH had least amount of calcium phosphate
deposition compared to other groups (p<0.05). Sodium borohydride treatment by itself
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did not inhibit calcification. GLUT+EtOH though calcifying less did not retain enough
GAGs when compared to NEO+EtOH. NEO+EtOH treatment was very effective in
reducing calcification almost 2/3rd fold more than GLUT+EtOH treatment. This could
potentially reduce several problems imposed by the threat of calcification on the BHV
durability. Though GLUT+EtOH treatment was very effective in reducing calcification
compared to conventional GLUT fixed valves, NEO+EtOH calcification was
significantly least compared to GLUT+EtOH. NEO+EtOH treatment can be seen to have
very least and almost close to nil calcification. Therefore, neomycin fixation followed by
ethanol incubation could ultimately lead to increased GAG retention and reduced
calcification eventually leading to increased durability of BHVs.

6.5. Conclusions and recommendations
The following conclusions could be drawn from our anticalcification and
neutralization studies:
•

Anti-calcification treatment by ethanol incubation resulted in increased stability
of GAGs in neomycin fixed cusps both in vitro and after in vivo subdermal
implantation.

•

Ethanol treatment also resulted in the least calcification in neomycin fixed valves.

•

Sodium borohydride treatment by itself did not result in increased GAG stability
or reduced calcification.

•

Neomycin fixed cusps followed by ethanol treatment were found to be the ideal
group for GAG stabilization after in vitro and in vivo enzymatic degradation.

162

They were also found to have the least calcification. Therefore this treatment
could ideally used for bioprosthetic heart valves for their improved durability and
longevity.
•

Further studies using a sheep circulatory model could help us determine valve
stability using this treatment during function along with in vivo implantation.
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CHAPTER SEVEN
CHARACTERIZATION OF BIOMECHANICAL PROPERTIES OF
BIOPROSTHETIC HEART VALVE CUSPS

7.1. Introduction
Cardiac valves play an important role in controlling blood flow throughout the
body [225]. They act essentially as a check-valve that serves to prevent retrograde blood
flow [226]. The aortic valve is subjected to 30–40 million cycles of opening and closing a
year, which translates to approximately 3 billion cardiac cycles in a lifetime [226].
Hemodynamic environment in a heart imparts several mechanical forces on a functional
heart valve. Transvalvular pressure, axial, shear, and bending stresses and cyclic flexure
are some of the forces acting on the valves [47, 143, 144, 226]. The fact that heart valve
diseases preferentially occur in the aortic side (fibrosa) of the valvular cusps, where they
are exposed to unstable flow conditions, highlights the importance of shear in heart valve
biology and pathobiology [47] Normal hemodynamic forces have been shown to cause
constant ECM turnover in aortic valves. Altered mechanical forces are believed to induce
changes in aortic valve biology possibly leading to valvular disease [227]. However, as
bioprosthetic heart valve tissue is devitalized, BHVs cannot remodel as a response to
acting mechanical forces and are more prone to degradative failure. It is unclear if GAG
loss plays any significant role in BHV failure. A thorough study of the biomechanics of
the bioprosthetic heart valves either with or without GAGs would assist in understanding
the role of GAGs in tissue biomechanics. Thus we performed equibiaxial and uniaxial
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testing to see if the neomycin mediated GAG fixation alters the mechanics of cusps
compared to the glutaraldehyde crosslinked cusps.
Flowchart 7.1 shows the design of experiments for the biomechanical studies.

Flowchart 7.1: Design of experiments for biomechanical studies
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7.2. Methods
7.2.1. Tissue Preparation:
Mechanical testing was performed on cusps fixed with GLUT and NEO. Cusps in
both groups were treated with GAGase mixture (HAase+CSase) to see the effect of GAG
loss on tissue biomechanics. Aortic valves freshly obtained from the abattoir were fixed
in either GLUT or NEO fixatives as explained in section 4.2.1. Cotton balls were placed
behind cusps for the valves to maintain a closed geometry during the fixation process.
Subsequently, the cusps were excised from the fixed valves, rinsed well in 100mM
ammonium acetate buffer, pH 7.0, and incubated for 24 hours in either enzyme or buffer
as described previously in Section 4.2.3. Following digestion, cusps were stored in
buffered 0.2% glutaraldehyde until testing was conducted (no longer than 14 days).
Uniaxial cyclical tensile testing was performed in our laboratory while biaxial
mechanical testing of cusps was performed in the laboratory of Dr. Michael Sacks at The
McGowan Institute for Regenerative Medicine at The University of Pittsburgh.

7.2.2. Equibiaxial testing setup:
The fixed cusps were carefully excised from the aortic root and a 1 X 1 cm2
sample was carefully cut out from the belly region of the cusps (n=7 per group).
Specimen lengths were measured using a ruler and the specimen thickness (in triplicate)
was measured using a dial caliper micrometer to an accuracy of 0.25 mm. Care was taken
to make sure the samples remained hydrated with PBS during preparation and all biaxial
testing experiments were performed in PBS buffer. The square sample was glued with
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four markers on the ventricularis side using a cyanoacrylate adhesive (Permabond 268,
Permabond LLC). The markers were approximately separated by ~ 2.5 mm (Figure 7.1).

Figure 7.1: Sample preparation for biaxial testing
The load cells on the biaxial testers were calibrated before each use to get
accurate measurements. Two loops of Vicryl surgical sutures of equal length were
attached to each side of the specimen using four stainless steel surgical hooks. The
specimens were then mounted onto the biaxial device with the radial and circumferential
directions aligned with the lab axes. In this study, we used membrane stress (Tij, N/m)
instead of a measure of the three-dimensional stress since not all layers of the cusp bear
equal amounts of load. Tij is defined as the axial force per unit length of tissue over which
it is applied. Tij along each axis was slowly ramped up to 0.5 N/m during pre-stress
testing. Specimens were cycled for 10 cycles during preconditioning at 0.5 N/m. The
specimens were then loaded at 60 N/m along T11 and T22 where the subscripts 1 and 2
refer to the circumferential and radial direction respectively. The loading time for the
samples, typically called as the half cycle time, was usually 15 sec during both
preconditioning and testing. Figure 7.2 shows the equipment setup. The images of
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markers during free float, during precondition, after preconditioning, and during testing
were acquired using a camera. The acquired data in MathCAD was converted into excel.
The data obtained was further analyzed and plotted. The data was calculated using the
formula shown below:
F = U*R
where F denotes force, U denotes stretch and R denotes rotation.

Figure 7.2: Sample setup and equipment setup for biaxial testing
The data was acquired using Texas Instruments’ LabVIEW software. From the
acquired data, areal stretch versus tension average curve was plotted. Percent hysteresis
would be a measure of the viscoelastic nature of the tissue. The hysteresis was calculated
by obtaining the area under the loading and the unloading curve. From this, % hysteresis
is obtained using the following formula.

% Hysteresis = {(Loading area – Unloading area) * 100} / Loading area
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The maximum areal stretch is a representation similar to strain. It is calculated
from the maximum stretch U11 and U22 corresponding to the maximum tension T11 and
T22. Maximum areal stretch is calculated using the following formula.

Maximum Areal Stretch = (U11 * U22) – 1
The graphs of %hysteresis and maximum areal stretch were plotted for different
groups and compared.

7.2.3. Uniaxial cyclical mechanical testing setup:
The fixed cusps were carefully excised from the aortic root and 5 mm circumferential
strips were cut out from the belly region of the cusps (n=6 per group). Figure 7.3 shows
the schematic of the sample preparation for uniaxial tensile testing. All tests were
performed by keeping the tissue hydrated at all times in saline. The samples were tested
using MTS Synergie 100 tensile testing machine (Eden Prairie, MN). The sample sizes
were carefully measured using a ruler and the thickness measurements using a Vernier
caliper. The protocol used for testing was a multicycle advanced tensile testing to stress
points. Samples were preconditioned and tested for 10 cycles. The stress end point was 1
MPa and it was kept constant for all samples. The hold time or loading time was 0.5 sec
and the speed of testing was 1.5 mm/min. Testworks software program used to acquire
the data. The data was exported to excel for analyses.
The %hysteresis was calculated as explained before in Section 7.2.1 from the
loading and the unloading curve. Apart from hysteresis, load versus % extension curve
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was also plotted to see the extension of cusps corresponding to the strain from various
groups.

Figure 7.3: Sample preparation for uniaxial cyclical tensile testing

7.2.4. Modified fixation of cusps:
The neomycin concentration during fixation was varied to study the effect of
extent of neomycin crosslinking on tissue biomechanics (Table 7.1).
Group ID

Treatment Conditions
0.6% glutaraldehyde (in 50 mM HEPES buffered saline , pH 7.4) for

GLUT

24 hrs followed by 0.2% glutaraldehyde (in 50 mM HEPES buffered
saline, pH 7.4) for 6 days
0.5 mM neomycin trisulfate (in 50 mM MES hydrate, pH 5.5) for 1 hr

0.5 mM NEO-

followed by 0.6% glutaraldehyde (in 50 mM HEPES buffered saline,

MF

pH 7.4) for 24 hrs followed by 0.2% glutaraldehyde (in 50 mM
HEPES buffered saline, pH 7.4) for 6 days
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1 mM neomycin trisulfate (in 50 mM MES hydrate, pH 5.5) for 1 hr
1 mM NEO-

followed by 0.6% glutaraldehyde (in 50 mM HEPES buffered saline,

MF

pH 7.4) for 24 hrs followed by 0.2% glutaraldehyde (in 50 mM
HEPES buffered saline, pH 7.4) for 6 days

Table 7.1: Modified fixation: Group identification and fixation procedure

7.3. Results
7.3.1. Equibiaxial tensile testing:
Percent hysteresis and maximum areal stretch of cusps fixed in different groups
and treated with and without GAGases were calculated (n=7 per group). Figure 7.4
shows the percent hysteresis data before and after GAGase digestion. The maximum
areal stretch which is a representation of corresponding strain of the samples is showed in
Figure 7.5. Though there was no significant difference in %hysteresis (p<0.05), it was
clear from the maximum areal stretch analysis that the NEO samples seem to be stiffer
than GLUT samples. This was expected as neomycin chemistry adds more crosslink
points in the tissue.

7.3.2. Uniaxial tensile testing:
Percent hysteresis of cusps fixed in NEO and GLUT before and GAG digestion
were plotted for 3 different cycles namely cycle 1, 5, and 10. Figure 7.6 shows percent
hysteresis for NEO and GLUT before GAG digestion and Figure 7.7 shows percent
hysteresis after GAG digestion.
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Figure 7.4: Biaxial tensile testing: percent hysteresis data before and after GAG
digestion on NEO and GLUT fixed cusps

Figure 7.5: Biaxial tensile testing: Maximum areal stretch denoting the extension of
cuspal samples fixed in NEO and GLUT
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Figure 7.6: Uniaxial Mechanical testing: Percent hysteresis of undigested cusps fixed in
NEO and GLUT for cycles 1, 5 and 10.

Figure 7.7: Uniaxial tensile testing: Percent hysteresis of GAG digested cusps fixed in
NEO and GLUT for cycles 1, 5 and 10.
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NEO samples before and after digestion had significantly lower percent hysteresis
compared to GLUT samples (p<0.05) (Figure 7.6 and Figure 7.7). This suggested that
the uniaxial mechanical testing data tends to follow the trend similar to biaxial tensile
testing.
The load versus percent extension from the uniaxial tensile testing was also
plotted for both NEO and GLUT before and after GAG digestion. NEO fixed valves were
found to be stiffer than GLUT fixed valves significantly (p<0.05) before and after GAG
digestion (Figure 7.8).

Figure 7.8: Uniaxial tensile testing: Load Vs percent extension
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7.3.3. Modified fixation: Uniaxial tensile testing:
In order to eliminate the stiffness of the NEO fixed valves, modified fixation
chemistry by omitting the EDC/NHS was used. The modified fixation chemistry should
also preserve the GAGs present in the valve cusps after GAG digestion, for the valves to
be durable. Modified neomycin fixed groups are denoted as NEO-MF where MF refers to
modified fixation. Hexosamine assay was performed on valve cusps after modified
fixation. Figure 7.9 shows the hexosamine data suggesting that there was no significant
GAG loss in NEO-MF groups (1mM and 0.5 mM) after GAG digestion, compared to
GLUT group (p<0.05). Thus this chemistry without EDC/NHS is also as effective in
stabilizing GAGs present in the valve cusps.
Uniaxial tensile testing was again performed before and after GAG digestion on
GLUT control and two NEO-MF groups (0.5 mM and 1 mM). Figure 7.10 shows percent
hysteresis for NEO-MF and GLUT before GAG digestion and Figure 7.11 shows percent
hysteresis for them after GAG digestion. Figure 7.12 shows load versus percent
extension for the modified fixation. Though there was significant difference in
%hysteresis before GAG digestion between GLUT and NEO-MF groups, there was no
significant difference in %hysteresis after GAG digestion (p<0.05). This suggests that
they have similar viscoelastic properties. Load versus percent extension shows that
GLUT cusps becomes stiff after GAG digestion, while NEO-MF cusps (1 mM and 0.5
mM) extends after GAG digestion. 0.5 mM NEO-MF after GAG digestion has greater
extension than GLUT after GAG digestion.
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Figure 7.9: Modified fixation studies: Hexosamine of cusps before and after GAG
digestion following modified fixation

Figure 7.10: Modified fixation: Percent hysteresis before GAG digestion
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Figure 7.11: Modified fixation: percent hysteresis data after GAG digestion

Figure 7.12: Modified fixation studies: Load versus % extension of cusps fixed in
different groups
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The hexosamine analysis on modified fixation groups suggested that the new
fixation chemistry with 0.5 mM NEO-MF followed by glutaraldehyde can stabilize
GAGs against enzymatic degradation. After biomechanical studies, it is also found to
have better extension than GLUT group and no significant difference in %hysteresis
compared to GLUT fixed tissue.

7.4. Discussions
The aortic heart valve is essentially a check valve preventing the retrograde blood
flow. This function though seemingly simple, has several factors to be considered. The
valves should posses the necessary structural strength and durability needed to overcome
the failure due to fatigue. Typically, heart valves cycles to about 30 – 40 million cycles in
a single year, which amounts to ~ 3 billion cycles in a lifetime. No valve made from non
living materials has shown comparable performance and durability [226, 228].
Effectively, the replacement valve should biomechanically function and be able to
survive throughout the lifetime of the patient. The biomechanical aspect of valve
development, function, and disease is still poorly understood [47]. Therefore, it becomes
very important to analyze for the biomechanical properties of these valves. The
biomechanical properties can be analyzed using computational approaches as they can be
applied realistically. Dynamic modeling, finite element analysis etc., could also be used
to study the varied biomechanical properties of tissues. An approach which had gained
popularity over the past two decades is biaxial mechanical testing. This approach is best
suited to biomechanical studies, as it tends to account for the coupling between the layers
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present in the tissue compared to uniaxial testing. Therefore, we perform biaxial testing
and compare it with uniaxial testing results to see if the result matches. These studies
would help us quantify the extensibility as well as the viscoelasticity of the tissues.
Material properties of the tissue such as stiffness and strength could also be obtained
from these studies.
The biomechanical analysis using equibiaxial testing and uniaxial tensile testing
of cusps fixed in NEO and GLUT suggested that NEO was stiffer than GLUT both before
and after GAG digestion. Though NEO was found to preserve GAGs even after 1.5 years
of storage and after 50 million cycles fatigue, the fixation chemistry using neomycin
following by EDC / NHS and glutaraldehyde could have resulted in more crosslinking
leading to stiffer valve. This increased stiffness of the NEO valves could ultimately result
in the premature failure of the BHVs.
Regular fixation using neomycin resulted in increased stiffness of the valves as
described above. Therefore, in an attempt to minimize crosslinking without affecting
GAG stability we chose to modify fixation chemistry. This was done by omitting EDC /
NHS from the fixation chemistry. As carbodiimide was omitted, carboxyl groups of
GAGs will not participate in the crosslinking thus reducing overall crosslink points in the
tissue. Neomycin has few amino groups that can participate in GLUT crosslinking, thus it
still can be linked to the tissue with glutaraldehyde alone. GAGs are long chain
macromolecules and leach out from tissue only when degraded to smaller fragments by
GAG degrading enzymes. Significantly increased amounts the GAG degrading enzymes
were seen after in-vivo implantation of GLUT fixed valves [133]. If we could prevent
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enzyme action, we could prevent GAG loss from the tissue. Thus, we can hypothesize
that binding neomycin to the tissue collagen would be sufficient to prevent GAG
degradation. Furthermore, as GAGs are not crosslinked to neomycin in modified fixation
chemistry, they could freely slide and this could result in reduced stiffness of the tissue.
Modified fixation chemistry with neomycin (0.5 mM NEO-MF or 1 mM NEO-MF) was
found to stabilize GAGs against enzymatic degradation similar to regular fixation
chemistry with EDC/NHS followed by GLUT. Therefore, the modified fixation
chemistry is equally effective in preventing enzyme mediated GAG degradation. Thus
binding of neomycin to the tissue is enough to prevent enzymatic GAG loss. Ideally, we
need to attach as small amount of neomycin to the tissue as necessary to minimize effect
on tissue mechanics. Thus modified fixation chemistry without EDC / NHS, using 0.5
mM NEO-MF would be a better choice for GAG stabilization.
Percent hysteresis data after modified fixation showed that, though there was a
significant difference in groups before GAG digestion (p<0.05), there was no significant
difference after GAG digestion. Also, load versus percent extension graphs show that 0.5
mM NEO-MF cusps have better extensibility than GLUT fixed cusps after GAG
digestion. The graph also shows a unique trend. In case of NEO valves, the valves extend
more after GAG digestion whereas GLUT valves become stiffer after GAG digestion.
Previously it has been shown that the depth of buckling in GLUT increases after GAG
digestion where as it decreases in NEO [220]. We know from our results that GAGs are
lost in GLUT after enzymatic degradation, whereas neomycin fixation stabilizes them
even after enzyme degradation. The stiffness that is seen in GLUT fixed valves after
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enzymatic GAG degradation could be attributed to the loss of GAGs from these valves.
In NEO fixed valves, since we know that GAGs are not lost after enzyme degradation,
the increased extensibility after GAG digestion is not due to GAG loss. There could be
two possible reasons by which NEO fixed valves extend more after GAG digestion.
Firstly, there could be re-alignment of the ECM matrix elements which might result in
better extensibility. Secondly, the enzymes used for GAG degradation could break some
GAG bonds in the tissue without removing them from tissue, making the tissue more
extensible and elastic. These are just hypotheses and more studies are needed to prove the
mechanisms of this increased extensibility in NEO group after GAG digestion.
Better extensibility of 0.5 mM NEO-MF cusps compared to GLUT cusps could
result in better biomechanics of NEO cusps than GLUT fixed valves. This better
biomechanics exhibited by NEO-MF fixed cusps could ideally improve the durability of
these valves.

7.5. Conclusions and recommendations
The following conclusions could be drawn from the biomechanical studies:
•

After regular fixation using EDC/NHS in the crosslinking chemistry for NEO
fixed valves, NEO cusps were found to be stiffer than GLUT fixed valves, as
shown by biaxial and uniaxial tensile testing.

•

Modified fixation without EDC / NHS in the crosslinking chemistry, resulted in
0.5 mM NEO-MF showing better GAG stabilization and biomechanics than
GLUT fixed valves after GAG digestion.
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•

NEO fixed valves extended more after GAG digestion while GLUT valves
became stiffer after GAG digestion. This increased extensibility may be due to
either breakage of some GAG bonds or may be due to realignment of matrix
elements in case of NEO fixed cusps.

The following recommendations are given for future work.
•

At this point we do not know minimal concentration required to stabilize GAGs
without causing excessive change in mechanical properties of valves. It is still
possible to lower neomycin concentration and study its effects on GAG stability
and biomechanics of cusps.

•

We only show uniaxial testing data after new fixation omitting EDC. Biaxial
mechanical testing could be performed after modified fixation chemistry to
further confirm our results from uniaxial testing.

•

Small Angle Light Scattering (SALS) and three point bending studies could be
performed to further analyze the biomechanical properties of these tissues. SALS
will help us analyze for the orientation of the collagen fibers in the tissue and
three point bending studies would help us analyze for flexural rigidity of the
tissue. In particular, SALS could shed some light on the mechanisms of increased
in extensibility seen in NEO group after GAG digestion.
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CHAPTER EIGHT
CONCLUSIONS AND RECOMMENDATIONS

In this report we show that GAGs, one of the important ECM components of the
cusp tissue matrix, are not stabilized by glutaraldehyde chemistry. Furthermore we show
that GAGs are continuously lost from the tissue during storage. This is an important
observation as these valves are stored up to three years before they are implanted in
humans. We also show that GAGs are lost as early as 10 million cycles in vitro. What
this means is that GAGs will be depleted from the valve within first three months after
implantation making it vulnerable to fatigue failure. Previously it was shown that main
mechanism of GAG loss was due to enzymatic action of GAG degrading enzymes, either
present in the tissue or enzymes that infiltrate the cuspal tissue after implantation. These
studies clearly led us to think of new crosslinking chemistries that would stabilize GAGs
in the tissue against GAG degrading enzymes. Thus, the main scope of the project was to
improve the overall longevity and durability of bioprosthetic heart valves by stabilizing
the GAGs present in the valves. Enzyme mediated GAG degradation was prevented by
linking neomycin to the tissue as a GAGase inhibitor. We optimized the amount of
neomycin in the crosslinking reaction so that enough neomycin will be linked to the
tissue to prevent GAG loss. We could show that when 1 mM neomycin was used in EDC
based chemistry; it could effectively stabilize the ECM components of heart valves such
as GAGs, collagen, and elastin from enzymatic degradation. Moreover, this new
chemistry with neomycin stabilized GAGs after long-term storage and in vitro cyclic
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fatigue better than glutaraldehyde fixed cusps. As described previously valves fail due to
two main reasons, namely degeneration and calcification. GAG stabilization was mainly
studied to address degeneration of the valves. We did not know what neomycin linking
will do to the calcification of valve tissue. When these cusps were implanted
subdermally, we found that NEO cusps calcified little less than GLUT cusps. We were
happy to observe that NEO chemistry did not exacerbate calcification, but at the same
time disappointed to see that cusps did calcify and GAG stabilization alone did not
prevent calcification of cusps. Thus, it was decided to combine GAG stabilization
chemistry with clinically used ethanol based anti-calcification treatment. When these
cusps were implanted subdermally, we observed that the cusps retained all GAGs as well
as they did not calcify. These studies were encouraging to us as it showed that GAG
stabilization chemistry was compatible with the ethanol anti-calcification treatment. The
results clearly showed for the first time that it is now possible to prevent degeneration
and calcification at the same time by judicious choice of chemical treatments of valves.
Next we looked at biomechanical properties of cusps after combining neomycin
chemistry with ethanol. Studies of depth of buckling after GAG digestion showed this
combined treatment was better that GLUT as buckling depth in NEO-ethanol group was
similar to native fresh cusps while it was significantly higher in GLUT-ethanol group.
We also did two different types of biomechanical experiments: uniaxial testing and
equibiaxial testing to study valve mechanics and hysteresis. These results, however,
showed that NEO fixed groups were much stiffer that GLUT fixed tissues. We do not
know if this increased stiffness would ultimately cause valve failure earlier than
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expected. We then decided to modify neomycin chemistry to minimize crosslinking
density. We omitted EDC from the reaction scheme so that carboxyl groups of proteins
will not participate in the chemistry and reduce potential crosslink points. This
modification led to very similar GAG stability as before shown with EDC chemistry.
Importantly, cuspal stiffness was considerably reduced by this new modification and was
comparable to GLUT fixation. In summary, our studies suggested that neomycin fixation
could potentially be used in combination with ethanol anti-calcification to prevent both
degeneration and calcification of valve cusps. Thus, this fixation could be a stepping
stone towards achieving the ideal bioprosthetic heart valve.

8.1. Conclusions
The following specific conclusions could be drawn from the studies performed in
this work:
•

GAGs were lost from glutaraldehyde fixed cusps. GAG stability after enzymatic
GAG degradation was only partially effective in tissues fixed with carbodiimide,
followed by glutaraldehyde.

•

Neomycin fixed tissue prevented GAG degradation by GAGase enzymes. This, to
our knowledge, was the first time that bound neomycin was shown to be effective
in preventing GAG degradation in BHVs. When control de-oxystreptamine was
linked to the tissue (which has similar structure as neomycin but lacks inhibitory
activity against GAGases), we observed only partial stability of GAGs, clearly
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showing that enzyme inhibitory action of neomycin is partially responsible for its
efficacy.
•

Thermal denaturation temperature and percent weight loss study using
collagenase suggested that neomycin fixation stabilized collagen better than
glutaraldehyde. Quantitative collagen content measurement by hydroxyproline
studies suggested that collagen is adequately preserved in fixed tissue compared
to fresh tissue.

•

Elastin is another major ECM component of valve cusps. Elastin is not stabilized
by GLUT fixation. Therefore, it is important to ensure its stability for the
durability of these valve implants. Immunohistochemistry and percent weight loss
suggested elastin was stabilized using neomycin crosslinking better than other
fixatives. However, quantitative elastin content by desmosine analysis yielded no
significant differences among various groups.

•

Neomycin inhibited GAG degradation for upto 1.5 years of storage. Neomycin
also inhibited GAG degradation for upto 50 million cycles fatigue suggesting
GAGs were preserved in neomycin stabilized cusps during valvular function.

•

In subdermal implantation studies neomycin fixed cusps retained more GAGs
compared to other groups. However, neomycin fixation did not result in complete
inhibition of calcification.

•

Ethanol anti-calcification treatment resulted in increased stability of GAGs in
neomycin fixed cusps both in vitro and after in vivo subdermal implantation.
Ethanol treatment also resulted in inhibition of calcification in neomycin fixed
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valves. Sodium borohydride treatment by itself did not result in increased GAG
stability or reduced calcification. This suggests that ethanol treatment in addition
to neomycin fixation on cusps could potentially eliminate the degenerative and
calcific modes of valve failure there by improving the life-time durability of the
implant.
•

Biomechanical studies were performed using both equibiaxial testing and uniaxial
testing. Fixation chemistry using EDC / NHS, showed neomycin fixed cusps was
highly crosslinked and that led to stiffer cusps than glutaraldehyde fixation alone.
Modification of the fixation process by omitting EDC / NHS in the crosslinking
chemistry resulted in significantly less stiff cusps without reducing GAG stability.

Overall, neomycin fixation with improved GAGs and ECM matrix stability
combined with and least calcification following ethanol anti-calcification treatments
could ideally eliminate both the degenerative and calcific modes of valve failure. The
prevention of both the modes of failure by neomycin fixation could be a stepping stone in
achieving an ideal bioprosthetic heart valve with longer durability.

8.2. Recommendations
We are encouraged with our studies with neomycin based crosslinking. We
clearly show that it can lead to GAG stabilization without affecting collagen and elastin
stability. Thus one can envision better stabilized valves in the future for increased
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durability. However, our studies also raised many questions that need to be studied in
detail in future studies. Some of the recommendations are noted below.
•

It is still possible to optimize neomycin concentration and time of reaction to
obtain cusps that are biomechanically similar to glutaraldehyde crosslinked cusps
but with complete GAG stability. Thus optimum neomycin concentration for
fixation and GAG preservation should be analyzed using radioactively tagged
neomycin for fixation.

•

We have shown here that neomycin fixation inhibits enzyme mediated GAG
degradation. The biochemistry and the molecular mechanisms behind the
inhibition and preservation of GAGs by neomycin are still poorly understood and
could be further investigated extensively. For example, known quantities of HA
and collagen gels can be crosslinked with varying concentrations of neomycin.
These gels could be treated with GAG degrading enzymes to find out the
minimum concentration which is required for complete prevention of HA
degradation. Additionally, gel zymography could be performed to assess the
ability of bound neomycin in stabilizing GAGs.

•

Fluorophore Assisted Carbohydrate Electrophoresis (FACE) could be performed
on the extracted GAGs from the cusps to determine the different types of GAGs
present in the cusps after the novel neomycin crosslinking.

•

For a valve to be durable all the major ECM components such as GAGs, collagen
and elastin should be adequately preserved. GAGs and collagen are shown to be
effectively stabilized by neomycin fixation. Weight loss studies and
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immunohistochemistry showed that neomycin fixed valves had better elastin
stability than glutaraldehyde fixed valves. However, quantitative desmosine
content showed no significant difference between groups. This suggests that
elastin could still be vulnerable to degradation which might result in valve failure.
Therefore, further studies could be conducted by combining neomycin fixation
chemistry using elastin stabilization chemistries such as penta-galloyl glucose
(PGG).
•

Storage studies could be performed for upto 3 years of storage to see the effective
GAG loss during shelf-life. Functioning of the valve could be tested for GAG
stability following more fatigue cycles. The valves could be cycled for upto 200
million fatigue cycles and the GAG stability further determined. This could
further help us strengthen our claim about the better GAG stability by neomycin
after long-term storage and cyclic fatigue.

•

Accelerated fatigue testing could be performed in fluids at physiologic conditions
such as viscosity to analyze the damage to the valves due to shear. SEM could be
used to analyze the surface microstructural damage due to shear.

•

Additional biomechanical testing using SALS and three point bending would help
us analyze for the collagen fiber orientation of the valves as well as the flexural
rigidity of these valves.

•

In our in vivo studies, only a subdermal implantation model was used. Such
model is good as a first screen, however, it lacks hemodynamic environment
experienced by BHVs. Thus sheep mitral valve replacement model could be used.
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This model would show the efficacy of GAG stabilization against the action in
vivo degradative enzyme, blood interactions, in vivo cyclic fatigue, and under
shear and physiologic pressures on the valves.
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Appendix
GAG Quantification Assays and their limitations
GAGs are linear anionic acid mucopolysaccharides. They have repeating disaccharide
subunits made up of an amino sugar (either N-acetyl glucosamine or N-acetyl
galactosamine) and a uronic acid (either D-glucuronic acid or L-iduronic acid) [36].
These GAGs are typically attached to a core protein with a glycosidic bond and these
macromolecules are called as proteoglycans [36]. GAGs are highly hydrophilic in nature
as they contain carboxylic and sulfonic acid groups. There are a total of five types of
GAGs found in the body. They are hyaluronic acid (HA), chondroitin sulfate (CS),
dermatan sulfate (DS), keratin sulfate (KS), and heparan sulfate (HS) [36, 37].
Hyaluronic acid does not contain sulfate groups and it is not bound to a protein core.
Hyaluronic acid, chondroitin sulfate and dermatan sulfate are the major GAGs present in
the aortic valve cusps [36, 37]. Usually, the GAGs molecules are quantified by analyzing
for the uronic acid portion in the GAG molecule by uronic acid assay or the amino sugar
portion by hexosamine assay.

Figure A-1: Disaccharide unit of Chondroitin 4-Sulfate
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Carbazole technique for uronic acid content as described by Bitter and Muir can
be used to assess GAG content on tissue extracts [229]. Uronic acid is a component of all
GAGs except keratin sulfate [37]. Uronic acid assay is not chosen for our experiments
for the following reason. Except for modified fixation studies, all our studies used
carbodiimide for fixation of cusps (NEO and ENG group cusps). Since EDC / NHS
activates and binds to the carboxyl group portion of GAGs, and carboxyl groups are
involved in carbazole chemistry, quantification of GAGs using Uronic acid assay
becomes difficult as crosslinking interferes with GAG detection.
We opted for hexosamine assay (as described in section 4.2.3) because it
measures amino sugar residues of GAGs. The major limitation with the hexosamine
assay is that it measures the non-GAG associated amino sugars in the cuspal tissues. Thus
total hexosamines content of the tissue could be larger than total GAGs present in the
tissue. Previous research from our lab has quantified non-GAG related hexosamines and
a usual baseline value of ~90 µg of hexosamine per 10 mg of dry tissue is accounted as
the non-GAG associated hexosamine [21, 26, 38]. Thus, hexosamines assays in our study
were used only to compare GAG content in different groups rather than to obtain absolute
GAG content.
In an effort to measure, match and, compare the amount of released GAGs in the
enzyme / buffer liquid, we performed Dimethylmethylene Blue (DMMB) assay on the
digestate as described in section 4.2.4. [193, 194, 230, 231]. Our enzyme digest solution
contains fragments of hyaluronic acid and chondroitin sulfate as cuspal tissues were
usually treated with a mixture of hyaluronidase and chondroitinase ABC. Farndale et al.
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clearly

suggest

that

this

assay

is

meant

to

determine

only

the

sulfated

glycosaminoglycans [193]. Though proportionate, the slight mismatch from the
hexosamine assay data and DMMB assay data in our results could be due to the fact that
DMMB measures only the chondroitin sulfate released into the enzyme and not the HA.
Biglycan assay could be used to determine the HA content in the enzyme solutions. The
limitation for this assay, though, is based on the size of the HA fragments after digestion.
The fragments > ~100 kDa are easily detected by biglycan assay. The hyaluronidase used
for our studies was bovine testicular hyaluronidase (H3631, Sigma Corporation, MO,
USA). This enzyme randomly cleaves β-N-acetylhexosamine-(1→4) glycosidic bonds of
hyaluronic acid, chondroitin, and chondroitin sulfate. Since the hyaluronidase fragments
HA to smaller fragments (<100 kDa), biglycan assay could not be used for our studies.
Blyscan™ glycosaminoglycan assay could also be performed on the enzyme solution to
determine the released GAGs. Again, this assay measures only the sulfated GAGs and
does not measure HA content. The Blyscan™ assay is marketed by Accurate Chemicals
and Scientific Corporation [232]. Cationic dyes such as toluidine blue have been used to
quantify the GAGs by some researchers [233-235]. A textbook on the different protocols
for proteoglycan quantification is also available [236]. All of the reported assays for
GAGs are targeted to free GAGs in the tissue. We are crosslinking GAGs to the tissue
and thus, it is difficult to choose one assay that will work in our case. Hexosamine assay
was the one used finally as we obtained consistent results with this assay.
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